

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:35:32 ; Search time 21 seconds
(without alignments)
2485.761 Million cell updates/sec

Title: US-09-759-207-2
Perfect score: 2842
Sequence: 1 MLRSKPALPPPLMLLLGP.....LPATSPFVIRNAKVAACI 543
Scoring table: BL0SUM62
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	897.5	31.6	480	2 JC7506	heparanase protein
2	416	14.6	521	2 T45608	hypothetical prote
3	169.5	6.0	190	2 T01953	hypothetical prote
4	112.5	4.0	356	2 F64383	hypothetical prote
5	111.5	3.9	575	2 T12094	beta-fructofuranos
6	111	3.9	670	2 T10666	hypothetical prote
7	111	3.9	688	2 S32961	hypothetical prote
8	111	3.9	2298	2 T49648	hypothetical prote
9	109.5	3.9	879	2 E91031	probable outer mem
10	108.5	3.8	411	2 S74760	hypothetical prote
11	107.5	3.8	500	2 D87541	beta-xylosidase [i
12	106	3.7	879	2 F85875	probable fibrinol
13	105	3.7	670	2 T38446	microtubule-associ
14	104.5	3.7	788	1 S00652	phosphoribosylamin
15	104	3.7	433	2 F70411	adenylosuccinate s
16	104	3.7	2013	2 A11489	probable peptidogl
17	103.5	3.6	587	2 S36231	beta-fructofuranos
18	103.5	3.6	676	2 AF1153	transcription anti
19	103.5	3.6	687	2 F85188	retrotransposon li
20	103	3.6	796	2 D97065	transketolase [imp
21	101	3.6	594	2 A82913	hypothetical prote
22	101	3.6	644	2 A97268	methionyl-tRNA syn
23	100.5	3.5	805	2 C86525	DNA gyrase subunit
24	100.5	3.5	805	2 H72098	DNA gyrase, chain
25	100.5	3.5	989	2 AE2140	toxin secretion AB
26	99.5	3.5	510	2 H69893	conserved hypotet
27	99.5	3.5	837	1 A31842	endo-1,4-beta-xyla
28	99	3.5	897	2 G02529	dynein heavy chain
29	99	3.5	4644	1 A38905	dynein heavy chain

30	98.5	3.5	596	2 T04506	hypothetical prote
31	98.5	3.5	629	2 C64180	hypothetical prote
32	98.5	3.5	654	2 T14202	NADH2 dehydrogenase
33	98.5	3.5	699	2 F95146	DNA topoisomerase
34	98.5	3.5	701	2 D98014	DNA topoisomerase
35	98.5	3.5	746	2 T46821	stereophore recept
36	98.5	3.5	746	2 A95420	RhA Rhizobactin r
37	98.5	3.5	1012	2 JC5925	hypothetical prote
38	98	3.4	465	2 T19113	membrane klotho pr
39	98	3.4	716	1 C60008	RNA-directed RNA p
40	98	3.4	760	2 T34414	hypothetical prote
41	98	3.4	817	2 H75035	probable membrane
42	97.5	3.4	454	2 T20829	probable serine ca
43	97.5	3.4	511	2 S61166	probable membrane
44	97.5	3.4	604	2 E75119	hypothetical prote
45	97.5	3.4	804	2 G71546	probable DNA gyras

ALIGNMENTS

RESULT 1

JC7506
heparanase protein 2a - human
C:Species: Homo sapiens (man)
C:Date: 17-Nov-2000 #sequence_revision 17-Nov-2000 #text_change 01-Dec-2000
C:Accession: JC7506
R:McKenzie, E.; Tyson, K.; Stamps, A.; Smith, P.; Turner, P.; Barry, R.; Hancock, Biochem. Biophys. Res. Commun. 276, 1170-1177, 2000
A:Title: Cloning and expression profiling of Hpa2, a novel mammalian heparanase fa
A:Reference number: JC7506
A:Accession: JC7506
A:Molecule type: mRNA
A:Residues: 1-480 <MCK>
A:Cross-references: GB:AF282865
C:Comment: This protein, a intracellular membrane-bound enzyme, has biological and therapies.
C:Genetics:
A:Gene: hpa2a
A:Map position: 10q23-10q24
C:Keywords: heparin binding; membrane bound

Query Match	31.6%	Score 897.5	DB 2	Length 480
Best Local Similarity	36.0%	Pred. 2.6e-59		
Matches	202	Conservative	74	Mismatches 146; Indels 139; Gaps 9;
Oy	20	PLGPIISGAL-----PRPA-----QAQVVDLDFTOEPILHVS	55	
Db	18	PACIAPGALYIALLLHLSLSSQAGDRRLPYDRAAGLKEKTLILLDVSTKNPVRTVMEN	77	
Oy	56	PLSVTDANLADPRFLILGSPKLTARGLSPAYLRFPGTKTDFLIF-----DPKKEST	111	
Db	78	FSLQDPSIITHD-GWLDLFSKRLVTLARGLSPAFRLRGKRTDFLOQNLRNPAKSR-	135	
Oy	112	FEERSWQSQVNDICKYISIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSSSYD	171	
Db	136	-----GGPGPD-----YLLKNE-----	148	
Oy	172	VLYTRANSGDLIFGLNALFTADLQNNSSNAQLLDYCSSKGYNISWELNEPNSFLK	231	
Db	149	-----DEPNNTKT	156	
Oy	232	KADIFNGSOLGEDYIOLHKLRK-STFNNAKLYGPDVGPORPKRTAKMLKSLFKAGGEVI	290	
Db	157	MHGKRAVNSQLKDKDYIOLKSLQPIRIYSRASLYGPNIGRPKNVIALDGFMKVAGSTV	216	
Oy	291	DSVTWHYVYVLRGRTATREDFLNPDVLDIFISSVQVFPQVVESTPRGKKVWLGESYAYCG	350	
Db	217	DAVTQHCYIDRVRVVKVNDFLKTRILLDLSQDIRIKQKVVNYYTPGKKIMLEGVYTSAG	276	
Oy	351	GAPLSDFFPAAGFMKLDKISARMKIEYVNRQVFPAGCNHYLDENRDPDPLDYLSLIF	410	
Db	277	GNINLSDSYAAGFLMLNTLGLMLANOGIDIVVIRHSFDDHYNHLVDQNNPNPLPDVWLSLY	336	

```

OY 411 KLVGKTVLMASVQSGRR-----KLRVYLHCTNTDNPYKESDGLTVAINLHNVT 461
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 337 KRLGPKVLAVHVAQLGRKPRGRVJRDKLRVIAHCHNHNHNHVRSGITLFIINLHRSR 396
OY 462 KYLRPLPPSNKQVNDKLLRPLGPHGLSKSVOLNGLTLTKVNDOTLPLMEKPLRGSS 521
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 397 KKKLGGTLRDKLVHQLDLPYQGEGLSKSVOLNGLTLTKVNDOTLPLMEKPLRGRT 456
OY 522 LGLPAPSYSPFFVIRNAKVAAC 542
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 457 LVIPVYTMGFVVKVNAALAC 477

RESULT 2
T45608
hypothetical protein F13G24.30 - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cross)
C:Date: 04-Feb-2000 #sequence_revision 04-Feb-2000 #text_change 04-Feb-2000
C:Accession: T45608
R:Bevan, M.; Van Der Schueren, J.; Chuang, Y.J.; Voel, M.; Robben, J.; Volckaert, G.; Ba
submitted to the Protein Sequence Database, December 1999
A:Reference number: 223009
A:Accession: T45608
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-521 <BEV>
A:Cross-references: EMBL:AL133421
A:Experimental source: cultivar Columbia; BAC clone F13G24
C:Genetics:
A:Map position: 5
A:Introns: 53/3; 66/1; 127/2; 177/1; 256/1; 319/2; 361/2; 394/3
A:Note: F13G24.30

Query Match          14.6%; Score 416; DB 2; Length 521;
Best Local Similarity 29.2%; Pred. No. 3.3e-23;
Matches 154; Conservative 68; Mismatches 184; Indels 122; Gaps 24;

OY 75 LGSPLKLTARGLSPAYLRFGCTKTDLPDPKKESTFEERSYQSOVNODICKYGSIPP 134
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 55 LTRPLLTAKAKFKRPLRIRIGSLQDPQVIVDGNLKT-----PCR----- 94
OY 135 DVEEKLRLMPYQDOLLREHYOKFRNS---TYSRSSV-----DVIYTFANCSGLDLIF 186
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 95 -----PFGKM-----NSGLFGFSKGLMKMRWDELNSFLTATGAVVTF 132
OY 187 GLNALRTADLQ-----WSSNAOLLIDYCSSKGYNI-SWETGNPNPFLKADFIIN 238
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 GLNALGRHKLRGKAMGANDHINTQDFLNTYVSKGVIDSWFEGNELSG--SGVGASYS 190
OY 239 GSQLGEDYIOLHKLKSTFKNAKLYGPDVGOP-----RRKTKMKLSFLKAGEVIDSV 293
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 191 AELYGCDLIVLKDVINK-VYKNSMLHPRILVAFGGEQWQMYTKLEI---SGPSVYDV 246
OY 294 TNNHYULNGRT--ATREDELNPVLDLFISSVQVF---QVESSTRPKKXVVLGETSSA 347
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 247 TNNHYULNGRT--ATREDELNPVLDLFISSVQVF---QVESSTRPKKXVVLGETSSA 302
OY 348 YGCGAPLSDPTFAAGFAMLDLKLGSARMGIEVVRQVFGAGNVHLVDE--NFRPLDPYWL 406
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 303 YNCGGRHVSPTFIDSFYIDLQGLMSARHNKVVYCROTLVG--GYGLEKKTFFPNPDYIS 361
OY 407 SLLEFKLVGTVLMASVQSGRRKLRLVYLHCTNDNPYKESDGLTVAINLHNVTYVL-- 464
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 362 ALLMHLRMGKGLAVQDGRP--QLRYAHKSC-----GRAGVTILLINLSNQSDPTVS 413
OY 465 -----RLPYPS---NKQVNDKYLRLP---LGPNG--LLSKSVOL 495
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 414 VSNGINVNLAEGRKKSLIDTLKRPFSWIGSKASDGYLNRREYHLTPENGVLRSKTMVL 473
OY 496 NGLTKLVNDOTLPLMEKPLRP-GSSIGLPAPSYSPFFVIRNAKVAAC 542
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 474 NGAS:KPTATGDIPLSL-EPVLRVSNPFLNVLPLSMSTFIYLPNDASAC 520

```

```

RESULT 3
T01953
hypothetical protein T2L5.6 - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cross)
C:Date: 26-Feb-1999 #sequence_revision 26-Feb-1999 #text_change 21-Jan-2000
C:Accession: T01953
R:Geisel, C.; Smith, A.; Le, T.
submitted to the EMBL Data Library, October 1998
A:Description: The sequence of A. thaliana T2L5.
A:Reference number: 214470
A:Accession: T01953
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-190 <GEI>
A:Cross-references: EMBL:AF096371; NID:g3695386; PID:g3695392
A:Experimental source: cultivar Columbia
C:Genetics:
A:Map position: 4
A:Introns: 36/2; 69/3
A:Note: T2L5.6
C:Superfamily: Arabidopsis thaliana hypothetical protein T2L5.6

Query Match          6.0%; Score 169.5; DB 2; Length 190;
Best Local Similarity 27.8%; Pred. No. 2.1e-05;
Matches 54; Conservative 34; Mismatches 57; Indels 49; Gaps 9;

OY 382 ROYFPGAGNVHLVD--ENPDLDPYWLSLFKLVGKTVLMASVQSGRRKRLRYLHCTNT 440
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 12 ROSLIG-GNGLNTTNTFPNPDIYSALIMROLMGKALFTTSGTK--KINSYTHCA-- 66
OY 441 DNPYKESDGLTVAINLHNVT-----TKYLRPLPPSNKQVNDKYLRLP 483
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67 ---RQSGK-ITVLMMLDNTTVYAKVELNNSFSLRHTKMK-----SYKRASSQLFG-- 115
OY 484 GPRGLL-----SKSVOLNGLTLKAVNDOTLPLMEKPLRGSSGLPAPS 528
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 116 GPMGVIOREHYLTAQGNLHQSOTMLNGLNGLVNSMGDLPIEPYHINSTEPIITAPYS 175
OY 529 YSPFVIRNAKVAAC 542
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 176 YFVHMRNVVPRAC 189

RESULT 4
F64383
hypothetical protein M10670 - Methanococcus jannaschii
C:Species: Methanococcus jannaschii
C:Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 21-Jul-2000
C:Accession: F64383
R:Bull, C.J.; White, O.; Olsen, G.J.; Zhou, L.; Fleischmann, R.D.; Sutton, G.G.;
Retch, C.I.; Overbeek, R.; Kirkness, E.F.; Weissstock, K.G.; Merrick, J.M.; Glo
rson, J.D.; Sadow, P.W.; Hanna, M.C.; Cotton, M.D.; Roberts, K.M.; Hurst, M.A.
Science 273, 1058-1073, 1996
A:Authors: Kaine, B.P.; Borodovsky, M.; Klenk, H.P.; Fraser, C.M.; Smith, H.O.; V
A:Title: Complete genome sequence of the methanogenic archaeon, Methanococcus jar
A:Reference number: A64300; MUID:96337999; PMID:8688087
A:Accession: F64383
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-356 <BUJ>
A:Cross-references: GB:U67514; GB:L77117; NID:g2826304; PIDN:AAB98664.1; PID:g155
C:Genetics:
A:Map position: REV596956-595886
A:Start codon: GTG

Query Match          4.0%; Score 112.5; DB 2; Length 356;
Best Local Similarity 21.2%; Pred. No. 1;
Matches 85; Conservative 48; Mismatches 143; Indels 125; Gaps 18;

OY 126 ICKY-----GSLPPVEEKLRLMPYQDOLLREHYOKFRKSTYSRSSVD----- 171
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

Db 14 JAKYKINNGKEDIKERLIKE-----LKEEHVETEDGTTLKADEEEMHSKV 66
 Oy 172 -----VLTFFANCGLDIFPLMLRTADLOMSSNQLLDVCSGYNISWELGEP 226
 Db 67 GALKELAIYKFAKPS-----KITDL-----SNPR-VLDLCSGMYNAIALAHYNK 109
 Oy 227 NS-----FL-----KKADIFINGSGEDYIOAHKLKRSTF 258
 Db 110 MAELDMVEICEVLFLLPLIPYKEHEITIDKREYFLN--KIGIEF-----KSDY 159
 Oy 259 KNAKLYGPDVGQPRRKTAAMKLSFLKAGEVIDSVTHHYYLNGRTAT--REDFLNPVYL 316
 Db 160 DNIMLY---VGDARFKIISKDKY-----NVFHDARSPRKDPITYLTYDFL----- 202
 Oy 317 DIFISSVOKVQVVESTRPPKKVNLGETSSAYGGAPLLSTFPAAGFPMMLDKLISAMG 376
 Db 203 -----KEIKRMEDN--GVLI-----SYSSAIPRPSALVDCGFIYSEKESGRRG 246
 Oy 377 IEVVMROVFCAGNVHLVDENFD-----PLPDVWLSLFLKKLIVGTFLMAVSGSKRR 429
 Db 247 ITLAVKNPFPKPNRIEYDERVIALSVALPYPDETLSLTOKITIEDREERREKLKEKLI 306
 Oy 430 KLRVYLHCTNTDNPYKEGDLTYLA--INLHNVTYLRPLPY 468
 Db 307 KIGVYLSTKQIKKGNIPPEILIKOKEDLNSSEIITKMMRLKF 347

RESULT 5

112094
 beta-fructofuranosidase (EC 3.2.1.26) - fava bean
 C:Species: Vicia faba (fava bean)
 C:Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 21-Jul-2000
 C:Accession: T12094
 R:Weber, H.; Borisjuk, L.; Helm, U.; Buchner, P.; Wobus, U.
 A:Title: Seed coat-associated invertases of Fava bean control both unloading and storage
 A:Reference number: 217416; MUID:96093423; PMID:855137
 A:Accession: T12094
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-575 <WEB>
 A:Cross-references: EMBL:Z35162; NID:9861154; PIDN:CAA84526.1; PID:9861155
 A:Experimental source: cv. Fribo, seed coat
 C:Genetics:
 A:Gene: CWIN1
 C:Superfamily: beta-fructofuranosidase
 C:Keywords: cell wall; glycoprotein; glycosidase; hydrolase

Query Match 3.9%; Score 111.5; DB 2; Length 575;
 Best Local Similarity 21.4%; Pred. No. 2.5; Mismatches 107; Indels 109; Gaps 19;
 Matches 72; Conservative 48;

Oy 46 QEPHLVS-----PSFLSVTIDANLATDPRFLILGSPKRLTLARGLS-----P 89
 Db 228 KHPHSARRTGMMECPDYPVSLSEKNGLD--LSMMGMNKNHVLKNSLDITREYEYTI 285
 Oy 90 AYLR-----FGGKTDF-----LIFPKKSTFEERSYW--OSOVNQ 124
 Db 286 TYLQMODKVIIPDKTSEDMGGLRYDGNFYASKSFDPPTK---NRIITGMANESDKE 341
 Oy 125 DICKG-----SIPPDV-----EELKLEMPYOEQLLR-----EHYOKKFNSTYSRSV 170
 Db 342 DDVKKMGAGIOAIPRTVWLDSRRQLR--QMPVEELNRLRGQOVENKKNLKKGT----L 396
 Oy 171 DVLYTFANCGLDIFGLNALRTADLOWNSSNQLLDVCSGYNISWELGNEPNSFL 230
 Db 397 EVKGITASQADVEYTFSSSLDKAEAPDPWNEAE--DLCAQKSGKVRGCG--PFGLL 451
 Oy 231 KKADIFINGSGEDYIOL-----HKLL-----RKSTFKNAKLYGP-----DV 268
 Db 452 TLA-----SKLEEYTSVFFRVFAANKHAIKMSDKASSLNLRELKPSFAGFVNDL 505
 Oy 269 GQPRRKTAAMKLSFLKAGEVIDSVTHHYYLNGRT 304

Db 506 GNNKKLSLRL-----IDHSVSEFGVGCKT 531

RESULT 6

110666
 hypothetical protein F6E21.40 - Arabidopsis thaliana
 C:Species: Arabidopsis thaliana (mouse-ear cress)
 C:Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 16-Feb-2001
 C:Accession: T10666
 R:Bevan, M.; Lennard, N.; Quail, M.; Harris, B.; Rajandream, M.A.; Barrell, B.G.;
 submitted to the Protein Sequence Database, June 1999
 A:Reference number: Z16533
 A:Accession: T10666
 A:Molecule type: DNA
 A:Residues: 1-670 <BEV>
 A:Cross-references: EMBL:AL049914; GSPDB:GN00062; ATSP:F6E21.40
 A:Experimental source: cultivar Columbia; BAC clone F6E21
 C:Genetics:
 A:Gene: ATSP:F6E21.40
 A:Map position: 4
 A:Insertions: 47/3; 87/1; 123/3; 203/3; 230/2; 255/3; 284/3; 305/1; 335/3; 347/3; 370.
 C:Superfamily: Schizosaccharomyces pombe negative regulator of mitosis skbl

Query Match 3.9%; Score 111; DB 2; Length 670;
 Best Local Similarity 22.4%; Pred. No. 3.4; Mismatches 194; Indels 156; Gaps 33;
 Matches 123; Conservative 77;

Oy 51 LVSPFLSVTIDANLATDPRFLILGSPKRLTLARGLSPAY--LRFGGTKTDFLIFPK- 107
 Db 47 LVDPYSRSLVEGN--GVDTOVLPGGSDLY-----LSPSQMSSHYVGKISSMIDLDSED 99
 Oy 108 -----KESTFEERSWOSOVNODICKYGSIPPDVEEKRLREMPYOEQLLREHYOKKFK 161
 Db 100 EVLMDSETTLKOEIATMATHLSLMCE-----PD-----LTPRHYLAGCL 139
 Oy 162 NSTYSRSV---DVLV-----TFANCS--GIDLIFGLNALRTADLOWNSSNQLD 207
 Db 140 RVSCRSSEFISDEFTLKITNTNQLATFCGSSLPCLNVTSAKLMLRPLV--SEGDGM 196
 Oy 208 LDVCSGYNISWELGN-----EPNSFLKKA-DIFIN-----GSOLGEDYIOLHKL 253
 Db 197 DD--TSEGLNSWELMNSFRLCHDSKLSVALDYLSLTPSETSLGRMGES--VRAATLS 253
 Oy 254 RKSTFKNAKLYGPDVGP--RRKTAAMKSLF--KAGEVIDSVTHHYYLNGRTATREDF 310
 Db 254 TDAFLTNAR-----GYPCLSKRHOKLACGFDDHAQVYIGCKRPHNLQKPLDSSSECTE 307
 Oy 311 LNPVDLFISSVOKVQVVESTRPPKKVNLGETSSAYGGAPLLSDFFAAGFPMMLDKLG 370
 Db 308 KNP--LRIYLDYVAIYLFQKMESLSEOEKTELGYRDFLOAPLQPLNDLEAQTITFE--- 362
 Oy 371 LSAHMGIEVVMROVFCAGNVHLVDENFDPLPDVWLSLFLKKLIVGTFLMA----- 420
 Db 363 ---RDSVKYIYQ---RAVEKALVDR---VPDEKASEL-----TYLVAVVGAGRGPLY 406
 Oy 421 -ASVQSKR--RKLRYVLHCTNTDNPYKEGDLTYLAINLHNVTK-----YLRPLPY 468
 Db 407 RASLOAAEEDTRKLVY---AVERNPN-----AAVTLLNLVLMMEGMEDEVVTIISCDM 455
 Oy 469 PFNS--QVNDKYLRLPQPHGLSKSVQLNGLTLKNVDDOPLPLM---EKPLRGGSLG 523
 Db 456 RFMAAPADADIVSELGSGF-----DNEISPECLDGAQFLAP--DGIS 498
 Oy 524 LPAFSYFFV 533
 Db 499 IPS-SYTSFI 507

RESULT 7

S32961
 hypothetical protein YBR259W - yeast (Saccharomyces cerevisiae)
 N:Alternate names: hypothetical protein YBR1727

C.Species: Saccharomyces cerevisiae
 C.Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 19-Apr-2002
 C.Accession: S32961; S46140
 R.Dolignon, F.; Bileau, N.; Crouzet, M.; Aigle, M.
 Yeast 9, 189-199, 1993
 A.Title: The complete sequence of a 19,482 bp segment located on the right arm of chromo
 A.Reference number: S29348; MUID:93220397; PMID:8465606
 A.Accession: S32961
 A.Status: translation not shown
 A.Molecule type: DNA
 A.Residues: 1-688 <DOI>
 A.Cross-references: EMBL:X70529; NID:q1907246; PIDN:CA449923.1; PID:9296558
 R.Aigle, M.; Bacle, M.C.; Barthe, C.; Bileau, N.; Crouzet, M.; Dolignon, F.
 submitted to the Protein Sequence Database, August 1994
 A.Reference number: S45940
 A.Accession: S46140
 A.Molecule type: DNA
 A.Residues: 1-688 <AIG>
 A.Cross-references: EMBL:Z36128; NID:q536684; PIDN:CA485222.1; PID:q536685; MIPS:YBR259W
 C.Genetics:
 A.Cross-references: SGD:S0000463
 A.Map position: 2R
 C.Superfamily: Saccharomyces cerevisiae hypothetical protein YBR259w

Query Match 3.9%; Score 111; DB 2; Length 688;
 Best Local Similarity 22.5%; Pred. No. 3.5;
 Matches 67; Conservative 45; Mismatches 94; Indels 92; Gaps 16;

OY 126 ICKYSIPPDVEKRLERPEYOELLREHYOKKRNSTYSSS-----VDVLYT 175
 DB 164 MAEYSGLMDSDKKRQLOLMEFRMKLKECLVKEFNFDLOKSDPLLELIIPWEKIYV 223
 OY 176 FANCSGLDLIFGLNLRLFTADLQNNSSN-----AQLLDL-----YCSSKGY----- 216
 DB 224 -ANC--IAAFTEQYRIGACELIMTSKLNLFSSISSAVLRLLDLOMMSAFRYPGEALY 280
 OY 217 -----NISWELGNEPNSFLKA--DIF--INGSLG--EDVYQLHLKLR----- 255
 DB 281 QDFAHRLSLKMDSNKVESLIRALLFNDMFYFNKEQYDTRKDGIFFLRLKRNKEHIN 340
 OY 256 -----STFKR--AKLYGPDVCGPRRKTAMKLSFLAGGEV-----IDSV 293
 DB 341 DVKDRHIOYIKYLNQSFKNMSTLMTSSKTDRKSHNPPSILDDGNTIGHVSPIDE- 399
 OY 294 TWHNYLNC-----RTATREDFLNPDVLDIFISSVOKFOVVESTR--PGKK 338
 DB 400 -YSHFIDNEPLMRDKVYPRKIYTNQOTPRDASAIIDS--HKIYALISLRYLPEKR 454

RESULT 8
 T49648
 Hypothetical protein B8B20.20 [imported] - Neurospora crassa
 C.Species: Neurospora crassa
 C.Date: 02-Jun-2000 #sequence_revision 02-Jun-2000 #text_change 02-Jun-2000
 C.Accession: T49648
 R.Schulte, U.; Aigle, V.; Hoheisel, J.; Brandt, P.; Partmann, B.; Holland, R.; Nyakatura,
 submitted to the Protein Sequence Database, May 2000
 A.Reference number: Z25022
 A.Accession: T49648
 A.Status: preliminary
 A.Molecule type: DNA
 A.Residues: 1-2298 <SCH>
 A.Cross-references: EMBL:ALJ55933; GSPDB:GN00116; NCSP:B8B20.20
 A.Experimental source: BAC clone B8B20; strain OR74A
 C.Genetics:
 A:Gene: NCSP:B8B20.20
 A:Map position: 6
 A:Introns: 426/3

Query Match 3.9%; Score 111; DB 2; Length 2298;
 Best Local Similarity 19.3%; Pred. No. 22;
 Matches 114; Conservative 79; Mismatches 190; Indels 208; Gaps 28;

OY 78 PKLRLARGLSPA-----YLRFGTKYDFLIPDPKKESTFEERSYOSOV-NQDIC 127
 DB 1447 PAVDLIERLRTLSNMHKEACLINIRAMNOLARLYVNGSGSAPFPITRRNNVNOIJD 1506
 OY 128 KYGSIPDVEEKL-----LEMPYOELLREHYOKKRNSTYSSSVDLYTFAN 178
 DB 1507 QYMSAESDLEQDFRLSAENMSIDAANREELITN-----KATADLIJHTSAR 1555
 OY 179 CSGDLIFGLNL-----LRTADLQ-----NNSNAOLLDDCSSKGYNI 218
 DB 1556 AS-LDVLAQAKTLEAITYTLANTLOQKMTTLHFGSPGDKILNAL-----DTHAHL 1609
 OY 219 SN-ELGNEPNSFLKADIFINGSLGGEYIOLHKLKSTFNNAKLYGPDVGPARRTAK 277
 DB 1610 GWIFTSSEYOYSNNESSADIDRLEDALILQEKLTKEFFWMA-----RELLAL 1659
 OY 278 MLKSLKAGGEYID-SYVHHNYLNGRRATREDFLNPDVLDIFISSVOKFOVVESTRPG 336
 DB 1660 PLKAITTEGKQTEQYVACTEKTVTTLAKLAAR-----FIO--ERVTVLPYPOPG 1706
 OY 337 K-----KWLGETSSAYGGAPLLSDTFAAG-----FMALDK 368
 DB 1707 KYGLFPDPKRNKSGPERRL-----PLFIATLVNKNVDPFKDETILSLMWS 1755
 OY 369 LGLSAR-MGIEVYMRQVFFGAGNYHL--VDENFDLPDYWLSL-LFKKLVG--TRVL--- 419
 DB 1756 IKKPRFLGYETYLEAVLQORCLPFLADADVSAGMTPOVINHLDFSRAIHMYRKALRG 1815
 OY 420 -----MASVOGSK-----RRKLAVYLHCTNDPRYKESGLTLYALNLHVTYKL 464
 DB 1816 ATPPAGVYSSASTAGSSAOSIROREFSH----- 1847
 OY 465 RLPYFPNSKQVDKYLRLPG-----PHGLSKVOLNGLTKMVD-- 504
 DB 1848 TLQLAMTNIRKDLFLRELALADPRASSTEEHRODMATFHGLIS-LIASHGVIYVDSF 1906
 OY 505 -----DQTLPLMEKPLRPG-----SSLGPAFSYSP-FVIRANKVA 540
 DB 1907 FLTPSDSYSPLODQPLHTAGIMAYGVRLSEKDVPAASQLFWYLPNNPKVA 1957

RESULT 9
 E91031
 Probable outer membrane protein Ecs3221 [imported] - Escherichia coli (strain O15
 C.Species: Escherichia coli
 C.Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 18-Jul-2001
 C.Accession: E91031
 R.Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; He
 gasawara, N.; Yasunaga, T.; Kuhara, S.; Shibata, T.; Hattori, M.; Shinagawa, H.
 DNA Res. 8, 11-22, 2001
 A.Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 a
 A.Reference number: A99629; MUID:21156231; PMID:11258796
 A.Accession: E91031
 A.Status: preliminary
 A.Molecule type: DNA
 A.Residues: 1-879 <HAY>
 A.Cross-references: GB:BA000007; PIDN:BA836644.1; PID:913362691; GSPDB:GN00154
 A.Experimental source: strain O157:H7, substrain R1MD 0509952
 C.Genetics:
 A:Gene: Ecs3221

Query Match 3.9%; Score 109.5; DB 2; Length 879;
 Best Local Similarity 20.1%; Pred. No. 6.7;
 Matches 130; Conservative 68; Mismatches 208; Indels 241; Gaps 33;

OY 52 VSPFLSTTIANLATORPRLILGSPRLRLARGLSPAYLRFSGTKYDFLIPDPKKEST 111
 DB 20 MSGSYVNAWAEENIQFDSRFLELKGDKRI-DLKRPSGCGYEPG--RYNLQVOLNKPPLT 76
 OY 112 FEERSYOSOVNODICKGSIIPDVEEKL-----LEMPYOELLREHYOKKFKNS 163
 DB 77 EEYDIYWASENDASKYACLTPELVAFQGLKEDYAKRLQNIHQCKLAPQLE----- 130

OY 164 TYSSRSVDLYTFANCGLDIFGL-NALLFTADLQWNSN-----AQLLDYC----- 211
 DB 131 -----GIDIK--ADLSSALVLSLPQAVLETTDINMDPRSMWDGICSLINDYSTAOT 182
 OY 212 -----SSKGYNI-SWEL-GNEPNSFL--KKADIFINGSO----- 241
 DB 183 RHEENGDDSEISGNGFTGVNLAGMRLRADQDTLYLSKSNDDVDYINODDOTOKNWEMSR 242
 OY 242 -----LGEDYIOLHKLKSTF-----KKAALYGPV 268
 DB 243 YYAMRALPSLAKLGLGDDY-----LNSDIFDFGNVGGISTDDOMLPPMLRGYAPDI 296
 OY 269 GPRRRKTAKMLKSLKAGGEVI-----DSVTMHYLYNGLRATREDFLN 312
 DB 297 SGVAHTTAKVYSOL-----GRVYEVQVAGPFRIDLDGDSV-----SGLTHIIEEON 346
 OY 313 PDVLDIFISSYOKVFOVESTRPCK--KWL-----GETS----- 345
 DB 347 GOVEYDINTASMP-----LTPGQVRYKLMGPRQEMGHVEGFGSGEASMGIANGM 402
 OY 346 SAYGGAPLLSD-----TFPA-----GFMMLDKL-----GLSKR 374
 DB 403 SLYGGA---LADENYOSALGVRDLVSFGAFAFDITSHRFLDKETAYGKSGSLDGNFR 459
 OY 375 MGI-----EVMAROVFCAGNYHLVDENFDPLPDYMLSLFLFKLYGT---KVLMAVQGS 426
 DB 460 LSYKDPPELNSRYTFAG---YRSEENFMYSEF-LOASDEMYRTGNDKEMTYATYNO 515
 OY 427 KRRRLVYLCTNTDNPRYKEDLTLVAT-----NLHNVTK----- 462
 DB 516 NFRDQGVSVLYNTRHTYWDREOTNYVMLSHYENLGSIRMSISMGRYREYDNOADK 575
 OY 463 ---YLRLPYFNSKQVDKYLRLPHGLSKSVOLNGLTAKVDOOT 507
 DB 576 GVTYLSMPMGDSSTISY---NGMYGSGSDSOVG--YFSRVDDAT 616

RESULT 10

S74760

hypothetical protein slr1617 - *Synechocystis* sp. (strain PCC 6803)C:Species: *Synechocystis* sp.

C:Variety: PCC 6803

C:Date: 25-Apr-1997 #sequence_revision 25-Apr-1997 #text_change 08-Oct-1999

C:Accession: S74760

R:Keneko, T.; Sato, S.; Kotani, H.; Tanaka, A.; Asamizu, E.; Nakamura, Y.; Miyajima, N.;

O, K.; Okumura, S.; Shimpo, S.; Takeuchi, C.; Wada, T.; Watanabe, A.; Yamada, M.; Yasuda

DNA Res. 3, 109-136, 1996

A:Title: Sequence analysis of the genome of the unicellular cyanobacterium *Synechocystis*

S.

A:Reference number: S74322; MUID:97061201; PMID:8905231

A:Accession: S74760

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-411 <KAN>

A:Cross-references: EMBL:D90901; GB:AB001339; NID:g1651897; PIDN:BAA16911.1; PID:0101764

A>Note: the nucleotide sequence was submitted to the EMBL Data Library, June 1996

Query Match

3.8%; Score 108.5; DB 2; Length 411;

Best Local Similarity 21.4%; Pred. No. 2.5;

Matches 66; Conservative 55; Mismatches 94; Indels 93; Gaps 17;

OY 159 KFKNSTYSSVDLYTFANCGLDIF---GLNALLFTADLQWNSNAOL----- 206

DB 151 EFRLLISPTREOIDI---FAGSTKLDLASEENIDICIVHLANRVYTSNVAKGOTLTMLRN 207

OY 207 LLDVCSKSG---YNIWEL-----GNEPNSFLK-----ADIFINGSOIGE 244

DB 208 VIDVCLADIPLIYSSMEISYAGVTIHADESTPALPRGPYGETKIYLAELI----- 260

OY 245 DYIQLHKLKSTFKNALYGPVQOPRRKTKAKMLKSLKAGGEVIDSVTWHYLYNGLR 304

DB 261 DHCRTNCLRCALIRSSPVYSGMSDKP-----KTFNFKKASOGOKIVT--HHYING-- 311

OY 305 ATREDFLNPDV-----LDIFISSYOKVFOVESTRPCKVWLGETSSAYGCGAPLLSDTFA 360
 DB 312 -----NPKDLHLIDDLISSIVATL-----KSNFIGNLMI-----CGOLSSPLK 351
 OY 361 ACFMMLDKLIGLSA-----RMGIEVVMROVFCAGNYHLVDENFDPLPDYMLSLFLKLYG 415
 DB 352 IAEMLREDELSSSSMIQIQEVNTEVASIAMNYGRAN-HYLD-----WEPIFFE-QG 400
 OY 416 TKVLMASV 423
 DB 401 LKSLHLOI 408

RESULT 11

DB87541

beta-xyloridase [imported] - *Caulobacter crescentus*C:Species: *Caulobacter crescentus*

C:Date: 20-Apr-2001 #sequence_revision 20-Apr-2001 #text_change 20-Apr-2001

C:Accession: DB87541

R.Nierman, W.C.; Feldblyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Eisen, J.; Heidelberg

B.; Laub, M.T.; DeBoy, R.T.; Dodson, R.J.; Durkin, A.S.; Gwin, M.L.; Haft, D.H.

n, J.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser

Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001

A:Title: Complete Genome Sequence of *Caulobacter crescentus*.

A:Reference number: A87249; MUID:21173698; PMID:11259647

A:Accession: DB87541

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-500 <STO>

A:Cross-references: GB:AE005673; NID:g13423886; PIDN:AAK24328.1; GSPDB:GN00148

C:Genetics:

A:Gene: CC2357

Query Match

3.8%; Score 107.5; DB 2; Length 500;

Best Local Similarity 25.7%; Pred. No. 4;

Matches 56; Conservative 35; Mismatches 80; Indels 47; Gaps 15;

OY 165 TYSSRSVDLYTFANCGLDIFGLN---ALLFTAD---LOW--NSSNAOL-----LLD-- 209
 DB 81 YDMTKIDOLYDALAKGIKPIELGFTPEAMKTSQDTIFYMKGNYSHRKLGWRLLIDAF 140
 OY 210 -YCSSKGYNI-----SW-ELGNEPN--SFLKKADIFINGSOLEDYIOLHKLKSTFKN 260
 DB 141 VHLNLABYGVETVRWFPEVWNEPMLDGFWEKAD-----QAAYFELYDV---TARA 188
 OY 261 AKLYGPD--VGOPRRKTKAKMLKSL---KAGGEVIDSVTWHYLYNG---RTATREDPL 311
 DB 189 IKAIDPSLRVGGPATAGAWPEFLAHYKKSAGSADVTTHTYGVGGFLDEKGVQDTKL 248
 OY 312 NPDVLDIFISSYOKVFOVE--STRPGKVMYLGSETSSAY 348
 DB 249 SPSP-DAVVGDRRVREOIEASAPFGLPLPTWSTSY 285

RESULT 12

F85875

probable fimbrial usher Z3600 [imported] - *Escherichia coli* (strain O157:H7, substuC:Species: *Escherichia coli*

C:Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 14-Sep-2001

C:Accession: F85875

R.Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; J

iller, L.; Grobeck, E.J.; Davis, N.W.; Lim, A.; Diallanta, E.; Potamoukis, K.; Apr

Nature 409, 529-533, 2001

A:Title: Genome sequence of enterohemorrhagic *Escherichia coli* O157:H7.

A:Reference number: A85480; MUID:21074935; PMID:11206551

A:Accession: F85875

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-879 <STO>

A:Cross-references: GB:AE005174; NID:g12516702; PIDN:ANG57466.1; GSPDB:GN00145; UK

A:Experimental source: strain O157:H7, substrain EDL933

C:Genetics:

A:Gene: Z3600

A:Gene: ADL1; SPDB:SPBC405.01
A:Map position: 2
C:Superfamily: Saccharomyces cerevisiae ADE5 multifunctional protein: phosphoribosylamido
C:Keywords: cyclo-ligase; purine nucleotide biosynthesis
F:5-425/Domain: phosphoribosylamine-glycine ligase homology <PGL>
F:439-767/Domain: phosphoribosylformylglycinamide cyclo-ligase homology <PFCL>

Query March 3.7%; Score 104.5; DB 1; Length 788;

Best Local Similarity 27.7%; Pred. No. 13; Mismatches 114; Indels 33; Gaps 11;

Matches 70; Conservative 36; Mismatches 114; Indels 33; Gaps 11;

OY 297 HYLNGRTATRE--DPLNPDV-LDIFISSVOKVFOVEST--RPGKVMLETSSAY----- 348

DB 424 HHALNPKRKTREILREYSGSVSDNGNEVQIKDLVSTRPADADIGCGGIFDLKQ 483

OY 349 -GGAPLL-SDTFAAGFMKDLGASAR--MGIEVVMROVFFGAGNYHLVDENFPDL--P 402

DB 484 AGMNDPLVSAITDGVGSKLLIALSLNKHDTVCIDLVAMNV-----NDLVVOGAEPLIFL 537

OY 403 DYMLSLRLKLVGTAVLMASVQSGSKRRLRVYLHCTNTDNPRYKEGDLTLVAJNLHNVTK 462

DB 538 DIFATGSLDLKAVSTFVEGVAGCKQACGALVGETSEMPGLYHDSHYDANGTSVGAVSR 597

OY 463 YLRLPYPSNKOVDKYLRLPLGPHGLSKSVQNLGLTL--KNVD-----DQTLPLMEKPL 516

DB 598 DDILPKPESFSKGDILL-----GLASDGVHNGSVSLVRKIVEYSDLEYSVCPMKDV 650

OY 517 RPSGLGLPAFSY 529

DB 651 RLGDLSLIPTRIV 663

RESULT 15

F70411

adenylosuccinate synthetase - Aquifex aeolicus

C:Species: Aquifex aeolicus

C:Date: 08-May-1998 #sequence_revision 08-May-1998 #text_change 16-Jul-1999

C:Accession: F70411

R:Decker, G.; Warren, P.V.; Gaasterland, T.; Young, W.G.; Lennox, A.L.; Graham, D.E.; O'V.

Nature 392, 353-358, 1998

A:Title: The complete genome of the hyperthermophilic bacterium Aquifex aeolicus.

A:Reference number: A70300; MUID:98196666; PMID:9537320

A:Accession: F70411

A:Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-432 <AOE>

A:Cross-references: GB:AE000733; NID:g2983720; PIDN:AAC07286.1; PID:g2983724; GB:AE00065

A:Experimental source: strain VF5

C:Genetics:

A:Gene: pura

C:Superfamily: adenylosuccinate synthase

Query Match 3.7%; Score 104; DB 2; Length 432;

Best Local Similarity 23.9%; Pred. No. 5.8;

Matches 96; Conservative 39; Mismatches 128; Indels 138; Gaps 22;

OY 15 LLLGLPLGFLSPGALPRPAQADVDLD-----FFTQEPHLVSPS 55

DB 51 ILHLPLFTGILHEHVKGIVIAQGM-VVDLEVLHKEVKNLEEKGIYVKERLFTSDRAHLMPY 109

OY 56 PLSTVITDALNADPRFLILGSPK--LRTLARGLSPAYL-RFGCTKDFLIPDPKKESTF 112

DB 110 H-----KLLDSLFEKKKIGITTLKIGIPAYMEKYG--RKGIKISDLKDEKRF 154

OY 113 EERSYVQSOVNDICKYKGIIPDVEK-----LRLEMPYQEQLLREHYOKKFNSTY 165

DB 155 -----YTLLEDNLDIVK-----NICEKVCEKFDLDINOIYERQL---RYFEFEKENV- 199

OY 166 SNSSVDVLYTFANCSGLDLIFGLNALLRTADL---QMNSSNAQLLDYCSSKGYNISWE 221

DB 200 ----VDLBRFFNTQKGSVLEFGAOGTLDDVMGTYPYVTSNNSAL-----GLSNG 246

OY 222 LGNEPNSFLKKADIFING-----SOL-GEVDYIQLHKLRLKSTFKNAKLYG 265

DB 247 TGMPPKRYF---SDAFFLGVAKAYTTRVCEGPFPTLKEGEKEKLEL-----GGEYG 295

OY 266 PDVGOPRR---KTAKMLKSLKAGEVIDSVTHHHYILNGRTATREDEFLNP----- 313

DB 296 STTGRPRRCGLMDLVALKVAQVNG-----LDGFVITKLDVLDLPFDEVKCVVA 343

OY 314 -----DVLDFISSVOKVFOV--VESTRPGKKVMELETSSA 347

DB 344 YELDGEVIDYFPASTSELIRKVPYKTKLG---WKKSTKGA 381

Search completed: November 20, 2002, 11:38:11

Job time : 25 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:34:27 : Search time 14 Seconds

(without alignments)
1608.689 Million cell updates/sec

Title: US-09-759-207-2

Sequence: 1 MLRSKPLPPLPPLMLLGLP.....LPNFSYFVIRNAKAVACI 543

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database: SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	112.5	4.0	356	Y670_METUA	Q50804 methanococ
2	111	3.9	688	YB9F_YEAST	P38338 saccharomyc
3	105.5	3.7	1031	TEPT_EUPAE	O00939 euploetes ae
4	104.5	3.7	788	PUR2_SCHPO	P20722 s bifuncio
5	104	3.7	432	PUR2_KOUAE	O67321 aquifex ae
6	104	3.7	716	RRP2_IATKI	O91742 influenza a
7	103	3.6	796	PKH_CLOAB	O97363 clostridium
8	100.5	3.5	805	GYRB_CHLPM	O92883 chlamydia p
9	99.5	3.5	837	XYNZ_CLOTM	P10478 clostridium
10	99	3.5	897	DYHC_HUMAN	Q14204 homo sapien
11	99	3.5	4644	DYHC_RAT	P38650 ratius nov
12	98.5	3.5	629	T3MH_HAEIN	P71366 haemophilus
13	98.5	3.5	654	N05M_RHIST	P50367 rhizopus st
14	98.5	3.5	746	RHTA_RHIME	O92395 rhizobium m
15	98	3.4	716	RRP2_IATVI	P31343 influenza a
16	97.5	3.4	454	YUAE_CAEFL	P53715 caenorhabdi
17	97.5	3.4	804	GYRB_CHLTR	O84193 chlamydia t
18	97.5	3.4	1314	SS22_YEAST	P25390 saccharomyc
19	96.5	3.4	595	THIC_BACHD	O94804 bacillus ha
20	96	3.4	327	XYNA_ASPAC	O95859 aspergillus
21	96	3.4	557	COX1_NEUCR	P03945 neurospora
22	96	3.4	716	RRP2_IATZI	P31175 influenza a
23	96	3.4	1044	ITAV_MOUSE	P43406 mus musculu
24	95.5	3.4	358	VAL1_BCTV	P14991 beet curly
25	95.5	3.4	620	HEMA_MEASY	P28081 measles vir
26	95.5	3.4	5255	BACA_BACLI	O68006 b bacillaci
27	95	3.3	716	RRP2_IAKOR	P13170 influenza a
28	95	3.3	772	LP1G_DROME	P11997 h sortillia
29	95	3.3	2214	SORL_HUMAN	O92673 h sortillia
30	95	3.3	4644	DYHC_MOUSE	O91bud mus musculu
31	94.5	3.3	437	INV2_DAUCA	Q33619 daucus caro
32	94	3.3	437	ERF1_XENLA	P35615 xenopus lae
33	94	3.3	804	GYRB_CHLMU	O9pkk3 chlamydia m

ALIGNMENTS

RESULT 1	ID	Y670_METUA	STANDARD:	PRT:	356 AA.
AC	O50804	Y670_METUA			
DT	01-NOV-1997	(Rel. 35, Created)			
DT	01-NOV-1997	(Rel. 35, Last sequence update)			
DT	16-OCT-2001	(Rel. 40, Last annotation update)			
DE	Hypothetical protein M0670.				
CN	M0670.				
OS	Methanococcus jannaschii.				
OC	Archaea: Euryarchaeota: Methanococci: Methanococcales:				
OC	Methanocaldococcaceae: Methanocaldococcus.				
OX	NCBI_TaxID=2190;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN-JAL-1 / DSM 2661 / ATCC 43067;				
RX	MEDLINE=96337999; PubMed=6688087;				
RA	Bult C.J., White O., Olsen G.-J., Zhou L., Fleischmann R.D.,				
RA	Sutton G.G., Blake J.A., Fitzgerald L.M., Clayton R.A., Gocayne J.D.,				
RA	Kerlavage A.R., Dougherty B.A., Tomb J.F., Adams M.D., Reich C.I.,				
RA	Overbeek R., Kirkness E.F., Weinstock K.G., Merrick J.M., Glodek A.,				
RA	Scott J.L., Geoghagen N.S.M., Weidman J.F., Fuhrmann J.L., Nguyen D.,				
RA	Uutterback F.R., Kelley J.M., Peterson J.D., Sadow P.W., Hanna M.C.,				
RA	Cotton M.D., Roberts K.M., Hurst M.A., Kalne B.P., Borodovsky M.,				
RA	Klenk H.-P., Fraser C.M., Smith H.O., Weese C.R., Venter J.C.;				
RT	"Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii".				
RL	Science 273:1058-1073(1996).				
CC	-----				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -				
CC	the European Bioinformatics Institute. There are no restrictions on its				
CC	use by non-profit institutions as long as its content is in no way				
CC	modified and this statement is not removed. Usage by and for commercial				
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/				
CC	or send an email to license@isb-sib.ch).				
CC	-----				
DR	EMBL: U67514; AAB98664.1; -				
DR	TIGR: M0670;				
DR	InterPro: IPR000051; SAM_bind.				
KW	Hypothetical protein; Complete proteome.				
SO	SEQUENCE 356 AA; 41683 MW; D7B8BA2E16A92E11 CRC64;				
Query Match	4.0%: Score 112.5; DB 1; Length 356;				
Best Local Similarity	21.2%: Pred. No. 0.38;				
Matches	85; Conservative 48; Mismatches 143; Indels 125; Gaps 18;				
OY	126 ICKY-----GSTPDVEKRLRWYQDOLLRHYKKFNSTYSRSSVD-----				083062 treponema p
DB	14 IRKWKIKYNGKNEKDIKRLIKE-----LKEEIVLVEEDGYTTLKAEDDEEMHNSKV 66				P33277 schizosacch
OY	172 -----VLTFFANGSGLDLIFGNAALRTADLQWNSNMQLLDDCSSGYNINSMELGNEP 226				O9pk60 chlamydia m
DB	67 GALKKATYKFKPS-----KITDL-----SNPR-VLDLCSGNGYNALALAHYNK 109				O9pk60 mus musculu
OY	227 NS-----FL-----KKRADIFNGSOLGEDYIQLHLKLRKSTF 258				P13029 escherichia


```

Db 110 NAEDIVEICEVLFLLFLDIPYKEHEIITKDKVREYFLN--KIGLEY-----KSDY 159
Oy 259 KNAKLYPDVGOQPRKRTAKMLKSLKAGGEYIDVTWHYHLYNGRTAT--REDFLNDVL 316
Db 160 DNINLY---VGDAKKFKTKSDKKY-----NVVHDAFSPKRDPTLYTYDFL----- 202
Oy 317 DIFISSVQKVOVESTRPCKKVLGDTSSAYGGCAGLLSDTPAGFPMILDKGLSARMG 376
Db 203 -----KEIYKRMEDN--GYLI-----SYSAIPFRSALVDCGFISEKESVGKRG 246
Oy 377 IEVVMROVFFGAGNVYHLVDENFD-----PLDPYMLSLFKLVGTRKVLMAVQSGRR 429
Db 247 ITLAKKKNPKPNRINNEVDREVIALSVIALPYRDETLSLKDKIITEDREPREKXKLI 306
Oy 430 KLRVYLHCTNTDNPRIYEGSLIYLA--INLHNTKYLRLPY 468
Db 307 KICKYLTSTQIKKGNIPETILKIQEKEDLNSSEIHKMKLKF 347

```

RESULT 2

```

YB9F_YEAST          STANDARD:          PRT:          688 AA.
ID YB9F_YEAST
AC P38338;
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last annotation update)
DE Hypothetical 80.4 kDa protein in POP4-SH1L intergenic region.
GN YBR259W OR YBR1727.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932.
RN 111
RP SEQUENCE FROM N.A.
RC STRAIN=5288C;
RC MEDLINE=93220397; PubMed=8465606;
RA Doignon F., Bileau N., Crouzet M., Aigle M.;
RT "The complete sequence of a 19,482 bp segment located on the right
RT arm of chromosome II from Saccharomyces cerevisiae."
RT Yeast 9:189-199(1993).
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: X70529; CAA49923.1; -
CC DR EMBL: Z36128; CAA85222.1; -
CC DR PIR: S12961; S32961.
CC DR SCD: S0000463; YBR259W.
CC KW Hypothetical protein.
CC SEQUENCE 688 AA: 80426 MW: 0BA84837BD7AAB30 CRC64;

```

Query Match

3.9%: Score 111; DB 1; Length 688;

Best Local Similarity 22.5%: Pred. No. 1.3;

Matches 67; Conservative 45; Mismatches 94; Indels 92; Gaps 16;

```

Oy 126 ICAYGSIIPDVEEKLRLLEMPYQEOQLLREHYOKKFKNSYSSRS-----VVLVT 175
Db 164 MAEYSSMKWSDSKROQFYEFPRMKLECLVAFYENFDLOKSSDPLKELIIPWEKIVY 223
Oy 176 FANCSGDLIFGLMALRLTADLOMNSN-----AQLLD-----YSSKCY----- 216
Db 224 -ANC--IDAFTEGQVRIDGELIWTSKNLVFSISSAVLRLNDLOMNSAFPRYGEALY 280
Oy 217 -----NISWELGNENPSFLKKA--DIF--INGSOIG--EDYIOLHKLRLK----- 255
Db 281 QDFAHRSILKWDNSNDKVESILRALIRNDMPYFNKEQVDTKADGIFFLRLRNFKREHIN 340

```

```

Oy 256 -----STFKN--AKLYGPDVGOQPRKRTAKMLKSLKAGGEY-----IDSV 293
Db 341 DVKDFHIQVLYKXINLQSOFKNNYSTLMTSSKTQDRKSNHNPSSLLDQGNKGHMYSPIDE- 399
Oy 294 TWHHYLLNG-----RTATREDFLNDVLDIFISSVQKVOVESTR---PGK 338
Db 400 -YSHFIDNDEPLMRDQVYPRKTYTNEQTPPDASAIFDS--HKIYAIISLRYLPEKR 454

```

RESULT 3

```

TERT_EUPAE          STANDARD:          PRT:          1031 AA.
ID TERT_EUPAE
AC 000939;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE Telomerase reverse transcriptase (EC 2.7.7.-) (Telomerase catalytic
DE subunit) (telomerase subunit p123).
OS Euplotis aediculatus.
OC Eukaryota; Alveolata; Ciliophora; Spirotrichea; Hypotrichia;
OC Euplotida; Euplotidae; Euplotes.
OX NCBI_TaxID=5940;
RN 111
RP SEQUENCE FROM N.A.
RC MEDLINE=97274210; PubMed=9110970;
RA Lingner J., Hughes T.R., Shevchenko A., Mann M., Lundblad V.,
RA Cech T.R.;
RT "Reverse transcriptase motifs in the catalytic subunit of
RT telomerase."
RT Science 276:561-567(1997).
CC -1- FUNCTION: TELOMERASE IS A RIBONUCLEOPROTEIN ENZYME ESSENTIAL FOR
CC THE REPLICATION OF CHROMOSOME TERMINI IN MOST EUKARYOTES. IT
CC ELONGATES TELOMERES. IT IS A REVERSE TRANSCRIPTASE THAT ADDS
CC SIMPLE SEQUENCE REPEATS TO CHROMOSOME ENDS BY COPYING A TEMPLATE
CC SEQUENCE WITHIN THE RNA COMPONENT OF THE ENZYME.
CC -1- SUBCELLULAR LOCATION: Nuclear.
CC -1- SIMILARITY: BELONGS TO THE REVERSE TRANSCRIPTASE FAMILY.
CC
CC TELOMERASE SUBFAMILY.

```

```

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: U95964; AAC47515.1; -
CC DR InterPro: IPR000477; RVISE.
CC DR InterPro: IPR003545; Telomerase_RT.
CC DR Pfam: PF00078; ryl: 1.
CC DR PRINTS: PR01365; TELOMERASERT.
CC KW Transferase; RNA-directed DNA polymerase; Telomere; Nuclear protein;
CC DNA-binding.
CC SEQUENCE 1031 AA: 122562 MW: 57B87A63A1PED60F CRC64;

```

Query Match

3.7%: Score 105.5; DB 1; Length 1031;

Best Local Similarity 20.9%: Pred. No. 6;

Matches 81; Conservative 56; Mismatches 133; Indels 117; Gaps 17;

```

Oy 102 LIFDPKKESTFEERSYQSOVNODICKYGSIPDVEEKLRLLEMPYQEOQLLREHYOKKFK 161
Db 694 LIVEAKQNRNYFFKNDLQGVIN--ICQYNYI-----NENKRY 729
Oy 162 NST-----YSSSDVLYTFPANCGLDIF-----GLNALRTAD-----LOVN 200
Db 730 KQTKGIPQGLCVSSILSSFYATLESSSLGFLRDESMNPENNVNLMRLTDYLLITQ 789
Oy 201 SSNAOLLIDYSSKGINISWELGNE-----PNSFLKKAADIFINSGOGEYI 247
Db 790 ENNAVLFIE---KLINVSRENGKFFPMKKLQTSPLPSFKAKGMSVEQONIVQDYC 845
Oy 248 QL-----HKLRLKSTFKNAKLYG---PDVGQPRKRTA---KMLKSLKAGGEYIDSV 293

```

```

DB      846 DWIGISIDKLTALMPNINLIEGILCTLNLNMQKASMWMLKKLSFL-----MNNI 899
OY      294 TNNHHYLNCRATREDFLNPDVLDIFISSVQVFOVESTROCKKVMGLGETSSATGCGAP 353
DB      900 T--HYF--RKITTEDFANKTLNKLFLISGVYKMOCAKCYKDKHFKNNLMSMIDLEYSK 955
OY      354 LTSDFFAAGFMWLDKLGISARMGIEVVMQVFFGAGNLYLVNDPDLDPYLSLL----- 409
DB      956 ILYSTRAFFKYL-----VCNLDITFGEERH-----PDFLSTLTKHFI 994
OY      410 ----FKLVGTRVLMASVQGSRRKRLR 432
DB      995 EIFSTKKYIFNRVCM--ILKAKEAKLK 1019

RESULT 4
PURA_SCHPO STANDARD: PRT: 788 AA.
AC P20772: 09UUM5:
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DE 15-JUN-2002 (Rel. 41, Last annotation update)
DE Bifunctional purine biosynthetic protein Ade1 [includes:
DE Phosphoribosylamine--glycine ligase (EC 6.3.4.13) (GARS) (Glycinamide
DE ribonucleotide synthetase) (Phosphoribosylglycinamide synthetase);
DE Phosphoribosylformylglycinamide cyclase (EC 6.3.3.1) (AIRS)
DE (Phosphoribosyl-aminohimadazole synthetase) (AIR synthase)].
GN ADE1 OR SPBC4Q3.02C OR SPBC405.01.
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota: Fungi: Ascomycota: Schizosaccharomycetes:
OC Schizosaccharomycetales: Schizosaccharomycetaceae:
OC Schizosaccharomyces.
OX NCBI_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=972.
RX MEDLINE=89003164; PubMed=3502942;
RT McKenzle R., Schuchert P., Kibbey B.;
RT "Sequence of the bifunctional ade1 gene in the purine biosynthetic
RT pathway of the fission yeast Schizosaccharomyces pombe.";
RL Curr. Genet. 12:591-597(1987).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=972.
RX MEDLINE=21848401; PubMed=11859360;
RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
RA Sgouros J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA Collins M., Connor R., Cronin A., Davis P., Fellwell T., Fraser A.,
RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holtroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinowitsch E.,
RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
RA Skelton J., Simmonds M., Squares R., Squares S., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA Woodward J., Volckaert G., Aert R., Robben J., Grymoprez B.,
RA Wellens J., Vanstreels E., Rieger M., Schaefer M., Mueller Auer S.,
RA Gabel C., Fuchs M., Fritzc C., Holzer E., Moestl D., Hilbert H.,
RA Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R., Pohl T.M.,
RA Eger P., Zimmermann W., Medler H., Wambutt R., Purnelle B.,
RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaue V., Mottier S.,
RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas M., Rochet M., Galliard C., Tallada V.A., Garcon A., Rhode G.,
RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L.,
RA Cerrutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
RA Shpakovski G.V., Ussery D., Barrell B.G., Nurse P.;
RA "The genome sequence of Schizosaccharomyces pombe.";
RL Nature 415:871-880(2002).
-i- CATALYTIC ACTIVITY: ATP + 5-phospho-D-ribosylamine + glycine = ADP

```

```

CC      + phosphate + N(1)-(5)-phospho-D-ribosylglycinamide.
CC      -i- CATALYTIC ACTIVITY: ATP + 2-(formamido)-N(1)-(5)-phospho-D-
CC      ribosyl)acetamide = ADP + phosphate + 5-amino-1-(5-phospho-D-
CC      ribosyl)imidazole.
CC      -i- PATHWAY: De novo purine biosynthesis: second step.
CC      -i- PATHWAY: De novo purine biosynthesis: fifth step.
CC      -i- SIMILARITY: IN THE N-TERMINAL SECTION: BELONGS TO THE GARS FAMILY.
CC      -i- SIMILARITY: IN THE C-TERMINAL SECTION: BELONGS TO THE AIRS FAMILY.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (see http://www.isb.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
DR      EMBL: X06601; CAA29820.1; -
DR      EMBL: AL021730; CAA16823.1; -
DR      EMBL: AL035655; CAB38600.1; -
DR      PIR: S00652; S00652.
DR      HSSP: P08178; ICL1.
DR      InterPro: IPR000728; AIRS-related.
DR      InterPro: IPR000115; Gars.
DR      InterPro: IPR004733; PurM_c1igase.
DR      Pfam: PF00586; AIRS.1.
DR      Pfam: PF01071; GARS.1.
DR      Pfam: PF02769; AIRS_C.1.
DR      Pfam: PF02842; AIRS_B.1.
DR      Pfam: PF02843; GARS_C.1.
DR      Pfam: PF02844; GARS_N.1.
DR      TIGRfams: TIGR00877; purD.1.
DR      TIGRfams: TIGR00878; purM.1.
DR      PROSITE: PS00184; GARS.1.
KW      Multifunctional enzyme; Purine biosynthesis; Ligase.
FT      DOMAIN 1 430
FT      DOMAIN 2 440 750
FT      DOMAIN 3 750 850
SO      SEQUENCE 788 AA; 85231 MM; 0PDE64E5A5F9095D CXC64;

Query Match 3.7%; Score 104.5; DB 1; Length 788;
Best Local Similarity 27.7%; Pred. No. 4.8;
Matches 70; Conservative 36; Mismatches 114; Indels 33; Gaps 11;

OY      297 HYLYNGRTATRE--DELMPDV-LDIFISSVQVFOVEST--PPGKKVMGLGETSSAY---- 348
DB      424 HHALPKRRTREILTYEVSQVSDNGNEFVORIKDLVSTRPPGADADGGFGGIFDLKO 483
OY      349 -GGGAPLL-SDFFAAGFMWLDKLGISAR--MGIEVVMQVFFGAGNLYLVNDPDL--P 402
DB      484 AGWNPPLVYASNDVGSKLLALSLNKHDTVGIDLVANV-----NDLVYGAERPLFL 537
OY      403 DYWLSLKRKLVGTRVLMASVQGSRRKRLRYVLRHCTNTDNPYKGGDLTLVAIINLHNTK 462
DB      538 DYFAGSIDLKAKSTSEFVGVYVKGCKQACALVGGTSEMPGLYHGHYDANCTSGAVSR 597
OY      463 YLRLPYPSNKQVDYVLLRLPLGPHGLSKSVQNLGTLT--KWDV-----DQTLPLMEXPL 516
DB      538 DDILKRPESFSKGLDILL-----GLASGVHNSGYSLVRKLEYSDLEITYSVCPKMN 650
OY      517 RFGSSILGLPASY 529
DB      651 RIGDSLILPTRY 663

RESULT 5
PURA_AOUAE STANDARD: PRT: 432 AA.
AC 067321:
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DE 16-OCT-2001 (Rel. 40, Last annotation update)
DE Adenylosuccinate synthetase (EC 6.3.4.4) (IMP--aspartate ligase)
DE (AASS) (AMPase).

```

GN .PURA OR AQ_1290.
 OC Aquifex aolicus.
 OS Bacteria; Aquificae; Aquificae (class); Aquificales; Aquificaceae;
 OC Aquifex.
 OX NCBI_TaxID=63363:
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-VF5:
 RX MEDLINE=98196666: PubMed=9537320;
 RA Deckert G., Warren P.V., Gaasterland T., Young W.G., Lenox A.L.,
 RA Graham D.E., Overbeek R., Sneed M.A., Keller M., Anujay M., Huber R.,
 RA Feldman R.A., Short J.M., Olson G.J., Swanson R.V.;
 RT "The complete genome of the hyperthermophilic bacterium Aquifex
 aolicus".
 RT Nature 392:353-358(1998).
 RL Nature 392:353-358(1998).
 CC -I- FUNCTION: PLAYS AN IMPORTANT ROLE IN THE DE NOVO PATHWAY OF PURINE
 CC NUCLEOTIDE BIOSYNTHESIS.
 CC -I- CATALYTIC ACTIVITY: GTP + IMP + L-aspartate = GDP + phosphate +
 CC adenylosuccinate.
 CC -I- PATHWAY: AMP biosynthesis; first committed step.
 CC -I- SIMILARITY: BELONGS TO THE ADENYLOSUCCINATE SYNTHETASE FAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: AE000733; AAC07286.1;
 CC HSP: P12283.1ADE.
 DR InterPro: IPR001114: Asucc_synthase.
 DR Pfam: PF00709: Adenylosucc_synth.1.
 DR ProDom: PD001188: Asucc_synthase; 1.
 DR TrEMBL: TIGR00184: pura; 1.
 DR PROSITE: PS01266: ADENYLOSUCIN_SYN_1; 1.
 DR PROSITE: PS00513: ADENYLOSUCIN_SYN_2; 1.
 DR Purine biosynthesis: Ligase: GTP-binding: Complete proteome.
 FT NP_BIND 12 18 GTP (POTENTIAL).
 FT ACT_SITE 137 137 BY SIMILARITY.
 FT ACT_SITE 144 144 BY SIMILARITY.
 SO SEQUENCE 432 AA: 48854 MW: ACA52CE913DE62E7 CRC64:
 Query Match 3.7%: Score 104; DB 1; Length 432;
 Best Local Similarity 23.9%: Pred. No. 2.2; Mismatches 128; Indels 138; Gaps 22;
 Matches 96; Conservative 39; Mismatches 128; Indels 138; Gaps 22;
 OY 15 LLLSLPLSPGALPRPAODVVDL-----FTQEPHLVSPS 55
 DB 51 LHLPLPTGLIHEHVGVIAGQM-VVDLEVLHKEVKNLEKGIYKRLFISDRALHVMY 109
 OY 56 FLSTVITDANLATPRLPILLSGPK-LRTLANGLSPAYL-RFGGKTDFLIDPKKESFP 112
 DB 110 H-----KLLDSLFEKKKIGITTLRGIGRAYMFKYG-RKGRISDLDEKRF 154
 OY 113 EERSYWGQOVNODICKYGSIPPDVEEK-----LRLKPYQEOALLRHYYOKKFRNSY 165
 DB 155 -----YTLLEDNLDFVK-----NICEKYFCEKFDLDINOYEOL-RYEEREPEN- 199
 OY 166 SRSDVAVLYTFANCSGLDIFGLNALLRTADL-----QWSSNAOLLIDYCSSKGYNISWE 221
 DB 200 -----VDLLRFNTOKGVSIFEGACGTLDDVDMGTTPYVYSSNASL-----GLSMG 246
 OY 222 LCNERNPSFLKKADIFING-----SOL-GEDEVYQLHKLKSTFKNAKLYG 265
 DB 247 TCMPPRYF-----SDAFFLGAKAAYTRVGEGRPTTELKGECKELREL-----GGEYG 295
 OY 266 PVOGPRR-----KTAKMLSFLLKAGEVIDSVTHNYHLLNGRTAFREDFLNP----- 313
 DB 296 STTGRRRCGMIDLVALKAAYOVN-----LDGEVYITLVDLDTFDEVKVCVA 343
 OY 314 -----DVLDIFISSVOKVFOV-----VESTPRGKKVMLEGTSSA 347

DB 344 YELDGEVIDYFPAVSSELRVAPVYTKLNG-----WKSTGGA 381
 RESULT 6
 RRP2_IAKIT
 ID RRP2_IAKIT STANDARD: PRT: 716 AA.
 AC 091742:
 DT 30-MAY-2000 (rel. 39, Created)
 DT 30-MAY-2000 (rel. 39, Last sequence update)
 DT 15-JUN-2002 (rel. 41, Last annotation update)
 DE RNA-directed RNA polymerase subunit p2 (EC 2.7.7.48) (Polymerase
 DE acidic protein) (PA).
 OS Influenza A virus (strain A/Kitakyushu/159/93).
 OS viruses: ssRNA negative-strand viruses: Orthomyxoviridae;
 OC Influenza A viruses; Influenzavirus A.
 OX NCBI_TaxID=62478;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=98406205: PubMed=9733841;
 RA Lindstrom S.E., Hiromoto Y., Nerome R., Omoe K., Sugita S.,
 RA Yamazaki Y., Takahashi T., Nerome K.;
 RT "Phylogenetic analysis of the entire genome of Influenza A (H3N2)
 RT viruses from Japan: evidence for genetic reassortment of the six
 RT internal genes".
 RT J. Virol. 72:8021-8031(1998).
 RL -I- CATALYTIC ACTIVITY: N nucleoside triphosphate +
 CC (RNA)(N).
 CC -I- SUBUNIT: INFLUENZA RNA POLYMERASE IS COMPOSED OF THREE SUBUNITS:
 CC P1 (OR PB1), P2 (OR PA), AND P3 (OR PB2).
 CC -I- SIMILARITY: BELONGS TO THE INFLUENZA VIRUSES POLYMERASE PA FAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: AF037424; AAC63455.1;
 DR InterPro: IPR001009: RNA_pol_p2.
 DR Pfam: PF00603: Flu_PA.1.
 DR Transferase: RNA-directed RNA polymerase.
 SO SEQUENCE 716 AA: 82749 MW: 51A8D9A74AB5159 CRC64:
 Query Match 3.7%: Score 104; DB 1; Length 716;
 Best Local Similarity 19.7%: Pred. No. 4.5;
 Matches 102; Conservative 78; Mismatches 194; Indels 144; Gaps 25;
 OY 57 LSVITDANLATPRLPILLSGPKLRTLANGLSPAYLRFGGTDTDFLIDPKKESFPERS 116
 DB 253 VNAKIEPFLKTPRPRIKLPNG-----PCYOR-----SKFLMDALKLSTED--- 294
 OY 117 YWQOVNODICKYGSIPPDVEEKLRLKPYQEOALLRHYYOKKFRNSYSSRVLYTF 176
 DB 295 -----PSHDEGCIPLDYAI-----KCIPTFGWKRPYIVKPR-EKGINSTNLMSKOVLAEL 345
 OY 177 ANCSGLDIFGLNALLRTADLQW-----NSSNAOLLIDYCSS-KGYN-----IS 219
 DB 346 ODIEEKEKIPRTKNMKTSOLKWLALGEMNAPKVDFOKROISDLKOVDSDEPELRLSS 405
 OY 220 WELGNEPNSFLKKAD-ITINGSQLEDYIQLHKL-LKSTFKNAKLYGPDVGOPRRRTA 276
 DB 406 W-IQNEFKACELDTSIIEDEIGEDVAPLEYIASMRNPF-----TA 448
 OY 277 KMLKSFLLKAGEVIDSVTHNYHLLNGRTAFREDFLNPVDLFISSVOKVFOVESTPRG 336
 DB 449 EV-SHCATEYIMNGVYINTALLNASCANDDP-----LIPMISK-----RTREG 494
 OY 337 KKVVLGETSSAYG-----GAPLLSDTFAAGFMALDKLGLSARMGIEVVMROYFCAGNYH 392
 DB 495 RR-----KTNLYGFTIKGRSHLRNDTVVNFVSM-----FS 526

```

OY 393 LVDENPDPLOYWLSLKKLVGTAKVASVCGSKRRKRLVYLACTNTDNPRIKEDDTL 452
DB 527 LTPDPLE--PHKWEKYCVLEI--GDMILRSAGIOMSRPMFLVVRNGTSKIMKWMENR 582
OY 453 YAI--NLNINVTYLRPLPFPKSNKOVDKYLR-----PLG--PHG-----LLS 490
DB 563 RCLDSLOOIESMIAEBSVREKMDTKKEFFENKSEMPGEGSPKVEGSGIKVCTLLA 642
OY 491 KSV-----OLNGLJLKMVDQTLPLPMKPLRPGS 520
DB 643 KSVFNSLYASPOLGEGFSAESRKLVLVQALRDNLPGCT 680

```

RESULT 7

```

PHK_CLOAB STANDARD: PRT: 796 AA.
ID PHK_CLOAB
AC 097JEB3:
DT 15-JUN-2002 (Rel. 41, Created)
DT 15-JUN-2002 (Rel. 41, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Probable phosphoketolase (EC 4.1.2.*).
GN CAC1343.
OS Clostridium acetobutylicum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=1488;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-ATCC 824 / DSM 792 / VKM B-1787;
RX MEDLINE=21359325; PubMed=11466286;
RA Noelling J., Breton G., Omelchenko M.V., Makarova K.S., Zeng O.,
RA Glison R., Lee H.M., Dubois J., Oiu D., Hiltl Y.I.,
RA Tatusov R.L., Sabathe F., Doucette-Stamm L., Soucaille P., Daly M.J.,
RA Bennett G.N., Koonin E.V., Smith D.R.;
RT "Genome sequence and comparative analysis of the solvent-producing
RT bacterium Clostridium acetobutylicum."
RL J. Bacteriol. 183:4823-4838(2001).
CC -1- COFACTOR: Thiamine pyrophosphate (Potential).
CC -1- SIMILARITY: BELONGS TO THE XFP FAMILY.
CC
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: AE007645; AAK79311.1;
DR PROSITE: PS60002; PHOSPHOKETOLASE_1; 1.
DR PROSITE: PS60003; PHOSPHOKETOLASE_2; 1.
DR PROSITE: PS00187; TTP_ENZYMES; FALSE_NEG.
KW Lyase; Flavoprotein; Thiamine pyrophosphate; Complete proteome.
SQ SEQUENCE 796 AA: 90640 MW: 488219DC9778FAEF CRC64;

```

Query Match

Best Local Similarity 3.6%; Score 103; DB 1; Length 796;
Matches 77; Conservative 51; Mismatches 114; Indels 114; Gaps 18;

```

OY 27 GALPPAQAQDVDDPFFQEPILHLVSPFLSVTIDA--NLATDPRF-LILGSPKLT 82
DB 238 GKKPFVEGEDPEYHMKLMAETLDIVTEILMIQNAKARNNDCCSRKPMIYLRTPK--- 294
OY 83 LARGSPAYLRFSGTGTDFLJDPKKESTFEERSYQWQOVNDICKYGSIPDVEKTL 142
DB 295 -----GMTGPRFV-----DGVNCGSFRAHQVPLAVDRYHTENDQLE--- 332
OY 143 EM--PYQEQLLREHYQ--KKFKNSTYSSSVADVLYTFANCGDLITGLNALLTADQ 198
DB 333 EMLKSYKDEELFEDENYRLIPELELTLPKGNKRMANLIAN--GGL-----LRLRLTPDDR 386
OY 199 WNSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFNGSOLGEDYIQLHKLLR---- 254

```

```

DB 387 -----DYA-----VDVFPGSTVQDMIELKYYKDVYK 415
OY 255 -KSTFRNAKLYGD-----VGOPRRKTAKMLK---SFLKAGEVIDSVTWHN-- 297
DB 416 LMEDRNRFRIFCPDEFMSNRMLWAVEFGTRKRWMLSEIKENDFELSDGRIVDSMLSEHLIC 475
OY 298 -----YYLNGRTATREDPLNDVLDIFISSYQKQFOYVES--TRGRKVMLGERS 345
DB 476 EGMLEGYLLTGRHG-----FFASYEAPLRIYDSMTIOHGK--WLKVTY 516

```

RESULT 8

```

GYRB_CHLPN STANDARD: PRT: 805 AA.
ID GYRB_CHLPN
AC Q92BR3: Q9J044;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE DNA gyrase subunit B (EC 5.99.1.3).
GN GYRB OR CP04275 OR CP0484.
OS Chlamydia pneumoniae (Chlamydia pneumoniae).
OC Bacteria; Chlamydiales; Chlamydiaceae; Chlamydia.
OX NCBI_TaxID=83558;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-CWL029;
RX MEDLINE=99206606; PubMed=10192388;
RA Kalman S., Mitchell W., Marathe R., Lammell C., Fan J., Hyman R.W.,
RA Olinger L., Grimwood J., Davis R.W., Stephens R.S.;
RT "Comparative genomes of Chlamydia pneumoniae and C. trachomatis."
RL Nat. Genet. 21:385-389(1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN-AR39;
RX MEDLINE=20150255; PubMed=10684935;
RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,
RA White O., Hickey E.K., Peterson J., Utterback T., Berry C., Bass S.,
RA Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,
RA Gwin M., Nelson W., Deboy R., Kolonay J., McClarty G., Salzberg S.L.,
RA Eisen J., Fraser C.M.;
RT "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia
RT pneumoniae AR39."
RL Nucleic Acids Res. 28:1397-1406(2000).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN-J138;
RX MEDLINE=20330349; PubMed=10871362;
RA Shirai M., Hirakawa H., Kimoto M., Tabuchi M., Kishi F., Ouchi K.,
RA Shiba T., Ishii K., Hattori M., Kuhara S., Nakazawa T.;
RT "Comparison of whole genome sequences of Chlamydia pneumoniae J138
RT from Japan and CWL029 from USA."
RL Nucleic Acids Res. 28:2311-2314(2000).
CC -1- FUNCTION: DNA GYRASE NEGATIVELY SUPERCOILS CLOSED CIRCULAR DOUBLE-
CC STRANDED DNA IN AN ATP-DEPENDENT MANNER AND ALSO CATALYZES THE
CC INTERCONVERSION OF OTHER TOPOLOGICAL ISOMERS OF DOUBLE-STRANDED
CC DNA RINGS, INCLUDING CATENANES AND KNOTTED RINGS.
CC -1- CATALYTIC ACTIVITY: ATP-dependent breakage, passage and rejoining
CC of double-stranded DNA.
CC -1- SUBUNIT: MADE UP OF TWO CHAINS. THE A CHAIN IS RESPONSIBLE FOR DNA
CC BREAKAGE AND REJOINING; THE B CHAIN CATALYZES ATP HYDROLYSIS. THE
CC ENZYME FORMS AN A2B2 TETRAMER.
CC -1- SIMILARITY: BELONGS TO THE TYPE II TOPOISOMERASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: AE001612; AAD18424.1; -

```

DR EMBL: AE002210; AAF38314.1; -
 DR EMBL: AP002546; BAA98485.1; -
 DR HSSP: P06982; 1A56.
 DR PHCI-2DPAGE: 0928R3; -
 DR TIGR: CP0484; -
 DR InterPro: IPR003594; ATPbind_ATPase.
 DR InterPro: IPR002288; DNA_gyraseB_C.
 DR InterPro: IPR001241; DNA_topoisomII.
 DR InterPro: IPR002936; DNAPrim_toprim.
 DR Pfam: PF00204; DNA_gyraseB_C.1.
 DR Pfam: PF00986; DNA_gyraseB_C.1.
 DR Pfam: PF01751; toprim.1.
 DR Pfam: PF02518; HATPase_C.1.
 DR PRINTS: PR00418; TP12FAMILY.
 DR ProDom: PD00616; DNA_topoisomII.
 DR ProDom: PD14633; DNA_gyraseB_C.1.
 DR SMART: SM00387; HATPase_C.1.
 DR SMART: SM00433; TOP2c.1.
 DR TIGRFAMS: TIGR01059; gyrb.1.
 DR PROSITE: PS00177; TOPOISOMERASE_II.1.
 DR Topoisomerase: Isomerase: ATP-binding: Complete proteome.
 SO SEQUENCE 805 AA; 90571 MW; C082DF4CC6C71ECC CRC64;

Query Match 3.5%; Score 100.5; DB 1; Length 805;
 Best Local Similarity 20.4%; Pred. No. 9.9;
 Matches 121; Conservative 71; Mismatches 169; Indels 231; Gaps 32;

OY 48 PLHLVSPS-----FLSVTIDANLATPPRELILGSKLRTLARGLSPAVL 92
 DB 161 PLQVSVSDROGTEIVFPDPKIFSTCTD-----KSLMKRLLELFLNMGIT----- 209
 OY 93 REGGTDTDFIEPKKESTFEERSYQWQOVNODICKYGSIPDPVEEKLRLNMPYEQALL 152
 DB 210 -----IYEDDDVDVDFDKYTFYE-----GGIQSVS----- 236
 OY 153 REHYOKKFNSTYSRSSVDVLTFTFANGSGLDLFLGNALLRADIQWSSNMQLLDYCS 212
 DB 237 ---YLQNKESLFS---EPYICGTGVGDD---GEIEFQAALQWNSGYSLVYSYAN 284
 OY 213 SKGCVN--SMELCNERNPSFLKKADIFINGSQLGEDIYQLKRLKSTFFKAK--LYSPDVG 269
 DB 285 ---NIPTRQGGTHLTGFSTALTTRVIN-----TYIKAHNLA-----KNNKALTGEDT- 328
 OY 270 OPRRKAKMLKSLFKAGCEVIDSVTHHHYLYNGRTATREDPLNDV-----LDI 318
 DB 329 -----REGTLAVISVAKVPNPFEGQ--TKOKLNSDVSSVAQOVYGEALTI 372
 OY 319 FISS-----VQKVF-----QVVESTP-PCK-----K 338
 DB 373 FFEENPOIARMIVDKVFAQAAREAAKKARELTLRKALDSARLPCKLIDCLEKEPEKCE 432
 OY 339 VMIGETSSAYGCGA-----PLSDTFAGFMLDKLGLSARNGIEVVMQVVF 386
 DB 433 MIVIEDDSA-GGSAKOGRDRRFOALLPIGKILINVEKARLQIFQOETGIIIALGCGI 491
 OY 387 GAGNYHLVDENFDLPDYMLSLFKLVGCTKYL--ASYOGSKRRRLRV--YLHCTN-- 439
 DB 492 GADNFFL-----SKLRVRI-----IIMTDADVDSGSHIRLLLTFFYRHMTALI 535
 OY 440 -----TNPRTKESGDLTLVAINLNHTVTKYLRFPFSNKOVDKYLRLPGPH--GLLS 490
 DB 536 ENECVYIAOPPLYK-----VSKKKDFRYITLSEKEDSYLLM-LGTTNESSILF 581
 OY 491 KSV--QLNGLTLK-----NVDQOTLPLMEKPLRPGS-----SLGIPAF 527
 DB 582 KSTERELRGALSFNIVTLVDVSNFTNLEKKAIPSEPLEMKEGIGPLY 633

RESULT 9
 XYNZ_C1G1M
 ID XYNZ_C1G1M STANDARD: PRT: 837 AA.
 AC P10478;
 DT 01-JUL-1989 (rel. 11, Created)

DT 01-NOV-1991 (rel. 20, Last sequence update)
 DT 15-JUL-1999 (rel. 38, Last annotation update)
 DE Endo-1,4-beta-xylanase Z precursor (EC 3.2.1.8) (Xylanase Z)
 DE (1,4-beta-D-xylan xylohydrolase Z).
 GN XYNZ.
 OS Clostridium thermocellum.
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
 OC Clostridium.
 OX NCBI_TaxID=1515;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NCIB 10682;
 RX MEDLINE=89008072; PubMed=3139632;
 RA Grepinet O., Cheprou M.-C., Beguin P.;
 RT "Nucleotide sequence and deletion analysis of the xylanase gene
 (xynZ) of Clostridium thermocellum.";
 RL J. Bacteriol. 170:4582-4588(1988).
 RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 515-837.
 RC STRAIN=NCIB 10682;
 RX MEDLINE=95393242; PubMed=7664125;
 RA Dominguez R., Soucchon H., Spinel J.S., Dauter Z., Wilson K.S.,
 RA Chauvaux S., Beguin P., Alzart P.M.;
 RT "A common protein fold and similar active site in two distinct
 RT families of beta-glycanases.";
 RL Nat. Struct. Biol. 2:569-576(1995).
 CC -I- CATALYTIC ACTIVITY: Endohydrolysis of 1,4-beta-D-xylosidic
 CC linkages in xylans.
 CC -I- DOMAIN: A 24 RESIDUES DOMAIN IS REPEATED TWICE IN THIS ENZYME AS
 CC WELL AS IN OTHER C.THERMOCELLUM CELLULOSE ENZYMES. THIS DOMAIN
 CC MAY FUNCTION AS THE BINDING LIGAND FOR THE SL COMPONENT.
 CC -I- SIMILARITY: BELONGS TO CELLULOSE FAMILY F (FAMILY 10 OF GLYCOSYL
 CC HYDROLASES).
 CC -I- SIMILARITY: CONTAINS 1 XYNZ-TYPE CELLULOSE-BINDING DOMAIN (CBD).
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: M22624; AAA23286.1; -
 CC PIR: A31842; A31842.
 DR PDB: 1XYZ; 29-JAN-96.
 DR InterPro: IPR005084; CBM_6.
 DR InterPro: IPR002105; Dockerin_1.
 DR InterPro: IPR002048; EF-hand.
 DR InterPro: IPR001000; Glyco_hydro_10.
 DR InterPro: IPR000379; Ser_estra_site.
 DR Pfam: PF00331; Glyco_hydro_10; 1.
 DR Pfam: PF00404; Dockerin_1; 2.
 DR Pfam: PF03422; CBM_6; 1.
 DR PRINTS: PR00134; GLHYDRASE10.
 DR PROSITE: PS00018; EF_HAND; UNKNOWN_2.
 DR PROSITE: PS00448; CLOS_CELLULOSOME_RPT; 2.
 DR PROSITE: PS00591; GLYCOSYL_HYDROL_F10; 1.
 KM xylan degradation; Hydrolyase; Glycosidase; Repeat; Signal;
 KW 3D-structure.
 FT SIGNAL 1 28
 FT CHAIN 29 837
 FT ACT_SITE 645 645
 FT ACT_SITE 754 754
 FT DOMAIN 328 416
 FT DOMAIN 430 487
 FT REPEAT 430 453
 FT REPEAT 464 487
 FT DISULFID 4783 789
 SO SEQUENCE 837 AA; 92262 MW; DD4C29F04D1B6CD CRC64;
 Query Match 3.5%; Score 99.5; DB 1; Length 837;
 Best Local Similarity 19.3%; Pred. No. 12;

Matches: 63; Conservative 48; Mismatches 107; Indels 109; Gaps 16;

```

OY 145 PYOEOLLR-----HYOKR-----KNSTYSSSVVLYTFYFANCSGLDIFGLNALIR 193
DB 543 PTYNSILDRFSVMVCEMFKDALOPRONVDFSKGDLAFARNGO-----MK 594
OY 194 TADLOWNSSNOLLID-----YCCKGYNIMELGNE-----PNSF 229
DB 595 GHTLWMHONPSWLTNGNNRDSLLAVKNNITTYMTIKKIVKIDVANGCMDSGKGL 654
OY 230 LKKADIFNGSOLGEDIYQLHKLKRSFKNAKLYCP-----DYCGOPRKR7AK 277
DB 655 --RSSIMRN--VIGODYLDY-----AFRYAREADPPALLFYNDYNIEDLGPKSNAYFN 703
OY 278 MLKSPFKAGGEYDSVTNHHIYLNKRTATREDPLNDV-----LDIFISSVOKVQVYES 332
DB 704 MKS--MKRGVPIDCVGCCHIFNIGMSPEYLAIDONIKRYAEIVISFTEIDIRIPOS 762
OY 333 TRPG-----KKVNLGERSAVGCGAPLSDTFAGFMM--LDKLGLSARMG1 377
DB 763 ENPATAFOVOANNKELMKICLANPN-----CNTEV--MMGFTDKY----- 801
OY 378 EYVMROVFFGAGNHYLVDENFDPLDPY 404
DB 802 -TWIGTFPGYGNPLIYDSNVKPRAY 827

```

RESULT 10

```

DHYC_HUMAN
ID 014204; 092814; STANDARD; PRT; 897 AA.
AC 01-NOV-1997 (Rel. 35, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DE 16-OCT-2001 (Rel. 40, Last annotation update)
DE Dynein heavy chain, cytosolic (DYHC) (Cytoplasmic dynein heavy chain
DE 1) (DHC1) (Fragment).
GN DNCH1 OR DNECL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP MEDLINE=96234671; PubMed=8666668;
RA Vaisberg E.A., Grissom P.M., McIntosh J.R.;
RT "Mammalian cells express three distinct dynein heavy chains that are
RT localized to different cytoplasmic organelles."
RL J. Cell Biol. 133:831-842(1996).
RN [2]
RP SEQUENCE OF 755-895 FROM N.A.
RX MEDLINE=94043467; PubMed=8227145;
RA Vaisberg E.A., Koonce M.P., McIntosh J.R.;
RT "Cytoplasmic dynein plays a role in mammalian mitotic spindle
RT formation."
RL J. Cell Biol. 123:849-858(1993).
CC -!- FUNCTION: DYNEIN HAS ATPASE ACTIVITY. CYTOPLASMIC DYNEIN ACTS AS A
CC MOTOR FOR THE INTRACELLULAR RETROGRADE MOTILITY OF VESICLES AND
CC ORGANELLES ALONG MICROTUBULES.
CC -!- SUBUNIT: CONSISTS OF AT LEAST TWO HEAVY CHAINS AND A NUMBER OF
CC INTERMEDIATE AND LIGHT CHAINS.
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC -!- SIMILARITY: BELONGS TO THE DYNEIN HEAVY CHAIN FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation.
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL: U53530; AAB09727.1;
CC NCB1_TaxID=10116;
DR EMBL; L23958; AAA16065.1;

```

DR Genew: HGNC:2961; DNCH1.

DR MW: 600112;

Motor protein; Microtubules; Dynein; ATP-binding; Coiled coil.

```

FT DOMAIN 1 1
FT DOMAIN 42 74 COILED COIL (POTENTIAL).
FT DOMAIN 102 123 COILED COIL (POTENTIAL).
FT DOMAIN 228 244 COILED COIL (POTENTIAL).
FT NP_BIND 777 784 ATP (POTENTIAL).
FT CONFLICT 812 812 R -> M (IN REF. 2).
FT NON_TER 897 897
SO SEQUENCE 897 AA; 103012 MW; 7A95514D06CA7D42 CRC64;

```

Query Match 3.5%; Score 99; DB 1; Length 897;

Best Local Similarity 19.9%; Pred. No. 15; Mismatches 174; Indels 204; Gaps 27;

```

OY 41 LDFPTQEPHLVSPSFLSTIDANLATPDRFLILGSPKRLTLAGLSPAYLRFGGTGTD 100
DB 214 IDOMKEQPMWVSQPRKLRQNDLALLNQLSF-----PARLQYASVEFVORLLKGYMKIN 268
OY 101 FLIFPPKKESTFEERSTYQSOVNO-----DICKYGSIPPDV----- 136
DB 269 MLVIELKSEA-LKDR-HMKOLMKRLHVMVWVSELTGQIMVDLOKNEAIYKVDVLLVAG 326
OY 137 -----EE--KLRLPEYQOELLREHYOKKFNSTYSSSVVLYTFYFANCSGLDIFGLN 189
DB 327 EMALKEEFLKQIREVNTYELDLV--NYONKCR-----LIRGWD 362
OY 190 ALLRTADLOWNSSNOLLIDYCCKGYNV-----SMELGNEPNSFKKADIPTN----- 238
DB 363 DLFNKVKEHINSVSAMKLSPY-----YKVFEDALSWE--DKLNRIMALFDWIDVORRM 415
OY 239 -----GS-----QLCEDYIQLHKLKRSFKNAKLYCPVQVOPRKT 275
DB 416 VYLEGIFYSADIKILLPVEYTORFOSISTEFALMKKSKSPVMDVNIQOVOSLERI. 475
OY 276 AKMLKSPFKAGGEV1--DSVTMHNYLYNCRATREDPLNDPLDIF-----ISSVQVFO 328
DB 476 ADLLKIKOKALGEYLERESSFPRTFVG-----DEDLLEIIGSKNVAKLOKHIF- 525
OY 329 VESTRPGKKYWLGETSSAYGCGAPLSDTFAGFMMLDKLGLSARMG1EYVMROVFFGA 388
DB 526 -----KKMFAGVSS1-----ILNEDNSV-----VLGISSEGEVEVFKTP----- 560
OY 369 GNYHLVDENFDPLPYMLSLFLKLVGKYLMAVSGSKRRLRYLYLHCTNDNRYKEG 448
DB 561 -----VSITEHPKIMELTLVEREM--RYTLAKLLAESYVEVEIFGKATSIDPNTY--- 609
OY 449 DLTLYAINLHNTKYRLRYPFSNKQVDKY-----LRLPLPHG-- 487
DB 610 -----IT-----WIDKYQAOVLVLSNOJAMSENVETALLSMGCGGDA 646
OY 488 LLSKSVOLN-GTLTKMVDQTL--PMLKEPL 516
DB 647 APSDSVLNVSEYTLNVLADSVLMGPPRLRRRL 679

```

RESULT 11

```

DHYC_RAT
ID P38650; 063178; STANDARD; PRT; 4644 AA.
AC 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DE 16-OCT-2001 (Rel. 40, Last annotation update)
DE Dynein heavy chain, cytosolic (DYHC) (Cytoplasmic dynein heavy chain)
DE (MAP 1C).
GN DNCH1 OR DNCH1 OR DNEC1 OR MAP1C.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.

```

RC STRAIN=Wistar; TISSUE=Brain;
RA MEDLINE=93376715; PubMed=7690137;
RX Zhang Z., Tanaka Y., Nonaka S., Aizawa H., Kawasaki H., Nakata T.,
RA Hirokawa N.;
RT "The primary structure of rat brain (cytoplasmic) dynein heavy chain,
RT a cytoplasmic motor enzyme.";
RL Proc. Natl. Acad. Sci. U.S.A. 90:7928-7932(1993).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley; TISSUE=Brain;
RX MEDLINE=93264075; PubMed=7684332;
RA Mikami A., Paschal B.M., Mazumdar M., Vallee R.B.;
RT "Molecular cloning of the retrograde transport motor cytoplasmic
RT dynein (IMP 1C).";
RL Neuron 10:787-796(1993).
CC -1- FUNCTION: DYNEIN HAS ATPASE ACTIVITY. CYTOPLASMIC DYNEIN ACTS AS A
CC MOTOR FOR THE INTRACELLULAR RETROGRADE MOTILITY OF VESICLES AND
CC ORGANELLES ALONG MICROTUBULES.
CC -1- SUBUNIT: CONSISTS OF AT LEAST TWO HEAVY CHAINS AND A NUMBER OF
CC INTERMEDIATE AND LIGHT CHAINS.
CC -1- SUBCELLULAR LOCATION: CYTOSOL.
CC -1- SIMILARITY: BELONGS TO THE DYNEIN HEAVY CHAIN FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its use
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: D13896; BAA02996.1; -;
DR EMBL: L08505; AAA41103.1; -;
DR PIR: A38905; A38905.
DR InterPro: IPR004273; Dynein_heavy.
DR Pfam: PF03028; Dynein_heavy; 1.
KM Motor protein; Microtubules; Dynein; ATP-binding; Coiled coil.
FT DOMAIN 48 69 Coiled coil (POTENTIAL).
FT DOMAIN 179 200 Coiled coil (POTENTIAL).
FT DOMAIN 453 476 Coiled coil (POTENTIAL).
FT DOMAIN 541 564 Coiled coil (POTENTIAL).
FT DOMAIN 1169 1201 Coiled coil (POTENTIAL).
FT DOMAIN 1229 1250 Coiled coil (POTENTIAL).
FT DOMAIN 1355 1371 Coiled coil (POTENTIAL).
FT DOMAIN 2012 2040 MICROTUBULE-BINDING (POTENTIAL).
FT DOMAIN 3187 3273 Coiled coil (POTENTIAL).
FT DOMAIN 3394 3498 Coiled coil (POTENTIAL).
FT DOMAIN 3735 3798 Coiled coil (POTENTIAL).
FT DOMAIN 1904 1911 ATP (POTENTIAL).
FT NP_BIND 2222 2229 ATP (POTENTIAL).
FT NP_BIND 2593 2600 ATP (POTENTIAL).
FT NP_BIND 2935 2942 ATP (POTENTIAL).
FT NP_BIND 1024 1025 SR -> MP (IN REF. 2).
FT CONFLICT 1772 1772 P -> D (IN REF. 2).
FT CONFLICT 2098 2098 F -> A (IN REF. 2).
FT CONFLICT 2139 2139 F -> V (IN REF. 2).
FT CONFLICT 2175 2175 D -> A (IN REF. 2).
FT CONFLICT 2185 2185 K -> Q (IN REF. 2).
FT CONFLICT 2366 2366 L -> G (IN REF. 2).
FT CONFLICT 2382 2382 T -> S (IN REF. 2).
FT CONFLICT 2463 2463 G -> A (IN REF. 2).
FT CONFLICT 3219 3219 A -> D (IN REF. 2).
FT CONFLICT 4131 4131 R -> K (IN REF. 2).
FT CONFLICT 4366 4366 F -> S (IN REF. 2).
FT CONFLICT 4511 4511 A -> G (IN REF. 2).
SQ SEQUENCE 4644 AA; 532240 MW; 8C6ABDEDE875D82 CRC64;

```

Query Match      3.5%: Score 99; DB 1; Length 4644;
Best Local Similarity 19.5%: Pred. NO. 1.6e+02;
Matches 109; Conservative 85; Mismatches 188; Indels 178; Gaps 25;

QY 41 LDFPQEPHLVSPFSLSTIDANLATDPRIILGSPKRLRLARGSLSPAYIRFGSTKTD 100
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

Dd	1341	IDQKEDQPMWVYOPRKLRQWLDLQNLQNF-----PRLRQYASYEFPQRLKCYMK1N	1395
Oy	101	FLIFDPKKESTFEERSYQOVNO-----DICKYSGIPDV-----	136
Dd	1396	MLVIELKSEA-LKDR-HWQOLMKRLHVMNVVELTQJIMDVLOKNEAIVKDVLLVFNQ	1453
Oy	137	-----EE---KRLERMPQEODLLREHYQKKFNKNTYSRSSVDVLYTFPANCGLDIFGLN	189
Dd	1454	EMALEEFLKQIRVMWNTYELDLV--NYONKCR-----LIRGMD	1489
Oy	190	ALLTPAOLQWSSMAQQLLDYCSKQYNI-----SMELGNPNSPKKADIFIN-----	238
Dd	1490	DLEPKVKEHJNSVAKMLSPY-----YKPFEDALSWE---DKLNRIMALFDWIDVQWRM	1542
Oy	239	-----GS-----OLGEDYIOLHLKRLSTFKNAKLYGPDVGOPRRKT	275
Dd	1543	VYLEGIFITGSADIKHLLPVEQTFQOISTEFLALMKKVSPLYMDVYINIGOVQHSJERL	1602
Oy	276	AKMLKSLKAGGEYI--DSVTMHNYILNCRGTATREDFLNPVDLFI-----ISSYQVYQ	328
Dd	1603	ADLLGKIOKALGELYERESSPRPFYVG-----DEDLEIIGNSKNVAKLOKHFF-	1652
Oy	329	VVESTPRQCKVWMLGESSAAGCAPLLDSPPAAGFMWLDKLGLSRMGI EYVMRQVFFGA	388
Dd	1653	-----KKMFAGVSSITLINEDSSVY-----LGISREGEVWFKTP-----	1687
Oy	389	GNVHLVDENCPDLDPDYLLSLFFKLIVGTAVLMAVSQSKRRKLARYLLHCTNTDNERY---	445
Dd	1688	-----VSITHEHPKINEMULTVEKEM---RVTJAKLLAESVTEVELFGKATSIDPRTYITW	1739
Oy	446	---KEGDLTYAINL---HNVTYLRPLYPFSKNQVDKTYLRPLGPHGLKSSVOLNGLT	499
Dd	1740	IDKYOAOOLVYLSAQJAWSEVENALSNVGGGN-----VGPLQSVLSNWE---VT	1786
Oy	500	LKMWDDQTL---PRLMEKPL 516	
Dd	1787	LNVLADSVLMEQPLLRKRKL 1806	

RESULT 12			
ID	T3MH_HAE1N	STANDARD:	PRT: 629 AA.
AC	P71366;		
DT	16-OCT-2001 (Rel. 40, Created)		
DT	16-OCT-2001 (Rel. 40, Last sequence update)		
DT	16-OCT-2001 (Rel. 40, Last annotation update)		
DE	Putative type III restriction-modification system HindVIP enzyme mod		
DE	(EC 2.1.1.72) (HindVIP methyltransferase) (M.HindVIP).		
GN	H11056.		
OS	Haemophilus influenzae.		
OC	Bacteria; Proteobacteria; gamma subdivision; Pasteurellaceae;		
CC	Haemophilus		
CC	NCBI_TaxID=727;		
RI	[1]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN-Rd / KW20 / ATCC 51907;		
RC	MEDLINE=55350630; PubMed=7542800;		
RA	Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F.,		
RA	Kelavange A.R., Bult C.J., Tomb J.-F., Dougherty B.A., Merrick J.M.,		
RA	McKenney K., Sutton G., Fitzhugh W., Fields C.A., Gocayne J.D.,		
RA	Scott J.D., Shirley R., Liu L.-I., Glodex A., Kelley J.M.,		
RA	Weldman J.F., Phillips C.A., Spriggs T., Heblum M.D.,		
RA	Uetlback T.R., Hanna M.C., Nguyen D.T., Sauder D.M., Brandon R.C.,		
RA	Flane L.D., Frichman J.L., Fuhrmann J.L., Geoghegan N.S.M.,		
RA	Gnehm C.L., McDonald L.A., Small K.V., Fraser C.M., Smith H.O.,		
RA	Venter J.C.;		
RT	"Whole-genome random sequencing and assembly of Haemophilus influenzae		
RL	Science 269:496-512(1995).		
CC	-1- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + DNA adenine = S-		
CC	adenosyl-L-homocysteine + DNA 6-methylaminopurine.		
CC	-1- SUBUNIT: CONTAINS TWO DIFFERENT SUBUNITS: RES AND MOD. MOD IS		
CC	A HOMOTETRAMER (BY SIMILARITY).		

```
CC -! SIMILARITY: WITH OTHER TYPE III MOD PROTEINS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: U32786; AAC22721.1;
DR REBASE: 3701; M.Hindorf1056P.
DR TIGR: H11056;
DR InterPro: IPR001091; C4_Mettransf.
DR InterPro: IPR002295; D21N6_mltase.
DR InterPro: IPR002941; N6_N4_Mtase.
DR InterPro: IPR002052; N6_Mtase.
DR Pfam: PF01555; N6_N4_Mtase.1.
DR PRINTS: PRO0506; D21N6MTFRASE.
DR PRINTS: PRO0508; S21N4MTFRASE.
DR PROSITE: PS00092; N6_MTASE.1.
KW Hypothetical protein; Transferase; Methyltransferase; DNA-binding;
KW Restriction system; Complete proteome.
SQ SEQUENCE 629 AA; 71845 MW; 93ADAD909DB41E84 CRC64;

Query Match 3.5%; Score 98.5; DB 1; Length 629;
Best Local Similarity 21.8%; Pred. No. 9.8;
Matches 67; Conservative 56; Mismatches 107; Indels 77; Gaps 19;

OY 99 TDFL-IPDPKKESTFEESYQWQVODICKYGSIIPDVEEKLRLMEYQ-----EQL 150
D 242 TEFINVFESKNERELFLANVYOKTEVNEFIKN-----HDSCKSMKTYOVLIDLGKI 293
OY 151 LLREHYOKKFNSTYSRSDVLYTFANCGL--DLIFG--LMLLRPADLO----- 198
D 294 LLEE--KDFYHYHYPNAQMTSIVKFSODONLSKEIITYEYSHKYRTTNAOSSIRSKI 351
OY 199 ---WMSNAQLLDYCCSSKGYN-----ISMELGNEPNSFLKKADIFING----- 239
D 352 EDLSIKNGIVSIEYIPQKGNACNLIEVFYNASK-DPMFMLSMLIREKKKRYVLOKV 410
OY 240 SOLGEDYIQLHKLKRS---TFKNALKYGPVQOPRRRTAKMLKFLKAGGEVIDSYTMH 296
D 411 NTLMND-IQYNNLNKEGGYIDFKNCK-----KPEALLRRIIDMTTEGDLVDL----- 457
OY 297 HYVL-NGRTAFREDFLNPDVLDI---FIS--SVQKVFQVESTPRG--KKV-WLGETSS 346
D 458 -YHLGSGTTAAVAHKNMROYIGIEOMDYIETFLAVERLKKVIDGEGGISKAVNMGCGEF 516
OY 347 AYCGCAP 353
D 517 VYAE LAP 523

RESULT 13
NU5M_RHIST STANDARD: PRT: 654 AA.
ID NU5M_RHIST
AC P50367;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-DEC-1998 (Rel. 37, Last annotation update)
DE NADH-ubiquinone oxidoreductase chain 5 (EC 1.6.5.3).
GN NDS OR NAD5.
OS Rhizopus stolonifer (Rhizopus nigricans).
OC Mitochondrion.
OC Eukaryota; Fungi; Zygomycota; Zygomycetes; Mucorales; Mucoraceae;
OC Rhizopus.
OX NCBI_TaxID=4846;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=DAOM 148428;
RA Paquin B., Roewer I., Wang Z., Lang B.F.;
RT "A robust fungal phylogeny using the mitochondrially encoded nad5
```

```
RT protein sequence."
CC Can. J. Bot. 73:S180-S185(1995).
CC -! CATALYTIC ACTIVITY: NADH + ubiquinone = NAD(+) + ubiquinol.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: U17011; AAA99062.1;
DR InterPro: IPR003916; NADHUB_oxred5.
DR InterPro: IPR001750; Oxidored_q1.
DR InterPro: IPR001516; Oxidored_q1_N.
DR Pfam: PF00361; Oxidored_q1.
DR Pfam: PF00662; Oxidored_q1_N.1.
DR PRINTS: PRO1434; NADHGNASE5.
KW Oxidoreductase; NAD; Ubiquinone; Mitochondrion.
SQ SEQUENCE 654 AA; 72818 MW; 22D2E023B8D6E12D CRC64;

Query Match 3.5%; Score 98.5; DB 1; Length 654;
Best Local Similarity 21.3%; Pred. No. 10;
Matches 77; Conservative 55; Mismatches 132; Indels 97; Gaps 17;

OY 176 FANSGDLILGLNALRTADLQNNSSNAQLLDYCCSKGYNISMLGNEPNSFLKKADI 235
D 304 YSTCSQLGLFLV-----CGLSQYNVA--LFHLVNHAMFKALL 339
OY 236 FINGSQL-----GEDYIQLHKLKRSYFKNAKLYGPVQOPRRRTAKMLKFLKAGEV 289
D 340 FLKAGSYVHAMNDEODLRFGLSLRLPFTSMYV---IGLSLMLALPFLGFSK--DL 394
OY 290 IDSVTWHHYLYNGRTAFREDFLNPVDLIFISSQKVFQVESTPRCKKWLGETSSAYG 349
D 395 IELAYGHVSFGN-----LYVLAASVAAYFTAYSIKSLVLTFLG-----YP 437
OY 350 GG-----APLS-----DTFAAGMMLDKLGLSKRMGIEVVMROYVFGAGNYH 392
D 438 NGPKYNNNIHEAPLIMAPLVLAIVFSIFGQYTK-DLFVGMGDFYNNALFIHPNISI 496
OY 393 LVDENFPLPDPYMLSLFKKLVGTGYLVASVQGSRRRLRYV-----LHGTNDNP 443
D 497 LVDTIEFG-LP--MSKFLPLIGSLGTFGV-----LAIYMFDELPMKFISTKLCRG 545
OY 444 RYKEGDLTVAIINLHN--VTKYRLRPYFPFSKKQYDKYLLRPLGPHGLL---SKSVOLNG 497
D 546 IYRFFNQKYFDNIYNNLNKFLNFGYT-TNKLIDRGAIELVGPGLVNVKFSASNKYSG 604
OY 498 L 498
D 605 L 605

RESULT 14
RHTA_RHIME STANDARD: PRT: 746 AA.
ID RHTA_RHIME
AC Q92305;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Rhizodactin receptor precursor (Tromb-dependent siderophore receptor
DE rhtA).
GN RHTA OR RA1265 OR SMA2414.
OS Rhizobium meliloti (Sinorhizobium meliloti).
OC Bacterium; Proteobacteria; alpha subdivision; Rhizobiaceae group;
OC Rhizobiaceae; Sinorhizobium.
OX NCBI_TaxID=382;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=RCR2011 / SU47;
```


RX MEDLINE-21172875; PubMed-11274118;
 RA Lynch D., O'Brien J., Welch T., Clarke P., Cuiv P.O., Croa J.H.,
 RA O'Connell M.;
 RT "Genetic organization of the region encoding regulation, biosynthesis,
 RT and transport of rhizobactin 1021, a siderophore produced by
 RT *Sinorhizobium meliloti*."
 RN J. Bacteriol. 183:2576-2585(2001).
 RP
 RC
 RX STRAIN-1021;
 MEDLINE-21396509; PubMed-11481432;
 RA Barnett M.J., Fisher R.F., Jones T., Komp C., Abola A.P.,
 RA Barloy-Hubler F., Bowser L., Capela D., Galibert F., Gouzy J.,
 RA Gurjal M., Hong A., Huitzer L., Hyman R.W., Kahn D., Kahn M.L.,
 RA Kallman S., Keating D.H., Palm C., Surzyski R., Wells D.H.,
 RA Yeh K.-C., Davis R.W., Fedetspiel N.A., Long S.R.;
 RT "Nucleotide sequence and predicted functions of the entire
 RT *Sinorhizobium meliloti* pSyma megaplasmid."
 RL Proc. Natl. Acad. Sci. U.S.A. 98:9883-9888(2001).
 CC
 CC -1- FUNCTION: RECEPTOR FOR THE SIDEROPHORE RHIZOBACTIN.
 CC -1- SUBCELLULAR LOCATION: Outer membrane.
 CC -1- SIMILARITY: LOCAL TO OTHER TONB-DEPENDENT RECEPTOR PROTEINS.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isp-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC
 CC
 CC EMBL: AF110737; AAD09419.1; -
 DR EMBL: AE007312; AAK65923.1; -
 DR InterPro: IPR000531; TonB_boxc.
 DR Pfam: PF00593; TonB_boxc.1;
 DR PROSITE: PS00430; TONB_DEPENDENT_REC_1; FALSE_NEG.
 DR PROSITE: PS01156; TONB_DEPENDENT_REC_2; FALSE_NEG.
 DR Outer membrane; Iron transport; Transport; TonB box; Signal; Receptor;
 KM Plasmid; Complete proteome.
 FT SIGNAL 1 26 POTENTIAL.
 FT CHAIN 27 746 RHIZOBACTIN RECEPTOR.
 FT SITE 40 47 TONB BOX.
 FT SITE 729 746 TONB C-TERMINAL BOX.
 SO SEQUENCE 746 AA: 80633 MW: 16AE44A4025D5B23 CRC64;

Query Match 3.5%; Score 98.5; DB 1; Length 746;
 Best Local Similarity 21.8%; Pred. No. 13; Indels 163; Gaps 25;
 Matches 105; Conservative 55; Mismatches 159;

OY 90 AYLRFQGTKT-----DFLI FPKKEST- FEERSYMOQVNO DICKYGSIPDPVEEKL 140
 DB 207 ARLSIAGNRTGAFYDOSCTLLIPDITOTSTAFNER-----IDLNGSIGCYIDDDR 256
 OY 144 RLEW-----PYOEQL-----LREHYOKKFNKSTYSRSVDVLYTF 176
 DB 257 RVEFGQGYFDSKODSDYGLYGPFAALADPSLFTFRSGESDFNPOT-RRSMVLVYTD 315
 OY 177 ANCSGLDLIFGLNALRTADLQW-----SSNAOL-LLDVCSCKG---WNISWELNEP- 226
 DB 316 NQVFOOQL--LQSYRTFRIRKIFHPFPASGNETGPIYFGSSQDDYDYGIRALVAEPFD 373
 OY 227 -----NSFLKRAIDF--INSQLEDGYIOLHLKLRKSTFKNAKLYGPDVOP 271
 DB 374 ALKITYGIDADMDSFTARONIFDVAAGSGGLDF-----NTWIKGTGLY-PSI--- 420
 OY 272 RKKTKMKLSFLKAGEVIDSYTHHHYILNGRTATREDFLNPVDLIFISSVOKYQVYE 331
 DB 421 ---DVSTAGFAEASYEATDRLT-----LNG--GVRYOFVNTVEVD-FIGAAQV----- 464
 OY 334 STRPGKKVWLGSTSA---YGGCAPLLSDTFAAGFM---LDKLGLSARMGIEVVMROY 384
 DB 465 -----ALLOGRATSDITPGGGEVNDALFSAGATYQLTNTQOYANVSQGFELDPAPK 518

OY 385 FEGAGNYHLVDENFDLPDYWLSTLFFKKLVGTRKVLMAVSGSKRRRLRVYLCTWMDNR 444
 DB 519 YXGIGNVSFGS-----GHYTLVNSV----- 538
 OY 445 YKEGDLTYAIALNHNVTYKRLPYPPSKQVDRKYLRLPGPGLLSKSVOLN--GLTLKM 502
 DB 539 -NWGDSALEAIKTNSEFGEYRILDGTFNLETAAY-----YSLSDRSINLRSSIAVEI 590
 OY 503 VD 504
 DB 591 ID 592

RESULT 15
 RRP2_IAV17
 ID RRP2_IAV17 STANDARD: PRT: 716 AA.
 AC P31343;
 DT 01-JUL-1993 (Rel. 26, Created)
 DT 01-JUL-1993 (Rel. 26, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE RNA-directed RNA polymerase subunit P2 (EC 2.7.7.48) (polymerase
 DE acidic protein) (PA).
 OS Influenza A virus (strain A/Victoria/3/75).
 OC Viruses; ssRNA negative-strand viruses; Orthomyxoviridae;
 OC Influenza A viruses; Influenzavirus A.
 OX NCBI_TaxID=11483;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE-89370813; PubMed-2773594;
 RA de la Luna S., Martinez C., Orth J.;
 RT "Molecular cloning and sequencing of influenza virus A/Victoria/3/75
 RT polymerase genes: sequence evolution and prediction of possible
 RT functional domains."
 RL Virus Res. 13:143-156(1989).
 CC
 CC -1- CATALYTIC ACTIVITY: N nucleoside triphosphate - N diphosphate +
 CC (RNA)(N).
 CC
 CC -1- SUBUNIT: INFLUENZA RNA POLYMERASE IS COMPOSED OF THREE SUBUNITS:
 CC P1 (OR PA1), P2 (OR PA), AND P3 (OR PB2).
 CC
 CC -1- SIMILARITY: BELONGS TO THE INFLUENZA VIRUSES POLYMERASE PA FAMILY.
 DR PIR: C60008; C60008.
 DR InterPro: IPR001009; RNA_pol_P2.
 DR Pfam: PF00603; Flu_PA.1.
 DR Transferase; RNA-directed RNA polymerase.
 KW SEQUENCE 716 AA: 82821 MW: B1FC817C171BB50F CRC64;

Query Match 3.4%; Score 98; DB 1; Length 716;
 Best Local Similarity 19.3%; Pred. No. 13; Indels 144; Gaps 25;
 Matches 100; Conservative 80; Mismatches 194;

OY 57 LSVTIDANLADPRLILIGSKLRTLARGSLPAVLRFGTGTDFLFPKKESTFEERS 116
 DB 253 VNAKLEPLKTPTRIKLPDGP-----PCGR-----SKLLMDALKLSTED--- 294
 OY 117 YWOSOVNO DICKYGSIPDPVEEKLREMPYOEQLLREHYOKKFNKSTYSRSVDVLYTF 176
 DB 295 --PSHEGEGIPLYDAI-----KCMRTPEGMKEPYIVKPH--ERGINSYVLLSMKOVLAEL 345
 OY 177 ANCSGLDLIFGLNALRTADLQW-----SSNAOLLLDVCSCKG---KGVN-----IS 219
 DB 346 ODINEEKIIPRTKNAKKSOLKMWALGEMAEPEKDFDRCRDISLKOQDSPEPELRSLSS 405
 OY 220 WELGNEPNSFLKAD-IFINGSQLEDGYIOLHLK-LRKSTFKNAKLYGPDVOPRRKTA 276
 DB 406 W-IQNEFKAKCELDSDSIWELDEIGEDVAPLEIYIASMRNF-----TA 448
 OY 277 KMLKSLKAGEVIDSYTHHHYILNGRTATREDFLNPVDLIFISSVOKYQVYESTRPG 336
 DB 449 EV--SHCRATEYIMKGVYINTALLNASCAAMDFO-----LIPMSKIC-----RTEG 494
 OY 337 KKVWLGSTSSAVG---GAPLLSDTFAAGFMMLDKGLSARMGIEVVMROYVFGAGNYH 392
 DB 495 RR-----KTNLYGPIIKGRSHLRDNDVYVNSME-----FS 526

```

0y 393 LVENFDPDLPRVYMLSLFKKLVGKRYKVMASVQSGRRKKLVLYLHCTNDPRRYKEGDTL 452
Db 527 LTRDPRLE - PIKWKRYCVLEI - - GDMLLRSALIGMSRPMYLVFNTGTSKIKKKWGMEMR 582
0y 453 YAI - NLHNWYKYLRLPYPSNRKOVDRYLLR - - - - - PLG - PHG - - - - - LLS 490
Db 583 RCLLOSLOOIESMIEAESSVKEKDMTKKEFFENKSETPYIESRKGVEEGSIGVYCRLLLA 642
0y 491 KSV - - - - - QLNGLTLLKHWDDOTLPPLEKKPLRPGS 520
Db 643 KSVFNSLYASPOLGCFSAESRKKLLLVQALRDNLNRPOT 680

```

Search completed: November 20, 2002, 11:36:35
Job time : 19 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:34:52 ; Search time 39 Seconds
(without alignments)
2868.810 Million cell updates/sec

Title: US-09-759-207-2

Perfect score: 2842
Sequence: 1 MLRSKPALPPMLLLGP.....LPASYSFVIRNAKVAACI 543

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

SPTREMBL_21: *
1: sp_archaea: *
2: sp_bacteria: *
3: sp_fungi: *
4: sp_human: *
5: sp_invertebrate: *
6: sp_mammal: *
7: sp_mhc: *
8: sp_organelle: *
9: sp_phage: *
10: sp_plant: *
11: sp_rodent: *
12: sp_virus: *
13: sp Vertebrate: *
14: sp_unclassified: *
15: sp_virus: *
16: sp_bacteriophage: *
17: sp_archaeal: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2838	99.9	543	4	O9Y251
2	2817	99.1	543	4	O9UD39
3	2282	80.3	545	6	O9MY10
4	2123	74.7	536	11	O9QZFE
5	1645.5	57.9	523	13	O9QYK5
6	1154.5	40.6	592	4	O9HB37
7	1146.5	40.3	592	4	O8WMQ2
8	1013.5	35.7	548	4	O8WMQ1
9	936.5	33.0	534	4	O9HB38
10	897.5	31.6	480	4	O9HB39
11	696	24.5	515	5	O9T108
12	416	14.6	521	10	O9SDA1
13	416	14.6	543	10	O9PFI0
14	381	13.4	527	10	O9LRC8
15	363	12.8	536	10	O9FZP1
16	352.5	12.4	516	10	O9FLK8

17	169.5	6.0	190	10	O82604	082604 arabidopsis
18	160	5.6	935	5	O9VE79	O9VE79 drosophila
19	130.5	4.6	493	3	O9HK01	O9HK01 thermophilum
20	122.5	4.3	408	3	O9HEZ2	O9HEZ2 phanerochaete
21	122.5	4.3	408	3	O9HEZ1	O9HEZ1 phanerochaete
22	116.5	4.1	617	12	O40956	O40956 measles vir
23	113.5	4.0	617	12	O83295	O83295 measles vir
24	113.5	4.0	1829	2	O9KH44	O9KH44 pantoea agg
25	113	4.0	390	17	O8TP17	O8TP17 methanosarc
26	112.5	4.0	617	12	O83647	O83647 measles vir
27	111.5	3.9	493	17	O97960	O97960 thermophilum
28	111.5	3.9	575	10	O43855	O43855 vicia faba
29	111.5	3.9	617	12	O40931	O40931 measles vir
30	111.5	3.9	617	12	O98V15	O98V15 measles vir
31	111	3.9	670	10	O9M090	O9M090 arabidopsis
32	111	3.9	2319	3	O96U00	O96U00 neurospora
33	110.5	3.9	475	5	O8SU17	O8SU17 encephalito
34	109.5	3.9	617	12	O911F6	O911F6 measles vir
35	109.5	3.9	617	12	O910N9	O910N9 measles vir
36	109.5	3.9	879	16	O8XCP4	O8XCP4 escherichia
37	109	3.8	617	12	O98V76	O98V76 measles vir
38	108.5	3.8	411	16	P72895	P72895 synechocyst
39	108.5	3.8	617	12	O11381	O11381 measles vir
40	107.5	3.8	500	16	O9A5U0	O9A5U0 caulobacter
41	107.5	3.8	617	12	O89631	O89631 measles vir
42	107.5	3.8	617	12	O89764	O89764 measles vir
43	107.5	3.8	617	12	O40990	O40990 measles vir
44	107.5	3.8	617	12	O83633	O83633 measles vir
45	107.5	3.8	617	12	O83645	O83645 measles vir

ALIGNMENTS

RESULT 1
O9Y251 PRELIMINARY: PRT: 543 AA.
AC O9Y251;
DT 01-NOV-1999 (TREMBL) 12, Created)
DT 01-NOV-1999 (TREMBL) 12, Last sequence update)
DT 01-JUN-2002 (TREMBL) 21, Last annotation update)
DE HEPARANASE.
GN HPA.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-PLACENTA;
RX MEDLINE=99321249; PubMed=10395326;
RA Hulst M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J.,
RT Parish C.R.;
RT "Cloning of mammalian heparanase, an important enzyme in tumor
RT invasion and metastasis.";
RT Nat. Med. 5:803-809(1999).
RN [2]
RP SEQUENCE FROM N.A.
RA Vlodavsky I., Friedman Y., Elkin M., Aingorn H., Atzmon R.,
RA Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I.,
RA Spector L., Pecker I.;
RT "Mammalian heparanase: a novel gene involved in tumor progression and
RT metastasis.";
RT Submitted (Apr-1999) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=9937052; PubMed=10446189;
RA Toyoshima M., Nakajima M.;
RT "Human heparanase: Purification, characterization, cloning, and
RT expression.";
RL J. Biol. Chem. 274:24153-24160(1999).
RN [4]
RP SEQUENCE FROM N.A.

RC TISSUE=PLACENTA; PubMed=10405343;
 RA MEDLINE=99335379; PubMed=10405343;
 RA Kusie P.H., Hulmes J.D., Ludwig D., Patel S., Navarro E.C.,
 RA Seddon A.P., Giorgio N.A., Bohlen P.,
 RT "Cloning and Functional Expression of a Human Heparanase Gene";
 RL Biochem Biophys. Res. Commun. 261:183-187(1999).
 DR EMBL: AF165154; AAD4539.1;
 DR EMBL: AF144325; AAD41342.1;
 DR EMBL: AF155510; AAD54941.1;
 DR EMBL: AF152376; AAD54669.1;
 DR InterPro: IPR005199; Glyco_hydro_79n.
 DR Pfam: PF03662; Glyco_hydro_79n.1.
 SO SEQUENCE 543 AA; 61176 MW; AD262EC267334AB2 CRC64;

Query Match 99.9%; Score 2838; DB 4; Length 543;
 Best Local Similarity 99.8%; Pred. No. 7.8e-214;
 Matches 542; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 MLRSKRALPPMLLLGLPLSPCALPPRAOAOVDVDFDFTQEPHLVSPFLSVT 60
 DB 1 MLRSKRALPPMLLLGLPLSPCALPPRAOAOVDVDFDFTQEPHLVSPFLSVT 60
 OY 61 IDANLATDPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 120
 DB 61 IDANLATDPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 120
 OY 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 DB 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 OY 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 DB 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFANCS 180
 OY 181 GLDLIFGLNLLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFING 240
 DB 181 GLDLIFGLNLLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFING 240
 OY 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRRTAKMLSFLLAGEVIDSVWNNHYL 300
 DB 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRRTAKMLSFLLAGEVIDSVWNNHYL 300
 OY 301 NGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKKVWLGESSAAGCAPLLSDTFA 360
 DB 301 NGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKKVWLGESSAAGCAPLLSDTFA 360
 OY 361 AGFMWLDLGLSARMGIEVVMROVFFGAGNHLVDENPDLPDWLSLFFKLVGTAVL 420
 DB 361 AGFMWLDLGLSARMGIEVVMROVFFGAGNHLVDENPDLPDWLSLFFKLVGTAVL 420
 OY 421 ASVGSRRRLRYVYLHCTNTDNPYKKEGDLTYA1NLNHYTKYRLPYPSNKOVDKY 480
 DB 421 ASVGSRRRLRYVYLHCTNTDNPYKKEGDLTYA1NLNHYTKYRLPYPSNKOVDKY 480
 OY 481 RPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPSSSLGPAFSYFFVIIRNAKVA 540
 DB 481 RPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPSSSLGPAFSYFFVIIRNAKVA 540
 OY 541 ACI 543
 DB 541 ACI 543

RESULT 2
 O9UL39 PRELIMINARY; PRT; 545 AA.

AC O9UL39: 01-OCT-2000 (Tremblrel. 13, Created)
 DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
 DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
 DE Heparanase.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 OX NCBI_TaxID=9606;
 RN 11
 RP SEQUENCE FROM N.A.

RC TISSUE=PLACENTA; PubMed=10764835;
 RA MEDLINE=20229546; PubMed=10764835;
 RA Dempsey L.A., Plummer T.B., Coombs S.L., Platt J.L.,
 RT "Heparanase expression in invasive trophoblasts and acute vascular
 RT damage";
 RL Glycobiology 10:467-475(2000).
 DR EMBL: AF084467; AAD54516.1;
 DR InterPro: IPR005199; Glyco_hydro_79n.
 DR Pfam: PF03662; Glyco_hydro_79n.1.
 SO SEQUENCE 545 AA; 61418 MW; 67B80ACD73C5A9A1 CRC64;

Query Match 99.1%; Score 2817; DB 4; Length 545;
 Best Local Similarity 99.4%; Pred. No. 3.5e-212;
 Matches 542; Conservative 1; Mismatches 0; Indels 2; Gaps 2;

OY 1 MLRSKRALPPMLLLGLPLSPCALPPRAOAOVDVDFDFTQEPHLVSPFLSVT 58
 DB 1 MLRSKRALPPMLLLGLPLSPCALPPRAOAOVDVDFDFTQEPHLVSPFLSVT 58
 OY 59 VTIDANLATDPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 118
 DB 59 VTIDANLATDPRFLILGSPKLTARGLSPAYLRFSGTKTDFLIDPKKESTFEERSYWS 118
 OY 119 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 178
 DB 119 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 178
 OY 121 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 180
 DB 121 QSVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFNSTYSRSSVDVLYTFAN 180
 OY 179 CSGDLIFGLNLLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFIN 238
 DB 181 CSGDLIFGLNLLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFIN 240
 OY 239 GSGLEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRRTAKMLSFLLAGEVIDSVWNNHYL 298
 DB 241 GSGLEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRRTAKMLSFLLAGEVIDSVWNNHYL 300
 OY 299 YLNGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKKVWLGESSAAGCAPLLSDT 358
 DB 301 YLNGRTATREDPLNPVDLIFISSVQKVFQVESTPRGKKVWLGESSAAGCAPLLSDT 360
 OY 359 FAAGFMWLDLGLSARMGIEVVMROVFFGAGNHLVDENPDLPDWLSLFFKLVGTAV 418
 DB 361 FAAGFMWLDLGLSARMGIEVVMROVFFGAGNHLVDENPDLPDWLSLFFKLVGTAV 420
 OY 419 LMASVGSRRRLRYVYLHCTNTDNPYKKEGDLTYA1NLNHYTKYRLPYPSNKOVDKY 478
 DB 421 LMASVGSRRRLRYVYLHCTNTDNPYKKEGDLTYA1NLNHYTKYRLPYPSNKOVDKY 480
 OY 479 LMRPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPSSSLGPAFSYFFVIIRNAK 538
 DB 481 LMRPLGPHGLSKSVQNLGLTLKMDVDTLPPLMEKPLRPSSSLGPAFSYFFVIIRNAK 540
 OY 539 VAACT 543
 DB 541 VAACT 545

RESULT 3
 O9MY0 PRELIMINARY; PRT; 545 AA.

AC O9MY0: 01-OCT-2000 (Tremblrel. 15, Created)
 DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)
 DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
 DE Heparanase.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;
 OX NCBI_TaxID=9913;
 RN 11
 RP SEQUENCE FROM N.A.
 RC TISSUE=PLACENTA;
 RA Kizaki K., Nakano H., Takahashi T., Imai K., Hashizume K.;

RT "Expression of Heparanase mRNA in Bovine Placenta During Gestation."
 RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AF281160; AAF87301.2; -
 DR InterPro: IPR005199; Glyco_hydr_79n.
 DR Pfam: PF03662; Glyco_hydr_79n: 1.
 SQ SEQUENCE 545 AA: 61076 MW: FAC4ADFFD855B933 CRC64: "

Query Match	80.38;	Score 2282;	DB 6;	Length 545;
Best Local Similarity	79.88;	Pred. NO. 2.9e-170;		
Matches 435; Conservative	35;	Mismatches 73;	Indels 2;	Gaps 1.

Oy		1	MLKSKALPRLLYL--LIGPLGSPSLPPRAQAOVDVDFDFOERLYHVSFSLT	58
Dd		1	MLAKRKGLRPLLRLPRLGRLPGRCSPGRPAARAARDAAELEFFTERLHLVSATFLS	60
Oy		59	VTDANLATDRPRLILGSGPWLTLAGSLSPAYLRFGSTKDDELIDPKKESTFEERSYW	118
Dd		61	FTTDANLATDRPFPTFLSSKLRTLAGLAPARYLFCNGNGLDELPDPKKEPAEERSYW	120
Oy		119	OSOVNDOLCKKGSIIPRYVEEKLYLEMYOQDLRLREYOKKFKNSTYSRSXSVULYTPAN	178
Dd		121	LQSODNICKSGSIPSDVEEKLRLMEPFQBOVLLRDOYOKKFPNSTYSRSXYDMLTYFAS	180
Oy		179	CSGIDLIFGLUALRTADLDGNSSNAQLLDLYDCSSKUNYIWMELGNEPNSEFKKADIFIN	238
Dd		181	CSGIANLIFGVALLRTDDMHMDSSNAQLLDLYDCSSKUNYIWMELGNEPNSEFKKAGIFTIN	240
Oy		239	GSQLGEDYIQHLKLLRKSTFRNKALKGRPDGCGRRKTAKMLKSFLAAGEVIDDSVMNNY	298
Dd		241	GROJGEDPIETFRKRLLGKSAFNKKALKGRPIDGRPRNTVKLSFLAAGEVIDDSVMNNY	300
Oy		299	YLNRKTRTFREDFLRPDVLDLFISVQKVPOVESTPRGGKVVYLGETISSAYOGGARPLYSDT	358
Dd		301	YVNRIATKEDFLRPDLIDLFISVQKTLRIYEKIRPLKKVWLGETISSAFGGGAPELSMT	360
Oy		359	FAAGFMULDKIGLSARNGIEYVMHOVFEGAGNHLYDENDRPYDWLSLFFKVLGTGY	418
Dd		361	FAAGFMULDKIGLSARNGIEYVMHOVLEGAGNHLYDGENRPLRDYWLSSLFFKVLGNKY	420
Oy		419	LMASVOGSKRRKLRYVLIHCNTDNPRYKEGDLTLVLAIIHLNVTKYRLRYPFSSKNODYK	478
Dd		421	LMASVGPDRSKSFVYLIHCNTKHPRYKEGDLTLVLAIIHLNVTKYRLRYPFSSKNODYK	480
Oy		479	LRLRGHGHLGSLKSVQNLGTLMKMWDQDTLRLMKEXLARGSSLGPARFSYFVLRNKK	538
Dd		481	LIRKSGDGCLSKSVQNLGOGLKMWDDQTLRALTEKRLHPGSSLGMPFSYGFVLRNKK	540
Oy		539	VAACI 543	
Dd		541	VAACI 545	
RESULT 4				
O90ZF8				
O90ZFB				
AC	O90ZFB	PRELIMINARY:	PRT:	536 AA.
DT	01-MAY-2000	(TREMBLrel. 13, Created)		
DT	01-MAY-2000	(TREMBLrel. 13, Last sequence update)		
DT	01-JUN-2002	(TREMBLrel. 21, last annotation update)		
DE	Heparanase.			
GN	HBP.			
OC	Rattus norvegicus (Rat).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.			
OX	NCB1-TaxID=10116;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RA	Podyme K.A., Yokote H., Sakaguchi K., Ikuta M., Yanagishita M.;			
RT	"Heparanase from parathyroid cell line."			
RL	Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.			
DR	EMBL: AF184967; AAF04563.1; -			
DR	InterPro: IPR005199; Glyco_hydro_79n.			
DR	Pfam: PF03662; Glyco_hydro_79n; 1.			

SO	SEQUENCE	536	AA:	60569	MM:	6208B1FFD5EE28421	CNC64:
	Query Match	74.7%	Score	2123:	DB	11:	Length 536;
	Best Local Similarity	75.7%	Pred.	No.	8e-158;		
	Matches	405:	Conservative	51:	Mismatches	79:	Indels 0; Gaps 0;

Oy	9	LPRPLMLLGPPLPPLPSGALPPRAQOQDVDDPFDLPQPHLLVLAHPSFSLSVTIDANLATO	68
Db	2	LRLPLLLMLWMLRALTTOGTDPAGTAPPKKDVDDLEFYTKRLFOVSYSRPSFLSTTIDASLATO	61
Oy	69	PRFLJLGLSPKRLTLRANGLSRPAYLRFSGTJTDPLIPDKKESTPEERKSYSQOSOVNDICK	128
Db	62	PRFLTFPLGSPRLRALANGLSRPAYLRFSGTJTDPLIPDKKESTPEERKSYSQOSOVNDICK	121
Oy	129	YGSIPPDVPEEKLRLEMPYQOELLREHYYOKKFKNSTYSRSSVDVLYTFANCSCJLDLFGI	188
Db	122	SERVSADVLKRLQWEMPEFOELLRLREOYOREFKNSTYSRSSVDMLYSFACSRJLDLFGI	181
Oy	189	NALLRTADLQWNNSSNAQLLDDGCSKSYN1SWEIIGNPNSFLKKAOLFINGSLGDEGDIYQ	248
Db	182	NALLRTPLDLRWNNSSNAQLLDDGCSKSYN1SWEIIGNPNSFPMKKAOLFIDGLIGDEPVE	241
Oy	249	LHLKLRKSTPEFNALCYGDVGQOPRRKTAAMKSLFLKAGCEIVDSVTMHYYLNGRATRE	308
Db	242	LHLKLLQSAFONALCYGDIQOPRGKTVKLLRSLFLKAGCEIVDSVTMHYYLNGRATRE	301
Oy	309	DPLNPDVLDLFTISSVQVVFQVESTTRQKRYMLCETSSAVGCGAPLLSDPFAAGFMWLDK	368
Db	302	DFLSSDVLDPFTLISVQK1LKYTKLMTGKQKVMJLGETSSAVGCGAPLLSNFPAAGFMWLDK	361
Oy	369	LGLSARMGIEVYVMQVQVEFGAGNHLVDENFDPLPDYWL5LLFKKLVGTVKYLMA5VQSKR	428
Db	362	LGLSAQGLGIEVYVMQVQVEFGAGNHLVDENFEPLPDYWL5LLFKKLVGTVKYLMA5VRVGPDR	421
Oy	429	RKLRYVYLHCTMTDNPRLKREGDPLTXALINLINVRYLRLPYPFSKQVODKTLRLRPLGHG	488
Db	422	SKLRVYVYLHCTMTDNPRLKREGDPLTXALINLINVRYLRLPYPMFSRPYDKTLRLRPFSGDL	481
Oy	489	LKSKVQVNLGLKWKVDDOTPLPLMEKXPLRGCSSJGLPFAFYSFFVRLRNAAVACI	543
Db	482	LKSKVQVNLGLKWKVDDOTPLPALTEKXPLRGCSSJSLVAFYSYGFVRLRNAAIACI	536

Query Match	57.9%	Score 1645.5	DB 13	Length 523
Best Local Similarity	60.28	Pred. No. 2e-120		
Matches 320; Conservative	87	Mismatches 114	Indels 11	Gaps 3

Oy	13	LMLLILGPIGLSPCALPRPAOADVUDLEFFEOPLILHSPESLSTIAJANLTDPRFL	72
Dd	2	LVLILLVLLVLP-----RRFAELQGLREPIGANSFALSLTLDLSLRDRFV	52
Oy	73	ILLOSPKILRTIARGLSPAYLRFEGTGTDFELFDKCKESTEEBSRSWOSOVNODICKYGI	132
Dd	53	ALLHRPKLHTLASGSPGLFRFGGTSTDFELFNPKNSJSTWEEKYLSEFOA-KDYCEAMP	111
Oy	133	PRDYEEKRLMPROEOLLREHNOKKRNSYRSRDVLYTFPANCSDULLFPGNAL	199
Dd	112	FAYVPKLLLTOMPILOEKLLLEHSMKKHKNTTIRSTDULHTFPASSSGFLYFVGNALL	171
Oy	193	RTADLONNNSNAOLLIDYCCKSGKYNISWEIGNEPNISFLKADIFINSSOLGEDIYOLHL	252
Dd	172	RRAGLOMOSNAKOLGICGAORSYNISWEIGNEPNISFRKKSJCIGIDGFOGLGROPVHLROL	231
Oy	253	L-RKSTFRNALYCPDVOCPRRKAKMLKSTLAKGGEYIDSYTHNHYLYNGRATREDDFL	311
Dd	232	LSOHPLRHALYGLDGOOPRKHPOHLLRSMKSGGAIDSYTHNHYVNGRSATREDDFL	291
Oy	312	NPDWLIDFISSVQVFOVESTPRGKKVMLGETSSAAGGGAFLPILSDPFAGFMYLIDKLG	371
Dd	292	SPEVLDSPATVAIHDVGLIGVETAPGKKVYMLGETOSAVGGGAPOLSNYYVAGFMYLIDKLG	351
Oy	372	SABKGLIEVYMOVFFGAGNHLVDENEDPLPDYVLSLFLFKLVGTKYVLMASVOGSKRRKL	431
Dd	352	AARGCIDVYMOVSFEGAGSYLVDAGCFPLPDYVLSLFLYKLVGTBYLQASVFEADARRP	411
Oy	432	RVLHCTHTDNPARKCEDGLTYAINTLNNVYVLYLPFFSKNOVDXKLLPLRPGHLLSK	491
Dd	412	RVLHCTNPRIHPKXREDOVTLFALNISVNTOSIDLPOQLMSKSVDOYLLPLPHCKDLSLKR	471
Oy	492	SVOLNGLTLKAVDOOTLPRLMEKRLPRGSSSLGFLPASTSEFVYIRNAKVAACI	543
Dd	472	EVOLNGLQWODETLPALHEMLAAGSTGLPAPFSGYGVYIRNAKVAACI	523

RESULT	6
09HB37	
ID	09HB37
PRELIMINARY:	PRT;
592 AA.	
AC	09HB37;
DT	01-MAR-2001 (TrEMBLrel. 16, Created)
DT	01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT	01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE	Heparanase-like protein HPazC.
OS	Homo sapiens (human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX	NCBI_TaxID=9606;
RN	11
RP	SEQUENCE FROM N.A.
RX	MEDLINE=20483645; PubMed=11027606;
RA	McKenzie E., Tyson K., Stamps A., Smith P., Turner P., Barry R.,
RA	Hickcock M., Patel S., Barry E., Stubberfield C., Terrett J., Page M.;
RT	"Cloning and Expression Profiling of Hpa2, a Novel Mammalian
RT	Heparanase Family Member.";
RL	Biochem. Biophys. Res. Commun. 276:1170-1177(2000).
DR	EMBL: AF282887; AAC3423.1; "
DR	Interpro: IPR005199; Glyco_hydro_79n.
DR	Interpro: IPR005199; Glyco_hydro_79n.
CO	PF03662; Glyco_hydro_79n; 1.
SEQUENCE	592 AA: 66580 MW: 95C384AD9A74258E CRC64:

Query Match	40.68;	Score 1154.5;	DB 4;	Length 592;
Best Local Similarity	44.28;	Pred. No. 7.1e-82;		
Matches 251;	Conservative 81;	Mismatches 199;	Indels 37;	Gaps 8;

0y 10 PEPMLLLIGPLGPLSGCALPR-----AAADVDVDFDFTQERLLHYSSFSLYT 61
 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
 Db 24 PGALYLALLLHLSSISQAGDRPLPVDRAGLKEKTLILDVSTKMPFVNEPFLSL 83
 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
 0y 62 DANLATDPRLLILGSPKRLTLAGLSPAYLRFGTKTDFLIR--DPKKESTFEERSY 117
 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
 Db 84 DPSLIHD-GWIDPFSRSRLVTLTLAGLSAPFLRFGCKTDDLQCNLNNPKSGSGCPDV 142
 ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

Oy 118 MOSOVNOOI-----CKXGSIIPRVEEXKLREMPYEOUL-LLREHJOXKPFKNST 16
Db 143 YLKNTEEDDIIVSDDVALDKOKCKKIAQ--HPDMLELOREKAOMHIVLLEKEDFSMTYSVL 20
Oy 165 YSRSSVDVLYTFPANCGLDLIFGNALLRTADLOMNSSNAOLLIDYCSSKCYNI SWEIGN 22
Db 202 LTARELDLQVNFADCSGHLIFALNALBRNNMNSNSALSLLKYSASKKYNI SWEIGN 26
Oy 225 EPNSTLKAADLFINGSOLGEDYIOLHKLKR-STFKNAKLGPVGOGRKTKAMLSFL 28
Db 262 EPNNTRTMHGRAVNGSOLOKQYIOLKSLDQIRIYSRASYLGPNIIGRKKVVALLDGFM 32
Oy 284 KAGEVITDSVMHHNYULGFRATREDFLPVULIIFSSVOYOVEESTRPGKKWMLGE 34
Db 322 KVAGSTVDAYVMOHCYIDGRVYVKKMDPLKTYLLDLOTLSDQIRIKOVYNTYTRPGKKINLEG 38
Oy 344 TSSAYGCGARLLSDTPFAAGFMWLDLGLSARMIIEVUMROYFGAGNYHVDENFDRLPD 40
Db 382 VVTTTSAGSTNNLSYSAAGFMYLMTLGLMALNOGIDVUYI RHFSPDHGYNHILDOGFNPLR 44
Oy 404 YWLSLLEFKLIVGTGVULMAVSGGSKRR-----KLRYVUHCNPNDPRKKEEDLTLXA 45
Db 442 YWLSLTKKRLGPRVULAVHVAIGLORKRPRGVIRDKLRTIYANCTNNHNNHNVKOSTLFI 50
Oy 455 INLHNVTKYULRPYRFSNKQDYKULRPLRGPHGLSKSVOLNGLTLKAMVDOTDLPRLMEK 51
Db 502 INLHRSRKKIKLACGLRDKLIVHXLLOPYRGEGGLSKSVOLNCGRLVMMVDOGTLRDLKPR 56
Oy 515 PLRPGSSILGRLPASFYSFFVYIRNAKVAAC 542
Db 562 PLRAGRTLVLRPVYMGFFVYVKNVAAAC 589

```

RESULT 7		
08NM02		
ID	08NM02	PRELIMINARY;
AC	08NM02;	PRT: 592 AA.
DT	01-MAR-2002 (TREMBLrel. 20, Created)	
DT	01-MAR-2002 (TREMBLrel. 20, Last sequence update)	
DT	01-JUN-2002 (TREMBLrel. 21, Last annotation update)	
DE	Heparanase 2.	
OS	Homo sapiens (Human).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
OX	NCBI_TaxID=9606;	
RN	[1]	
RP	SEQUENCE FROM N.A.	
RC	TISSUE=PROSTATE;	
RA	Pessegue Safontas B.J.O.P.S.;	
RL	Submitted (SEP-2000) to the EMBL/GenBank/DBJ databases.	
RN	[2]	
RP	SEQUENCE FROM N.A.	
RC	TISSUE=PROSTATE;	
RA	Legoux P., Legoux R., O'Brien D., Salome M.;	
RL	Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.	
DR	EMBL: AJ299719; CAC82491.1; -	
DR	InterPro: IPR005199; Glyco_hydro_79n.	
DR	Pfam: PF03662; Glyco_hydro_79n; 1.	
SO	SEQUENCE 592 AA; 66520 MW; 9478841FEACD558B CRC64;	

Query Match	40.38;	Score 1146.5;	DB 4;	Length 592;
Best Local Similarity	44.08;	Pred. No. 3e-81;		
Matches 250;	Conservative 81;	Mismatches 200;	Indels 37;	Gaps 8

0Y PPLPLLILGRLGFLSGALPR-----AAADVDLDFTOEQLILVSPSVLT 61
10 PPLPLLILGRLGFLSGALPR-----AAADVDLDFTOEQLILVSPSVLT 61
Db PGALYLLLLHLHLSISQAGRRPLPVDRAAGLKEKLLILLDVSTKNPVRVNEPFLSTOL 83
24
62 DANLADPRLLILGSPKLTLAGLSPAYLARGCTDPLF---DPKESFEERY 117
84 DPSTIHD-GULDFFSSNRLLTLAGLSPALRFGCGRRFTQLONLRNPAKSGGCGPDY 142


```

Db 194 ---SNTVS-----NLIL-----202
Oy 219 SMLGNENPFLKADIFINGSQLEDYIOLHLKLR-STFKNAKLYGPDVGOPRRKTAK 277
Db 203 -----TEPNNTYRTMHGRAVNGSOLGKODYIOLKSLDPIRISRSALYGPINIGRRKNVIA 257
Oy 278 MLKSFLLAGGEVIDSVTHWHYLLNGRTATREDPLNDVLIFFISSVQKVFQVESTPRGK 337
Db 258 LLDFMKVACSTVDVAVTMOHCYIDGRVVKVMDPLKTRLLDPLTSDQIRKIOGVNTVTPGK 317
Oy 338 KVMLEGTSSAAGCAPLLSOTFAAGFMMLDKLGISARNGIEVVRKOVFFGAGNHLVDEN 397
Db 318 KIMLEGAVTTSAGGTNNLSDSYAAGFMLNTLGMLANOGIDVYIRHSFFDHGYNHLVDON 377
Oy 398 FDPPLPDYVLSLLFKKLVGTVMASVQSKRR-----KLRVYLHCTNTDPRYKEG 448
Db 378 FNPPLPDYVLSLLYKRLIGPKVLAVVAGLOKRRPKRYIRKLLIYAHCTNNHHNNHYRG 437
Oy 449 DLTLYAINLHNVTYRLPYPPFSNKOVDKYLLRPLRPHGLSKSVQNLGLTKMVDOTL 508
Db 438 SITLFIINLHRSRKKIKLAGTLRDKLVHQLYLOPYGEGGLSKSVQNLGQPLVWDDGTL 497
Oy 509 PRLMEKPLRPGSSLGCLAFSFFVIRAKVAC 542
Db 498 PELKPRPLRAGRTLVIIPVTMGFFVYKVNVALAC 531

```

RESULT 10

```

Oy 09HB39 PRELIMINARY: PRT: 480 AA.
AC 09HB39:
DT 01-MAR-2001 (Tremblrel. 16, Created)
DT 01-MAR-2001 (Tremblrel. 16, last sequence update)
DT 01-JUN-2002 (Tremblrel. 21, last annotation update)
DE Hepatranase-like protein HP2a.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606.
RN 11)
RP SEQUENCE FROM N.A.
RX MEDLINE=20483645; Pubmed=11027606;
RA McKenzie E., Tyson K., Stamps A., Smith P., Turner P., Barry R.,
RA Hircock M., Patel S., Barry E., Stubberfield C., Terrett J., Page M.;
RT "Cloning and Expression Profiling of Hpa2, a Novel Mammalian
RT Hepatranase Family Member."
RL Biochem. Biophys. Res. Commun. 276:1170-1177(2000).
DR EMBL: AF282885; AAG23421.1;
DR InterPro: IPR005199; Glyco_hydro_79n.
DR Pfam: PF03662; Glyco_hydro_79n.1.
SO SEQUENCE 480 AA; 53900 MW; F75F89F67AC1FFB3 CRC64;

```

Query Match 31.6%; Score 897.5; DB 4; Length 480;
 Best Local Similarity 36.0%; Pred. No. 7e-62;
 Matches 202; Conservative 74; Mismatches 146; Indels 139; Gaps 9;

```

Oy 20 PLGLSPGAL-----PRPA-----QAQDVVDLDFPFOEPLHLVSPS 55
Db 18 PPAALGALYLLALLHLSSQAGDRPLPVDAAGLKEVTLILLVSTKNRYTNNEN 77
Oy 56 FLVSTIDANLATDPRFLLGLSPKRLTLARCLSPAYLRFSGTKTDPLIF---DPKKEST 111
Db 78 FLSTQDLPSTIHD-CMLDPLSSSKRLVTLARCLSPAYLRFSGTKTDPLIF---DPKKEST 135
Oy 112 FEESYQSOVNOODICVYGSIPRVEEKLRLMEPYQOLLREHYOKKFKNSYTSRSVD 171
Db 136 -----GGGPGP-----YLLNKE-----148
Oy 172 VLYTFANCGLDLIFGLNALRTADLQMNSSNQLLDYCSSKGYNSWEIGNEPNSFLK 231
Db 149 -----DEPNNYRT 156
Oy 232 KADIFINGSQLEDYIOLHLKLR-STFKNAKLYGPDVGOPRRKTAKMLSKLAGEVIT 290

```

```

Db 157 MHGRAVNGSOLGKDYIOLKSLDPIRISRSALYGPINIGRRKNVIALDGFMKVAGSTV 216
Oy 291 DSVTHWHYLLNGRTATREDPLNDVLIFFISSVQKVFQVESTPRGKVMLEGTSSAAGC 350
Db 217 DAVTMOHCYIDGRVVKVMDPLKTRLLDPLTSDQIRKIOGVNTVTPGKIMLEGVNTTSAG 276
Oy 351 GAPLLSDTFAAGFMMLDKLGISARNGIEVVRKOVFFGAGNHLVDENFDPLPDYVLSLIF 410
Db 277 GTNNLSDSYAAGFMLNTLGMLANOGIDVYIRHSFFDHGYNHLVDONFNLPDYVLSLIT 336
Oy 411 KLVGTVMASVQSKRR-----KLRVYLHCTNTDPRYKEGDLTLYAINLHNVT 461
Db 337 KRLIGPKVLAVVAGLOKRRPKRYIRKLLIYAHCTNNHHNNHYRGSTLFIINLHRSR 396
Oy 462 KYLRPLPYPPFSNKOVDKYLLRPLRPHGLSKSVQNLGLTKMVDOTLPRLMKPLRPGSS 521
Db 397 KIKLAGTLRDKLVHQLYLOPYGEGGLSKSVQNLGQPLVWDDGTLPELKLPRLRAGRT 456
Oy 522 LGPLAFSFFVIRAKVAC 542
Db 457 LVIPVTMGFFVYKVNVALAC 477

```

RESULT 11

```

Oy 08T108 PRELIMINARY: PRT: 515 AA.
AC 08T108:
DT 01-JUN-2002 (Tremblrel. 21, Created)
DT 01-JUN-2002 (Tremblrel. 21, last sequence update)
DT 01-JUN-2002 (Tremblrel. 21, last annotation update)
DE Hepatranase-like protein.
CN BMHPPA.
OS Bombyx mori (Silk moth).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia;
OC Bombycoidea; Bombycidae; Bombyx.
OX NCBI_TaxID=7091.
RN 11)
RP SEQUENCE FROM N.A.
RC STRAIN=P50; TISSUE=POSTERIOR SILK GLAND;
RA Koike Y., Simada T., Suzuki M.G., Mita K., Abe H., Maeda S.,
RA Oseogawa K., Dejong P.J.;
RT "Genomic sequence of 320kb containing a kettin orthologue on the Z
RT chromosome in Bombyx mori."
RL Submitted (FEB-2002) to the EMBL/Genbank/DBJ databases.
DR EMBL: AB079860; BAB85191.1;
SO SEQUENCE 515 AA; 59769 MW; FB8100ABEGEDDADB CRC64;

```

Query Match 24.5%; Score 696; DB 5; Length 515;
 Best Local Similarity 35.1%; Pred. No. 4.8e-46;
 Matches 183; Conservative 83; Mismatches 182; Indels 74; Gaps 18;

```

Oy 46 OEPLHLVSPSLSVTTIDANLATDPRFLLGLSPKRLTLARCLSPAYLRFSGTKTDPLIFD 105
Db 42 OEDIKLISEDFLFGID-TIEIENYRNISDTRRELAALAPRLRGCTMSERLIF- 99
Oy 106 PKKESTFEESYQSOVNOODICVYGSIPRVEEKLRLMEPYQOLLREHYOKKFKNSY 165
Db 100 -SKENI-----PLSCNCSYKSYPSLCO--LIEKPC-----KKHAKFLPFFIM 140
Oy 166 SRSSVDVLYTFANCGLDLIFGLNALRTADLQMNSSNQLLDYCSSKGYNSWEIGNE 225
Db 141 TGNEMNOINDFCRKTNLKILFSLNMLARD-NHGNENKMARLEIEFSKIKHOYAIOWDOLGNE 199
Oy 226 PNSFLKADIFINGSQLEDYIOLHLKLRSTFKNAKLYGPDVGOP---RRKTAKMLKSF 282
Db 200 PMSFOHVFNEYSYPOILARCFEKLRLKLNHNGYRSLIVGPDTPRQPHRECLKYMIEF 259
Oy 283 LKAGEVIDSVTHWHYLLNGRTATREDPLNDVLIFFISSVQKVFQVESTPRGKAV-W 340
Db 260 LGNGSHYINVRSHOYLLNSKTAKLEDPMNPEFDLL---RDOIETMOTQTKYKXNPM 316

```



```

Oy - 341 LGFSSAAGGAPALLSTPTFAAGFPMWLKGLGISAAMGIEVMMPOVFCAGNYHLHREKDFD 400
      111111111111111111111111111111111111111111111111111111111111
Db 317 LSEFSSSSGGCAPLSSMTNTYACSPMLMDKLGLSAKYNTSYTIRSFQIG-GRYSLYDENLKP 375
Oy 401 LPDYMLSLPEKKILGYTVKVLMAVSOGSKRRKLRYVYLHCTNTDNPYKE--GDLTLYAIN-- 456
      111111111111111111111111111111111111111111111111111111111111
Db 376 LPDMWJISVLYKILGVNKKVL--QVQCNCSSRFQDLYIHCTNR--KYTNDTSAVTLYGVNLE 430
Oy 457 -----LN-----VTKYLRLPYPPSSNNKQVDKYYLRLPLGPHOLLSKSVQNGTL 500
      111111111111111111111111111111111111111111111111111111111111
Db 431 MAKARFPLNGTALHGLDGLIHHEYI-ISAPNNRK-----SKTILLNGMPL 474
Oy 501 KMYDDQRLPLMEKRLPRGSSGLGPAESYSEFVIRNAKVAAC 542
      111111111111111111111111111111111111111111111111111111111111
Db 475 YY--ESNLIHLRPMIHRYGKRYSLPPYSISGFWYIKKTSITVC 514

```

RESULT 12

ID	PRELIMINARY;	PRT;	521 AA.
AC	09SDM1:		
AD	01-MAY-2000 (TrEMBLrel. 13, Created)		
DT	01-MAY-2000 (TrEMBLrel. 13, last sequence update)		
DT	01-JUN-2002 (TrEMBLrel. 21, last annotation update)		
DE	Hypothetical 57.8 kDa protein.		
DE	P13G24.30.		
OS	Arabidopsis thaliana (Mouse-ear cress).		
OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;		
OC	Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;		
OC	eucosids II; Brassicales; Brassicaceae; Arabidopsids.		
OX	NCBI_Taxid=3702;		
OX	[1]		
RP	SEQUENCE FROM N.A.		
RP	Bevan M., Van Der Schueren J., Chuang Y.J., Voel M., Robben J.,		
RA	Volckaert G., Bancroft I., Mewes H.W., Lemcke K., Meyer K.F.X.;		
RL	Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.		
RL	[2]		
RP	SEQUENCE FROM N.A.		
RA	EU Arabidopsis sequencing project;		
RA	Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.		
RL	EMBL: AL133421: CAB2595.1: to the		
DR	InterPro: IPR005199; Glyco_hydro_79n.		
DR	InterPro: IPR001254; Ser_protease_Try.		
DR	Pfam: PF03662; Glyco_hydro_79n: 1.		
DR	ProSITE: PS00135; TRYPsin_SER; UNKNOWN_1.		
KR	Hypothetical protein.		
SO	SEQUENCE 521 AA; 57831 MW; 07DB664A4B305CC2 CRC64;		

Query Match	14.6%;	Score 416;	DB 10;	Length 521;
Best Local Similarity	29.2%;	Pred. NO. 4.2e-24;		
Matches 154;	Conservative 68;	Mismatches 184;	Indels 122;	Gaps 24;

Oy	75	LGSFKRLFLAGLSPPALYRFGSTDTDFLEIPPKKESFPEERSWSQOVODICKGYSIFP	134
Dd	55	LTRLLRLFAIKAFRLRIATRGISLODYIVDGLTKT-----PCR-----	94
Oy	135	DVEEKLREMPYOEOQLLREHYOKKFKNSS---TYSRSVY----DVLYTFANCSGLDLIF	186
Dd	95	-----PFOKM-----NSGLFFGFSKSCLIIMKRWDELNSTLTATGAVVTF	132
Oy	187	GLNALRLPTADLO-----WNSSNAOLLDLVCCSKGVNI--SWELGNENPSFLKKADIIN	238
Dd	133	GLMALRGNNIKLRGCANGCANDHITODPLTYATYSKGVIIDSMWRGNLSC--SGVCASVS	190
Oy	239	GSQLSEEDYLQHLKLKRSTFNAAKLYGRPDVQR-----RRKTAMKLSPFKAGEVIDSV	293
Dd	191	AELYGKDILYLRKVINK-VUKNSMLHKRPILAVAPGFEEYOOMUYKLELEI-----SGPSYVDV	246
Oy	294	TNNHYUULNGRT--TTREDPLRVLDLIEISYQVF-----OVESTPRKKVMYLGERTSA	347
Dd	247	TNNHYUNLSCGDRLRYLAKKINDPS-----YLSVSKTFPFADVMOITIOEHNRPAASPWGEGSGA	302
Oy	348	YGGAPRLSLDTFAAGFMWLCKLGLSARMKGLEVVNRQVFGAGNHNVLDE--NFDPRLPYWL	406

[illegible]

RESULT 13

```

AD O9FF10: PRELIMINARY: PRT: 543 AA.
AC O9FF10:
DT 01-MAR-2001 (TEMBLrel. 16, Created)
DT 01-MAR-2001 (TEMBLrel. 16, last sequence update)
DT 01-JUN-2002 (TEMBLrel. 21, last annotation update)
DE Similarity to heparanase.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons: core eudicots; Rosidae;
OC eustosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID:3702;
||
RN RP SEQUENCE FROM N.A.
RC STRAIN=COLUMBIA.
RX MEDLINE=97471969; PubMed=9330910;
RA Sato S., Kotani H., Nakamura Y., Kaneko T., Asamizu E., Fukami M.,
RA Miyajima N., Tabata S.;
RT "Structural analysis of Arabidopsis thaliana chromosome 5. I. Sequence
RT features of the 1.6 mb regions covered by twenty physically assigned
RT pl clones."
RL DNA Res. 4:215-230(1997).
DR EMBL: AB005249; BAB09947.1;
DR InterPro: IPR005199; Glyco_hydro.79n.
DR InterPro: IPR001254; Ser_protase_Try.
DR Pfam: PF03662; Glyco_hydro.79n.1
DR PROSITE: PS00135; TRYPSIN_SER; UNKNOWN_1
SO SEQUENCE 543 AA: 60250 MW: 0FA2248946282FF6 CMC64;

```

Query Match	14.68;	Score 416;	DB 10;	Length 543;
Best Local Similarity	29.28;	Pred. NO. 4.5e-24;		
Matches 154;	Conservative 68;	Mismatches 184;	Indels 122;	Gaps 24;

Oy	75	LCSPKLPYLAGLSBPATVLRFGCTTDPDLIPPKKESPIFEERSWOSOVODICKYSGTIP	134
Db	77	LTPRLTKATKAPFRLPRIRIGSLDODYIVGMLYKTF-----PCR-----	116
Oy	135	DVEEKLREMPYEQOLLREHYOKKFNKS---TYSRSSV-----DVLTYFANCSGULIF	186
Db	117	-----PFOKM-----NSGLFGFSKCKLIMKRWDELINSLTGTGAAYTF	154
Oy	187	GLNALTPYADIQ-----WNSSNAOLLVDYCSSEKGYNI-SWELGNEPNPSFLKADIFIN	238
Db	155	GLLMLRGKMLRKGCANGCANGDHITQDFELANTYSGVIVDSMERGENSLSC--SGVAGSAS	212
Oy	239	GSQJCEDTYQLIKLIRKSTERNKMLYGRDVGOP-----PRKTAAMLKSPFKAGEVIVDSV	293
Db	213	AELVGKDDLIYKLDVINK-VYKNSMLHKPILVAPGCFYEDQWYTKLEFI-----SGSVADV	268
Oy	294	TWNHYLLNGRT--ATREDFELPDVLDLFIISVOKVF-----QVESTPRGKKVLYGETSSA	347
Db	269	TNHHIYNIGSGNDRLAYKKIMDPS-----YLSQVSTKTFVDVNOJTOEHGNPMASPHYVGESGA	324
Oy	348	YGGCAPLLSDIYFAANGCMMLDKLGISARMGILEVYAKROVFCGACNTHLYDE-NFDPRLPDYWL	406
Db	325	YNSGRIHVSIDPIFDISFWYLDLQGSASAHNRTKYVCROTLPVIG-GEFGLLEKCTFVPNNPYYS	383

```

Oy 407 SLFFLKRLVYKVLMAVSGVSKRRKRLRYDHGCTNTDNPBPKCEGDLTLTYALNHLNVKYL-- 464
Db 304 ALLHMRIMKGVKVLAVOTDGP--QLRYVAHCKS-----GRGVITLLILNLSQSPFTVS 435
Oy 465 -----RLPYPFs--NKQYDKYLLRP--LGPHG--LLSKSVOL 495
Db 436 VSNGINVNLMAESRRKKSLDLDLKKRPFSWIGSKASDGYLNREYHLTPENGVLRSKTMVL 495
Oy 466 NGLTLKAWDDOTLPLPLMEKPLRP-GSSGLCLPAFSFSFYIRAKKAAC 542
Db 496 NKSLSLKPATGDIPLS-L-EPVLRKSVNSPLNVLPLMSFIVLPNFDASAC 542

RESULT 14
AC 09LRC8 PRELIMINARY: PRT: 527 AA.
ID 09LRC8
Df 01-OCT-2000 (TREMBlrel. 15, Created)
Df 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
Df 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
Df Beta-glucuronidase.
Df SGUS.
Df Scutellaria baicalensis.
Df Eukaryota, Viridiplantae: Streptophyta; Embryophyta: Tracheophyta;
Df Spermatophyta: Magnoliophyta: eudicotyledons: core eudicots:
Df Asteridae: easterids I; Lamiales: Lamiaceae: Scutellaria.
Df NCBI_TaxID=65409.
Df 11
Df SEQUENCE FROM N.A.
Df MEDLINE=20418130; PubMed=10858442;
Df Sasaki K., Taura F., Shoyama Y., Morimoto S.;
Df "Molecular characterization of a Novel beta-Glucuronidase from
Df Scutellaria baicalensis Georgi.";
Df J. Biol. Chem. 275:27466-27472(2000).
Df EMBL: AB040072; BAA97804.1;
Df InterPro: IPR001179; FKBP_PPIase.
Df InterPro: IPR005199; Glyco_hydro.79n.
Df Pfam: PF03662; Glyco_hydro.79n.1.
Df PROSITE: PS00453; FKBP_PPIASE.1; UNKNOWN.1.
Df SEQUENCE 527 AA; 58772 MW; ASDETC423F2A1E2B CRC64.
SO

Query Match 13.4%; Score 381; DB 10; Length 527;
Best Local Similarity 25.2%; Pred. No.2,4e-21;
Matches 133; Conservative 83; Mismatches 178; Indels 134; Gaps 22.

Oy 55 SFLSTTIANLADTPRFLILGSPKRLRLARGLSPAYLRFSGTKTDFLIDPKKSTEEF 114
Db 69 SFLNLDLNNNI-----IRNAVKEFAFLKLFRCGTLDDRLVYQTSRDEPCDS 114
Oy 115 RSYMOSONODICKYGSIPPOVEKRLRLPEWPOEDLLREHYQKKFKNSTVSRSVDVLY 174
Db 115 TFYNNFTNLID-----FSHACSLDRMDEIN 140
Oy 175 TFCANSGDLIFGLNAL-----LRTADLQNNNSNQLLDYCCSSKG 215
Db 141 OFILETGEAAYVGLNALRGKTVEIKGIIDGQYLGCTTTAVGEMDYSNSKFLIEYSLKGG 200
Oy 216 YN--ISMELGNENPSFLKADIFINGSQLGEYI---QLHLKRSKTFKNAKLYGPDVG 269
Db 201 YKHIGMFLGNE--LGGHFLFIVSP--EDYANDAKKLHFLVK-----EIQDOGT 247
Oy 270 QPRRKTAKLMSFLKAGEVID-----SVYWHYY--LNGRTATREDFLN 312
Db 248 MP-----LIARPAIFDLEWYTERITDTPRELHYATTHMYNLGSGGDDALKDVLIT 297
Oy 313 PDVLIDFISSVQKVFQVEYSTRPGKK--VWLGETSSAYGGGAPLLSDTPFAAGFMWLDKLG 370
Db 298 ASFDEATKRSMEGLQKIVN--RPGTKAVAMIGEACGAFNSGGDGISNFFINGFWYFLNMLG 356
Oy 371 LSAKMGIEVWARYOVFFGAGNHLVDE-NFDLPDYWLSLFFKLVGTYKVLMAVSGSKRR 429
Db 357 YSALDDTTFPCRQTLTG-CNYGLLQDTGTYIPNDPVYSLALLHMRIMKGVKVLKREIVGT-- 413

```

```

OY 430 KLRVHCTNTDNPRTYKESGDLTYALNHLNHNKYLRL---PVPFSKQVDXYLRLPLGPH 486
Db 414 NYVYTHACAK-----KSGNTMTLVLN-HDGEVSKVSLDPSKYSKR-EEYHLPVFN-N 464
OY 487 GLLSKSVOLNGLTLKMYVDQTLPLMEKPLRFGSSGLGPAFSYFFVI 534
Db 465 NLSQSLVYKLNGLLHLDPGVIPL--NPVEKDNSKOLEVARYSFMFV 510

RESULT 15
O9FZP1 PRELIMINARY: PRT: 536 AA.
AC O9FZP1:
DT 01-MAR-2001 (Tremblrel. 16, Created)
DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)
DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
DE Similarity to heparanase.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eunotios II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=COLUMBIA;
RA Kaneko T., Katoh T., Asamizu E., Sato S., Nakamura Y., Kotani H.,
RA Tabata S.;
RT "Structural analysis of Arabidopsis thaliana chromosome 5. XI.";
RL Submitted (JUN-1999) to the EMBL/Genbank/DBJ databases.
DR EMBL: AB028613; BAB10787.1;
DR InterPro: IPR005199; GLYCO_hydro_79n.
DR Pfam: PF03662; Glyco_hydro_79n; 1.
DR PRINTS: PR01656; VACCITOTOXIN.
DR SEQUENCE 536 AA; 59654 MW; 242028B8E2F3DB0E CRC64;

Query Match 12.8%; Score 363; DB 10; Length 536;
Best Local Similarity 24.6%; Pred. No. 6,2e-20;
Matches 127; Conservative 81; Mismatches 176; Indels 132; Gaps 20.

OY 88 SPAYLRFGCTKTDLPDKPKKESTFEERSYWOSOVNODICKYGSIPPOVEEKLRLMPYO 147
Db 91 APLKIRIGCTODIVIYE-----TPSKQPC--LPFT 120
OY 148 EOLLREHYOKKFNKST---YSRSSV-----DVLTYFANCSGLDILGJNLL----- 192
Db 121 -----KNSSLFPGTGGCLPMRRDELINAFPRKGTGVIVGLNLSGRSIS 167
OY 193 -RTADLQWSSNAOULLDYCSSKCYNI-SWELGNEPNSFLKADIFINGSOLE----- 244
Db 168 NGEAIGANNYINAESFIIFTAENNYTIDGWELGNE-----LCGSGCARVANO 216
OY 245 ---DYIQLHKLKRSSTFRNAKLYGPDVQOPRRKTKAMKLSFLKAGEVYIDSYTHHYLYN 301
Db 217 YAIPTLINLRNIVNR-VYKNVSPMLVYIGPGFEFVDWTFEYLKNAKENSINATTHIYDLG 275
OY 302 GRTATR--EDFLPNVDLDIFISSYQVQVQVESTPRPKVMYLGTSYAGGAPILSDPF 359
Db 276 PGVDHLEKLNLSYLDQDEAKSFRSLNIIKNSSTKAVANVYBEGCAYNSGRNLVSNAF 335
OY 360 AAGFMWLDKLGLSARMGILEVMVROVFCGAGNYHLVD--ENPDLPDYMWLSLFFKLVGTRV 418
Db 336 VYSEFWYLDQGLMASLYDTRKYTCROSLIG-GNYGLLNTNTFPNPIDYVSALIMRQLMGRKA 394
OY 419 LMASVQSGKRRKRLVLYLHCTNDNPRYREGDLYLAIMLHV-----T 461
Db 395 LFTFSGTR--KIRSTYHCA-----ROSKG-ITVLLMLDMNTTVAVAKVELNNSPSLRHT 446
OY 462 KYLRPLVPFSKQVDXYLRLPLGPHGLL-----SKSVOLNGLNLTLMYVDQ 506
Db 447 KHKM-----SKRASSQLFG--GRNGVIGREDEYHILTKADGNLHSOTMLLNGLNALQVNSMG 499
OY 507 TLPLMEKPLRFGSSGLGPAFSYFFVIIRNAKVAAC 542

```

DB 500 DLPPIEPHINSTEPTITAPYSIVFVHMNRNVVPAC 535

Search completed: November 20, 2002, 11:37:17
Job time : 40 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 20, 2002, 11:31:59 : Search time 39 Seconds

(without alignments)
1855.259 Million cell updates/sec

Title: US-09-759-207-2

Perfect score: 2842 1 MLRSKPPALPPLMLLGP.....LPATSFYVIRAKVAACT 543

Sequence: BL0SUM62

Scoring table: Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : Listing first 45 summaries

A_Geneseq_101002.*
1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.*
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2842	100.0	543	20	AAV02345
2	2842	100.0	543	21	AAAB0849
3	2842	100.0	543	21	AAV57590
4	2842	100.0	543	21	AAV52990
5	2842	100.0	543	22	AAV97635
6	2842	100.0	543	23	AB07813
7	2842	100.0	592	20	AAV02346
8	2842	100.0	592	21	AAAB0850
9	2838	99.9	543	20	AAV17082
10	2838	99.9	543	22	AAAB6206

11	2838	99.9	588	20	AAV30124	A human protein w/
12	2826	99.4	543	22	AAAB8361	human membrane or
13	2764	97.3	530	20	AAV34173	human pre-prohepar
14	2737	96.3	532	20	AAV17083	Seq ID No: 15 of W
15	2673.5	94.1	527	23	AB07815	Chicken signal pep
16	2146	75.5	535	21	AAAB08851	A murine heparanas
17	2146	75.5	535	23	AB07811	Mouse heparanas s
18	2123	74.7	536	23	AB07812	Rat heparanas seq
19	1645.5	57.9	523	23	AB07814	Chicken heparanas
20	1614	56.8	380	20	AAV17085	Rat heparanas enz
21	1602	56.4	380	20	AAV17084	Mouse heparanas e
22	1154.5	40.6	592	22	AAV07424	Human heparanas-1
23	1154.5	40.6	592	22	AAV97632	Human heparanas-1
24	1148.5	40.4	592	22	AAAB51052	Human heparanas-2
25	1147.5	40.4	592	22	AAAB5215	Heparanas-1 like pr
26	1142.5	40.2	582	23	AAE18336	Human heparanas-2
27	1112.5	39.1	538	22	AAV97633	Human heparanas-2
28	1106.5	38.9	528	23	AAE18337	Human heparanas-2
29	936.5	33.0	534	22	AAAB5216	Heparanas-1 like pr
30	936.5	33.0	534	22	AAV0337	Human prepro-hepar
31	927.5	32.6	492	22	AAAB4664	Amino acid sequenc
32	897.5	31.6	480	22	AAU07418	Novel human extrac
33	897.5	31.6	480	22	AAAB5217	Heparanas-1 like pr
34	897.5	31.6	480	22	AAV97634	Human heparanas-2
35	892.5	31.4	470	23	AAE18338	Human heparanas-2
36	891.5	31.4	439	22	AAU07423	Human heparanas-1
37	788	27.7	331	23	AAV050383	Human heparanas-1
38	663	23.3	488	22	AAAB1469	Amino acid sequenc
39	645	22.7	488	22	AAAB1470	Amino acid sequenc
40	642	22.6	488	22	AAAB1472	Amino acid sequenc
41	622	21.9	488	22	AAAB1471	Amino acid sequenc
42	528.5	18.6	214	22	AAV99905	Human excretory re
43	528.5	18.6	214	22	AAV3704	Human bladder anti
44	338.5	11.9	156	22	AAAG5963	Human heparanas-1
45	277.5	9.8	256	21	AAG13479	Arabidopsis thalia

ALIGNMENTS

RESULT 1
AAV02345
ID AAV02345 standard; Protein: 543 AA.
AC AAV02345:
XX
XX 09-JUL-1999 (first entry)
DT
XX
XX A human heparanas protein.
DE
XX
XX Heparanas: hp; modulator; heparin-binding growth factor;
KW cellular response; cytokine; cell interaction; plasma lipoprotein;
KW cellular susceptibility; infection; disintegration;
KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease; neutralise;
KW plasma heparin; micrometastasis; autoimmune lesion; renal failure.
XX
XX Homo sapiens.
OS
XX
XX WO9911798-A1.
PN
XX 11-MAR-1999.
PD
XX
XX 31-AUG-1998; 98MO-US17954.
PF
XX 02-JUL-1998; 98US-0109386.
PR 02-SEP-1997; 97US-0922170.
XX
XX (FRIE/) FRIEDMAN M M.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (INST-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodavsky I;

Dh 181 GLDLFGILNALLRTADLQNMSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFINGS 240
Qy 241 QLGEDYIQLHKLLRKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTMHHYLL 300
Dh 241 QLGEDYIQLHKLLRKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTMHHYLL 300
Qy 301 NGRTATREDFLNPVDLFISSVOKVQVVESTPRGKKWMLGETSSAYGGAPLLSDTFA 360
Dh 301 NGRTATREDFLNPVDLFISSVOKVQVVESTPRGKKWMLGETSSAYGGAPLLSDTFA 360
Qy 361 AGFWMILDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Dh 361 AGFWMILDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Qy 421 ASVQSKRRKRLRYVLIHCTNTDNPRYKEGDLTLVA1NLHNVTKYRLRPYPSNKOVDYLL 480
Dh 421 ASVQSKRRKRLRYVLIHCTNTDNPRYKEGDLTLVA1NLHNVTKYRLRPYPSNKOVDYLL 480
Qy 481 RPLGPHGLSKSVOLNGLTLMKVDOTLPLMEKPLRPGSSGLPAPSYSEFVIRNAKVA 540
Dh 481 RPLGPHGLSKSVOLNGLTLMKVDOTLPLMEKPLRPGSSGLPAPSYSEFVIRNAKVA 540
Qy 541 ACI 543
Dh 541 ACI 543
RESULT 3
AAV57590
ID AAV57590 standard; Protein: 543 AA.
XX AAV57590:
DT 02-MAR-2000 (first entry)
XX Human heparanase.
DE Human heparanase.
XX Human: heparanase; hpa; genetic modification; expression; anticancer;
KW angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumor;
KW anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
KW heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
KW metastasis; wound healing; restenosis; atherosclerosis; inflammation;
KW neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
KW micrometastasis; autoimmune lesion; kidney failure.
XX Homo sapiens.
OS
PN W0957244-A1.
XX 11-NOV-1999.
PD
XX 29-APR-1999: 99WO-US09256.
PE
XX 01-MAY-1998: 98US-0071618.
PR 02-MAR-1999: 99US-0260038.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX (FRIE/) FRIEDMAN M. M.
XX Ben-Artzi H, Ayal-Herskovitz M, Yacoby-Zeevi O, Pecker I, Feleg Y;
P1 Shlom Y;
XX WPI: 2000-062144/05.
DR N-PSDB: AA239195.
XX
XX Engineered cells that express recombinant heparanase, useful
PT therapeutically, e.g. for treating angiogenesis and to screen for
PT specific inhibitors, potential anticancer agents
XX
XX Claim 3: Page 107-109; 118pp; English.
CC The present invention describes genetically modified cells (A) containing
CC a polynucleotide (1) that encodes a polypeptide with heparanase activity.

CC and express recombinant heparanase (II). Heparanase cleaves heparan
CC sulphate (HS) at specific intrachain sites, resulting in release of
CC heparin-binding growth factors, enzymes and proteins that are sequestered
CC by HS in basement membranes, extracellular matrix or cell surfaces. It
CC may also be implicated in tumour angiogenesis and metastases. (II) is
CC potentially useful in wound healing and for treating angiogenesis,
CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
CC infection and cystic fibrosis. It can also be used to neutralise heparin
CC (an alternative to protamine) and to screen for specific inhibitors
CC (potentially useful for treating cancer and metastases). Antibodies
CC raised against (II) are used for immunodetection and diagnosis of
CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
CC in large quantities, in a form that is homogeneously processed and
CC activated/neutralised by a dedicated protease. The present sequence
CC represents human heparanase.
XX
SO Sequence 543 AA:
Query Match 100.0%; Score 2842; DB 21; Length 543;
Best Local Similarity 100.0%; Pred. No. 1,3e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MLRSKRALPPRLMLLLGLPLGPIPSGALPPPAQADVVDLDFPTOPHLVSPSPISVT 60
Dh 1 MLRSKRALPPRLMLLLGLPLGPIPSGALPPPAQADVVDLDFPTOPHLVSPSPISVT 60
Qy 61 IDANLATDPRFLILGSPKLTTLARGLSPAYLRFSGTKTDFLIFDPKKESTFEERSYWS 120
Dh 61 IDANLATDPRFLILGSPKLTTLARGLSPAYLRFSGTKTDFLIFDPKKESTFEERSYWS 120
Qy 121 QVNODICKYGSIPDVEEKRLLEMPYOEOLLRHYOKKFNSTYSNVDVLYTFANCS 180
Dh 121 QVNODICKYGSIPDVEEKRLLEMPYOEOLLRHYOKKFNSTYSNVDVLYTFANCS 180
Qy 181 GLDLFGILNALLRTADLQNMSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFINGS 240
Dh 181 GLDLFGILNALLRTADLQNMSSNAQLLDYCSSKGYNISWELGNEPNSFLKKADIFINGS 240
Qy 241 QLGEDYIQLHKLLRKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTMHHYLL 300
Dh 241 QLGEDYIQLHKLLRKSTFKNAKLYGPVQOPRRKTAMKLSFLKAGEVIDSVTMHHYLL 300
Qy 301 NGRTATREDFLNPVDLFISSVOKVQVVESTPRGKKWMLGETSSAYGGAPLLSDTFA 360
Dh 301 NGRTATREDFLNPVDLFISSVOKVQVVESTPRGKKWMLGETSSAYGGAPLLSDTFA 360
Qy 361 AGFWMILDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Dh 361 AGFWMILDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYWLSLFKKLVGTAVLM 420
Qy 421 ASVQSKRRKRLRYVLIHCTNTDNPRYKEGDLTLVA1NLHNVTKYRLRPYPSNKOVDYLL 480
Dh 421 ASVQSKRRKRLRYVLIHCTNTDNPRYKEGDLTLVA1NLHNVTKYRLRPYPSNKOVDYLL 480
Qy 481 RPLGPHGLSKSVOLNGLTLMKVDOTLPLMEKPLRPGSSGLPAPSYSEFVIRNAKVA 540
Dh 481 RPLGPHGLSKSVOLNGLTLMKVDOTLPLMEKPLRPGSSGLPAPSYSEFVIRNAKVA 540
Qy 541 ACI 543
Dh 541 ACI 543
RESULT 4
AAV52990
ID AAV52990 standard; Protein: 543 AA.
XX AAV52990:
XX 21-FEB-2000 (first entry)
XX Human heparanase protein sequence.
DE

KW Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
KW autoimmune disease; anticancer; kidney disease.
OS Homo sapiens.
PN MO957153-A1.
PD 11-NOV-1999.
PF 29-APR-1999; 99WO-US09255.
PR 01-MAY-1998; 98US-0071739.
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
XX (FRIE/) FRIEDMAN M M.
PI Pecker I, Vlodavsky I, Friedman Y, Perets T;
XX WPI: 2000-052944/04.
DR N-PSDB: AA233290.
XX
XX Heparanase-specific molecular probes useful for diagnosis and
XX treatment, e.g. of tumors, and for targeted drug delivery -
XX
XX Example: Page 81-82; 90pp; English.
XX The present invention describes heparanase-specific molecular probes,
XX useful for methods of detecting heparanase in situ. The probes and
XX anti-heparanase antibodies are used to detect or quantify the expression
XX of heparanase, for diagnosis and monitoring of diseases (especially
XX metastasis), for treatment of heparanase-associated diseases (e.g.,
XX tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
XX mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
XX metastases) derived from liver, prostate, bladder, breast, ovary
XX cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
XX disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
XX syndrome, sepsis and inflammatory or autoimmune disease), for targeted
XX drug delivery (e.g. of anticancer agents) and as research reagents.
XX The present sequence represents human heparanase, which is used in the
XX exemplification of the present invention.
SQ Sequence 543 AA:
Query Match 100.0%; Score 2842; DB 21; Length 543;
Best Local Similarity 100.0%; Pred. No. 1.3e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 301 NGRTATREDFLNDPVDLIDIFISSVQKVFQVESTRPCKKWLGETSSAYGGAPLSDTPA 360
OY 361 AGFWMLDKLGLSKRMGIEVVMROVFFGAGNYHLVDENFDPLPYWLSLFFKLVGTRKYL 420
DB 361 AGFWMLDKLGLSKRMGIEVVMROVFFGAGNYHLVDENFDPLPYWLSLFFKLVGTRKYL 420
OY 421 ASVQSKRRKRLRYLYLCTNTDNPYKKGDTLVAIHLNVTYLRPLPYPSNKOVDKYL 480
DB 421 ASVQSKRRKRLRYLYLCTNTDNPYKKGDTLVAIHLNVTYLRPLPYPSNKOVDKYL 480
OY 481 RPLGPHGLSKSVQVNLGLTKWVDOTLPLMEKPLRPSSSLGLPAFYSFVYIRNAKVA 540
DB 481 RPLGPHGLSKSVQVNLGLTKWVDOTLPLMEKPLRPSSSLGLPAFYSFVYIRNAKVA 540
OY 541 ACT 543
DB 541 ACT 543
RESULT 5
ID AAY97635 standard; Protein; 543 AA.
XX AAY97635;
XX
XX 20-APR-2001 (first entry)
XX
XX Human heparanase protein sequence.
XX
XX DE Heparanase; hnp1; wound healing; angiogenesis; restenosis; Scarpe;
XX KW atherosclerosis; inflammation; pulmonary disease; Alzheimer's disease;
XX KW neurodegenerative disease; Creutzfeldt-Jakob disease; viral infection;
XX KW gene therapy; human.
XX
XX OS Homo sapiens.
XX
XX PN WO200100643-A2.
XX
XX PD 04-JAN-2001.
XX
XX PF 19-JUN-2000; 2000WO-IL00358.
XX
XX PR 25-JUN-1999; 99US-0140801.
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX PI Pecker I, Michael I, Itzhaki H;
XX
XX DR WPI: 2001-137930/14.
XX
XX PT New polynucleotides and polypeptides that are distantly homologous to
XX heparanase, useful in wound healing, as well as in gene therapy
XX PT protocols for angiogenesis, restenosis, atherosclerosis, or
XX PT inflammation -
XX
XX PS Disclosure: Page 64-65; 67pp; English.
XX
XX CC This sequence represents a heparanase of the invention.
XX CC The heparanase DNA and protein sequences are useful in wound healing,
XX CC angiogenesis, restenosis, atherosclerosis, inflammation, pulmonary
XX CC disease, neurodegenerative diseases (such as Scarpe, Alzheimer's
XX CC disease, and Creutzfeldt-Jakob disease) or viral infections. The
XX CC heparanase coding sequence is particularly useful in gene therapy.
XX
XX SQ Sequence 543 AA:
Query Match 100.0%; Score 2842; DB 22; Length 543;
Best Local Similarity 100.0%; Pred. No. 1.3e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MLRSKPALPPMLLLGFLGFLSPGALPRPAQADVDLDFFTOEPLHLVSPSLSVT 60
|||||

```
Db 1 MLRSKPALPPPLMLLLGLPLGSPGALPPRAQADVDLDFFTOEPLHLVSPSFLSVT 60
Oy 1 DANLATDPRLILLGSPKRLTLAGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Db 61 IDANLATDPRLILLGSPKRLTLAGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Oy 121 QVNODICKYGSIPDVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Db 121 QVNODICKYGSIPDVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Oy 181 GIDLIFFGLNALLRTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINCS 240
Db 181 GIDLIFFGLNALLRTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINCS 240
Oy 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Db 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Oy 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMLEGTSSAYGGAPLLSDTFA 360
Db 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMLEGTSSAYGGAPLLSDTFA 360
Oy 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVTGYLM 420
Db 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVTGYLM 420
Oy 421 ASVQSKRRKRLRVYLHCTNTDNPRYKEGDLTYAINLHNVTYLRPLPYFSNKQYDKYLL 480
Db 421 ASVQSKRRKRLRVYLHCTNTDNPRYKEGDLTYAINLHNVTYLRPLPYFSNKQYDKYLL 480
Oy 481 RPLGPHGLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVINAKVA 540
Db 481 RPLGPHGLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVINAKVA 540
Oy 541 ACT 543
Db 541 ACT 543

RESULT 6
ABB07813
ID ABB07813 standard; protein: 543 AA.
XX
AC ABB07813:
XX
DT 03-JUL-2002 (first entry)
XX
DE human heparanase sequence.
XX
KW heparanase; catalytic; cytosolic; antiviral; antibacterial; enzyme;
KW anti-protocozon; neuroprotective; heparin; human.
XX
OS Homo sapiens.
XX
FH key Location/Qualifiers
FT Peptide 1..35
FT Protein /note= "signal peptide"
FT /note= "36..543"
FT /note= "mature protein"
XX
PN US2002034810-A1.
XX
PD 21-MAR-2002.
XX
PF 16-AUG-2001; 2001US-0930218.
XX
PR 20-SEP-2000; 2000US-0666390.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
PI Goldsmith O, Pecker I, Vlodavsky I, Michal I, Zcharia E.
XX
DR WPI: 2002-338926/37.
```

```
XX Nucleic acid encoding avian and reptile heparanase polypeptide is
PT useful to treat various heparin-related disorders and the signal
PT peptide is useful in production of membrane-targeted or secreted
PT recombinant proteins
XX
PS Disclosure: Fig 1a: 39pp: English.
XX
CC The invention relates to an isolated avian and reptile nucleic acid,
CC encoding a polypeptide with heparanase catalytic activity. The signal
CC peptide of the nucleic acid can be used to express membrane-associated or
CC secreted proteins in heterologous expression systems. The encoded
CC polypeptides can be used to prevent tumor angiogenesis, metastasis and
CC invasion, and to intervene with pathologies associated with impaired
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoa and bacterial infections or
CC disintegration of neurodegenerative plaques. The present sequence
CC represents a human heparanase protein sequence used in similarity
CC studies.
XX
SQ Sequence 543 AA:
XX
Query Match 100.0% Score 2842: DB 23: Length 543:
Best Local Similarity 100.0%: Pred. No. 1.3e-273:
Matches 543: Conservative 0: Mismatches 0: Indels 0: Gaps 0:
Oy 1 MLRSKPALPPPLMLLLGLPLGSPGALPPRAQADVDLDFFTOEPLHLVSPSFLSVT 60
Db 1 MLRSKPALPPPLMLLLGLPLGSPGALPPRAQADVDLDFFTOEPLHLVSPSFLSVT 60
Oy 61 IDANLATDPRLILLGSPKRLTLAGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Db 61 IDANLATDPRLILLGSPKRLTLAGLSPAYLRFSGTKTDFLIPDKKESTFEERSYWS 120
Oy 121 QVNODICKYGSIPDVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Db 121 QVNODICKYGSIPDVEEKLRLKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Oy 181 GIDLIFFGLNALLRTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINCS 240
Db 181 GIDLIFFGLNALLRTADLQMNSSNAQLLDYCSSKGYNISWELGNEPNSFLKKAADIFINCS 240
Oy 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Db 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTMHHYLL 300
Oy 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMLEGTSSAYGGAPLLSDTFA 360
Db 301 NGRTATREDPLNPVDLDFISSVOKVFOVESTRPCKKVMLEGTSSAYGGAPLLSDTFA 360
Oy 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVTGYLM 420
Db 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDVYLSLFFKLVTGYLM 420
Oy 421 ASVQSKRRKRLRVYLHCTNTDNPRYKEGDLTYAINLHNVTYLRPLPYFSNKQYDKYLL 480
Db 421 ASVQSKRRKRLRVYLHCTNTDNPRYKEGDLTYAINLHNVTYLRPLPYFSNKQYDKYLL 480
Oy 481 RPLGPHGLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVINAKVA 540
Db 481 RPLGPHGLSKSVOLNGLTLMKAVDQDTLPRLMEKPLRGSSIGLPAFSYSPFVINAKVA 540
Oy 541 ACT 543
Db 541 ACT 543

RESULT 7
AA02346
ID AA02346 standard; protein: 592 AA.
XX
AC AA02346:
```


XX 09-JUL-1999 (first entry)
 XX
 DE A human heparanase protein.
 XX
 KW Heparanase: hpa: modulator; heparin-binding growth factor;
 KW cellular response; cytokine; cell interaction; plasma lipoprotein;
 KW cellular susceptibility; infection; disintegration;
 KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
 KW atherosclerosis; inflammation; neurodegenerative disease; neutralise;
 KW plasma heparin; micrometastasis; autoimmune lesion; renal failure.
 XX
 OS Homo sapiens.
 XX
 PN WO9111798-A1.
 XX
 PD 11-MAR-1999.
 XX
 PF 31-AUG-1998: 98WO-US17954.
 XX
 PR 02-JUL-1998: 98US-0109386.
 XX 02-SEP-1997: 97US-0922170.
 XX
 PA (FRIE/) FRIEDMAN M M.
 PA (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 XX
 PI Feinstein E, Pecker I, Vlodavsky I;
 XX
 DR WPI: 1999-302255/25.
 DR N-PSDB: AAX35650.
 XX
 PT New human polynucleotide useful for treating angiogenesis,
 PT restenosis, and inflammation
 XX
 PS Claim 6: Page 65-66; 63pp: English.
 XX
 CC The specification describes a polypeptide having heparanase (hpa)
 CC activity. The recombinant protein is used as a modulator of
 CC heparin-binding growth factors, cellular responses to heparin-binding
 CC growth factors and cytokines, cell interaction with plasma lipoproteins,
 CC cellular susceptibility to viral, protozoal and bacterial infections
 CC or disintegration of neurodegenerative plaques. Heparanase may be
 CC useful for conditions such as wound healing, angiogenesis, restenosis,
 CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
 CC infections. Mammalian heparanase can be used to neutralize plasma
 CC heparin, and anti-heparanase antibodies may be applied for
 CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
 CC and renal failure in biopsy specimens, plasma samples, and body fluids.
 CC The present sequence represents human heparanase.
 XX
 SO Sequence 592 AA:
 Query Match 100.0%; Score 2842; DB 20; Length 592;
 Best Local Similarity 100.0%; Pred. NO. 1.5e-273;
 Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 241 QLGEDYIQLHLKLRKSTFKNAKLYGPDVGOPRRRTAKMLKSPFKAGGEVIDSVTHHHYLL 300
 DB 290 QLGEDYIQLHLKLRKSTFKNAKLYGPDVGOPRRRTAKMLKSPFKAGGEVIDSVTHHHYLL 349
 OY 301 NGRTATREDPLNDPVI.DIFISVQKVOVESTRPCKKWLGETSSAYGGAFLSDTFA 360
 DB 350 NGRTATREDPLNDPVI.DIFISVQKVOVESTRPCKKWLGETSSAYGGAFLSDTFA 409
 OY 361 AGFMWLDKGLSARMGIEVVMROVFFGACNHYLVDEFDPLPDYMLSLFKKLVGTRKVL 420
 DB 410 AGFMWLDKGLSARMGIEVVMROVFFGACNHYLVDEFDPLPDYMLSLFKKLVGTRKVL 469
 OY 421 ASVQSKRRKLRVYLCTNDNPRYEGDITLAIJLNHNTKYLRLPYPSNKOVDKXLL 480
 DB 470 ASVQSKRRKLRVYLCTNDNPRYEGDITLAIJLNHNTKYLRLPYPSNKOVDKXLL 529
 OY 481 RPLGPHGLLSKSVOLNGLTLKAVDDOTLPLMEKPLRPGSSJGLPAFYSYFFVIRNAKVA 540
 DB 530 RPLGPHGLLSKSVOLNGLTLKAVDDOTLPLMEKPLRPGSSJGLPAFYSYFFVIRNAKVA 589
 OY 541 ACI 543
 DB 590 ACI 592
 RESULT 8
 AAB08850
 ID AAB08850 standard; Protein: 592 AA.
 AC AAB08850;
 XX
 DT 15-JAN-2001 (first entry)
 XX
 DE Amino acid sequence of a human heparanase polypeptide.
 XX
 KW Human: heparanase: gene therapy; tumour; inflammation; autoimmunity;
 KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
 KW wound healing; infection; burn; angiogenesis; restenosis;
 KW atherosclerosis; inflammation; neurodegenerative disease;
 KW Gerstmann-Straussler Syndrome; Creutzfeldt-Jakob disease.
 OS Homo sapiens.
 XX
 PN WO200052178-A1.
 XX
 PD 08-SEP-2000.
 XX
 PF 14-FEB-2000: 2000WO-US03542.
 XX
 PR 01-MAR-1999: 99US-0258892.
 XX
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 PA (FRIE/) FRIEDMAN M M.
 PI Pecker I, Vlodavsky I, Feinstein E;
 XX
 DR WPI: 2000-579289/54.
 DR N-PSDB: AAX75053.
 XX
 PT New polynucleotides encoding a polypeptide having heparanase activity,
 PT useful in wound healing and in gene therapy, particularly in treating
 PT tumour, inflammation, autoimmunity, neurodegenerative diseases -
 XX
 PS Claim 22: Page 122-123; 152pp: English.
 XX
 CC The present sequence represents a human protein with heparanase catalytic
 CC activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
 CC particularly in treating tumour, inflammation or autoimmunity.
 CC Particularly, the polynucleotide is useful in modulating the
 CC bioavailability of heparin-binding growth factors, cellular responses
 CC to heparin-binding growth factors (e.g. bFGF) and cytokines
 CC (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,

CC cellular susceptibility to certain viral and some bacterial and protozoa
CC infections, or disintegration of neurodegenerative plaques. The
CC polynucleotide is also useful in wound healing (e.g. thermal, chemical
CC or radiation burns), and in the treatment of angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
CC Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,
CC bacterial or protozoa infections.

XX Sequence 592 AA:

Query Match 100.0%; Score 2842; DB 21; Length 592;
Best Local Similarity 100.0%; Pred. No. 1 5e-273;
Matches 543; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MLRSKPALPPMLLLGLPLGSPGALPRPAQODVVDLDFFTOEPLHLVSPSFLSVT 60
DB 50 MLRSKPALPPMLLLGLPLGSPGALPRPAQODVVDLDFFTOEPLHLVSPSFLSVT 109
OY 61 IDANLATOPRFLILGSPKRLTLARGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYMQS 120
DB 110 IDANLATOPRFLILGSPKRLTLARGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYMQS 169
OY 121 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLREHYOKKFNKSTYSRSSVDVLYTFPANC 180
DB 170 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLREHYOKKFNKSTYSRSSVDVLYTFPANC 229
OY 181 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKAKADIFINCS 240
DB 230 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKAKADIFINCS 289
OY 241 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 300
DB 290 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 349
OY 301 NGRTATREDFLNPVDLDFISSVOKVFOVESTRPCKKVMYLGETSAYGCGAPLLSDTFA 360
DB 350 NGRTATREDFLNPVDLDFISSVOKVFOVESTRPCKKVMYLGETSAYGCGAPLLSDTFA 409
OY 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 420
DB 410 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 469
OY 421 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTYAINLHNVTYLRPLPYFSKNOVDKYL 480
DB 470 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTYAINLHNVTYLRPLPYFSKNOVDKYL 529
OY 481 RPLGPHGLSKSVOLNGLTKKVVDDOTLPLMEKPLRGSSSLGDPAFSFSFVIRNAKVA 540
DB 530 RPLGPHGLSKSVOLNGLTKKVVDDOTLPLMEKPLRGSSSLGDPAFSFSFVIRNAKVA 589
OY 541 ACI 543
DB 590 ACI 592

RESULT 9
AAV17082
ID AAV17082 standard; Protein: 543 AA.
AC AAV17082;
XX 21-JUL-1999 (first entry)
DE Human heparanase enzyme.
XX
KM Heparanase: endoglucuronidase; heparan sulfate proteoglycan; enzyme;
KM metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KM arteriosclerosis; atherosclerosis; inflammation; tissue development;
KM human; HSPG.
XX
OS Homo sapiens.
XX
PN WO9921975-A1.

XX 06-MAY-1999.
PD
XX
XX 28-OCT-1998; 98WO-AU00898.
PF
XX
XX 09-DEC-1997; 97AU-0000812.
PR
XX 28-OCT-1997; 97AU-0000062.
PR
XX
XX (AUSU) UNIV AUSTRALIAN NAT.
PA
XX
XX Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
PI
XX WPI: 1999-312956/26.
DR
XX N-PSDB: AAX37259.
DR

Polynucleotides encoding mammalian endoglucuronidases, especially
heparanases, useful to promote wound healing

PS Claim 6: Page 69-73; 112pp: English.

CC The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG. The
CC present sequence represents a human heparanase.

SO Sequence 543 AA:

Query Match 99.9%; Score 2838; DB 20; Length 543;
Best Local Similarity 99.8%; Pred. No. 3.3e-273;
Matches 542; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 MLRSKPALPPMLLLGLPLGSPGALPRPAQODVVDLDFFTOEPLHLVSPSFLSVT 60
DB 1 MLRSKPALPPMLLLGLPLGSPGALPRPAQODVVDLDFFTOEPLHLVSPSFLSVT 60
OY 61 IDANLATOPRFLILGSPKRLTLARGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYMQS 120
DB 61 IDANLATOPRFLILGSPKRLTLARGLSPAYLRFGCTKTDPLIFDPKKESTFEERSYMQS 120
OY 121 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLREHYOKKFNKSTYSRSSVDVLYTFPANC 180
DB 121 QVNODICKYGSIPDVEEKLRLLEMPYOEOLLREHYOKKFNKSTYSRSSVDVLYTFPANC 180
OY 181 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKAKADIFINCS 240
DB 181 GDLIFGALNALLRTADLQWSSNAQLLDYCSSKGYNISWELGNEPNSFLKAKADIFINCS 240
OY 241 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 300
DB 241 QLGEDYIQLHKLLRKSTFKNAKLYGPDVGQPRRKAKMLSKLAKGCEYIDSVTHHHYLL 300
OY 301 NGRTATREDFLNPVDLDFISSVOKVFOVESTRPCKKVMYLGETSAYGCGAPLLSDTFA 360
DB 301 NGRTATREDFLNPVDLDFISSVOKVFOVESTRPCKKVMYLGETSAYGCGAPLLSDTFA 360
OY 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 420
DB 361 AGFMWLDKLGISARMGIEVVMROVFFGAGNHLVDENFDPLPDYMLSLFFKLVGTXVLM 420
OY 421 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTYAINLHNVTYLRPLPYFSKNOVDKYL 480
DB 421 ASVQSKRRKRLRVYLACTNTDNPRIKEGDLTYAINLHNVTYLRPLPYFSKNOVDKYL 480

CC it from degrading the extracellular matrix and releasing heparan sulfate
CC from the extracellular matrix surface. The heparanase protein or the
CC anti-heparanase antibody are used in pharmaceutical compositions for
CC treating warm blooded animals suffering from a disease resulting from
CC shortage or lack of the heparanase protein, or from excessive activity
CC or over-expression of the heparanase protein, respectively. The
CC heparanase protein is used in treating diseases such as trauma,
CC autoimmune disease, skin diseases, cardiovascular diseases and nervous
CC system diseases including Alzheimer's disease resulting from shortage or
CC lack of polypeptide. The anti-heparanase antibody is used in treating
CC the diseases like cancer, cancer metastasis, angiogenesis and
CC inflammation including arthritis resulting from excessive activity or
CC over expression of heparanase protein. The anti-heparanase antibody can
CC be used to detect the presence or absence of polypeptide and its
CC concentration.

SO Sequence 588 AA:

Query Match 99.98: Score 2838: DB 20: Length 588:
Best Local Similarity 99.88: Pred. No. 3.8e-273:
Matches 542: Conservative 1: Mismatches 0: Indels 0: Gaps 0:

OY 1 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 60
DB 46 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 105
OY 61 IDANLATDPPRFLILGSPKLTARGLSPAYLRFPGGKTDFLFDPKKESTFEERSYWG 120
DB 106 IDANLATDPPRFLILGSPKLTARGLSPAYLRFPGGKTDFLFDPKKESTFEERSYWG 165
OY 121 QVNODICKYGSIPPDVEEKLRLMPYOEOLLEHRYOKKKNSTYSSSVLYTPANC 180
DB 166 QVNODICKYGSIPPDVEEKLRLMPYOEOLLEHRYOKKKNSTYSSSVLYTPANC 225
OY 181 GLDLIFGLNALPTADLQNNSSNAQLLDYCSSKGYNISWELGNEPSPFLKADIFNGS 240
DB 226 GLDLIFGLNALPTADLQNNSSNAQLLDYCSSKGYNISWELGNEPSPFLKADIFNGS 285
OY 241 QLEDGYQLHKLRLKSTFKNAKLYGPVGOGRKRTAKMLKSFLLAGEVVIDSVTHNYL 300
DB 286 QLEDGYQLHKLRLKSTFKNAKLYGPVGOGRKRTAKMLKSFLLAGEVVIDSVTHNYL 345
OY 301 NGRTATREDPLNPVDLFISSVOKVQVVESTPRGKKWLGETSSAYGGAPLLSDTFA 360
DB 346 NGRTATREDPLNPVDLFISSVOKVQVVESTPRGKKWLGETSSAYGGAPLLSDTFA 405
OY 361 AGFAMLDKLGISARNGIEVWVROVFGAGNYHLVDENPDLPDYLWLSLFLKKTGYVLM 420
DB 406 AGFAMLDKLGISARNGIEVWVROVFGAGNYHLVDENPDLPDYLWLSLFLKKTGYVLM 465
OY 421 ASVOGSKRRKRLVYLHCTNTDNPRYKEGDLTLVA1NLHNVTKYLRPLYPFSNKOVDKYL 480
DB 466 ASVOGSKRRKRLVYLHCTNTDNPRYKEGDLTLVA1NLHNVTKYLRPLYPFSNKOVDKYL 525
OY 481 RPLGPHGLSKSVOLNGLTLKAVDQTLPLMEKPLRPGSSLGIPARSYSFFYRNKVA 540
DB 526 RPLGPHGLSKSVOLNGLTLKAVDQTLPLMEKPLRPGSSLGIPARSYSFFYRNKVA 585
OY 541 ACI 543
DB 586 ACI 588

RESULT 12
AAB88361
ID AAB88361 standard: Protein: 543 AA.

XX AAB88361:
XX 23-MAY-2001 (first entry)
XX Human membrane or secretory protein clone PSEC0090.
DE

KW Human: secretory protein; membrane protein; vaccine; gene therapy;
KW rheumatoid arthritis; diabetes.

XX Homo sapiens.

XX EP1067182-A2.

XX 10-JAN-2001.

XX 07-JUL-2000: 2000EP-0114090.

XX 08-JUL-1999: 99JP-0194179.

XX 11-JAN-2000: 2000JP-0118775.

XX 02-MAY-2000: 2000JP-0183766.

XX (HELI-) HELIX RES INST.

PI Oca T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K.

DR WPI: 2001-093989/11.

DR N-PSDB: AAF93788.

PS Claim 1: SEQ ID 90: 609pp + CD ROM; English.

XX This invention relates to nucleic acid sequences AAF93744 - AAF93916

CC which encode human secretory or membrane proteins represented by

CC AAB88317 - AAB88419. Included in the invention are primers

CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the

CC cDNA sequences of the invention. The invention also includes methods for

CC the production of antibodies directed against the proteins, and cDNA

CC sequences, which can be used in vaccines. The polynucleotide sequences

CC can be used in gene therapy. The polynucleotide sequences and the

CC proteins they encode may be used in the prevention, treatment and

CC diagnosis of diseases associated with inappropriate secretory

CC protein/membrane protein expression. The nucleic acids and complementary

CC sequences may also be used as DNA probes in diagnostic assays

CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the

CC presence of similar nucleic acid sequences in samples. They may also be

CC used to study the expression and function of secretory proteins/membrane

CC polypeptides and their role in metabolism. The polypeptides may be used

CC as antigens in the production of antibodies against them and in assays to

CC identify modulators (agonists and antagonists) of expression and

CC activity. The antibodies and antagonists may also be used as therapeutic

CC agents to down regulate expression and activity. The antibodies may also

CC be used as diagnostic agents for detecting the presence of the

CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay

CC (ELISA). Examples of diseases which may be treated include rheumatoid

CC arthritis and diabetes.

SO Sequence 543 AA:

Query Match 99.48: Score 2826: DB 22: Length 543:
Best Local Similarity 99.48: Pred. No. 5.2e-272:
Matches 540: Conservative 2: Mismatches 1: Indels 0: Gaps 0:

OY 1 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 60
DB 1 MLRSKPALPPMLLLGLGPGALPPPAOAOVDVLDFTFOEPHLVSPFLSVT 60
OY 61 IDANLATDPPRFLILGSPKLTARGLSPAYLRFPGGKTDFLFDPKKESTFEERSYWG 120
DB 61 IDANLATDPPRFLILGSPKLTARGLSPAYLRFPGGKTDFLFDPKKESTFEERSYWG 120
OY 121 QVNODICKYGSIPPDVEEKLRLMPYOEOLLEHRYOKKKNSTYSSSVLYTPANC 180
DB 121 QVNODICKYGSIPPDVEEKLRLMPYOEOLLEHRYOKKKNSTYSSSVLYTPANC 180
OY 181 GLDLIFGLNALPTADLQNNSSNAQLLDYCSSKGYNISWELGNEPSPFLKADIFNGS 240
DB 181 GLDLIFGLNALPTADLQNNSSNAQLLDYCSSKGYNISWELGNEPSPFLKADIFNGS 240

```

OY 241 QIACEDYIOLHKLLRKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSVTHHHYLL 300
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 241 QIACEDYIOLHKLLRKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSVTHHHYLL 300
OY 301 NGRTATREDFLNDVDLDFISSVQVYFQVVESTPRGKKWMLGETSSAYGCGAPLLSDTFA 360
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 301 NGRTATREDFLNDVDLDFISSVQVYFQVVESTPRGKKWMLGETSSAHGCGAPLLSDTFA 360
OY 361 AGFMWLDKLGLSARMGIEVVMKQVYFQVYAGAGNYHLVDENFDPLDPYWLSTLFFKKLVGTRVLM 420
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 361 AGFMWLDKLGLSARMGIEVVMKQVYFQVYAGAGNYHLVDENFDPLDPYWLSTLFFKKLVGTRVLM 420
OY 421 ASVOGSKRRKRLRYLHCTNTDNPYKEGDLTLTAIINLHNTKYLRIPYPSNKQVOKYLL 480
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 421 ASVOGSKRRKRLRYLHCTNTDNPYKEGDLTLTAIINLHNTKYLRIPYPSNKQVOKYLL 480
OY 481 RPLGPHQLLSKSVQVNLGLTLKMWDDOTLPLPMEKPLRPSSSLGLPAFVSFFVIRNAKVA 540
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 481 RPLGPHQLLSKSVQVNLGLTLKMWDDOTLPLPMEKPLRPSSSLGLPAFVSFFVIRNAKVA 540
OY 541 AC1 543
    |||
Db 541 AC1 543

RESULT 13
AA34173
ID AAY34173 standard; Protein: 530 AA.
AC AAY34173;
XX
DT 15-NOV-1999 (first entry)
DE Human pre-proheparanase protein sequence.
XX
KW Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
KW inflammation; psoriasis; diabetic retinopathy; solid tumour; arthritis;
KW heparin degradation; anticoagulant neutralisation; asthma; CDS disease;
KW inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
KW tumour growth; fibroproliferative disorder; neurodegenerative disease;
KW therapy.
XX
OS Homo sapiens.
XX
PN WO9943830-A2.
XX
PD 02-SEP-1999.
XX
PF 18-FEB-1999; 99MO-US01489.
XX
PR 26-MAR-1998; 98US-0079401.
XX
PR 24-FEB-1998; 9805-0075706.
XX
PA (PHAA ) PHARMACIA & UPJOHN CO.
XX
PI Fairbanks MB, Heinrikson RL, Mildner AM.
XX
DR WPI: 1999-540598/45.
XX
DR N-PSDB: AA211236.
XX
PT New isolated platelet heparanase polypeptides, used to develop
XX products for, e.g. wound healing and blocking angiogenesis
XX
PS Claim 12: Fig 7: 57pp: English.
XX
CC This sequence is the human pre-proheparanase of the invention. This
CC sequence was isolated from human platelets. The heparanase can be used
CC for identifying agents which alter heparanase activity. The heparanase
CC can be used for wound healing or for blocking angiogenesis or
CC inflammation. It can be used for treating e.g. psoriasis, diabetic
CC retinopathy or solid tumours, or for the degradation of heparin and the
CC neutralisation of heparin's anticoagulant properties during surgery.

```

```

CC Inhibitors of heparanase activity can be used in the treatment of
CC arthritis, asthma, and other inflammatory diseases, vascular restenosis,
CC atherosclerosis, tumour growth and progression, fibroproliferative
CC disorders, and central nervous system (CNS) and neurodegenerative
CC diseases. The products can also be used for detection and diagnosis. The
CC purified heparanase, both recombinantly produced human heparanase and
CC heparanase isolated from human platelet activity, allows for the
CC convenient selection of compounds having anti-heparanase activity,
CC i.e. inhibitors of heparanase activity, by measuring inhibition of
CC heparanase activity. Inhibition of heparanase activity can be measured by
CC blocking heparanase-mediated release of radioactive fragments from in
CC vivo radiolabelled (HSPG)/heparin.
XX
SQ Sequence 530 AA.
XX
Query Match 97.3%; Score 2764; DB 20; Length 530;
Best Local Similarity 99.4%; Pred. No. 7,4e-266;
Matches 527; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
OY 14 MLLLGPLGRLSPGALPPAODVDVLDLFFQEPRLHVSFSLSTIDANLATDPRFLI 73
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 MLLLGPLGRLSPGALPPAODVDVLDLFFQEPRLHVSFSLSTIDANLATDPRFLI 60
OY 74 LIGSPKRLTLARGLSFAYLRFEGTKTDFLIIPDKKESTFEERSYMOQVNOODICKYGISP 133
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 LIGSPKRLTLARGLSFAYLRFEGTKTDFLIIPDKKESTFEERSYMOQVNOODICKYGISP 120
OY 134 PVEEKLRLMPYOEOLLRHNYOKKFNKSTYSRSSVDVLYFPANCSDGLIFGLNALLR 193
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 PVEEKLRLMPYOEOLLRHNYOKKFNKSTYSRSSVDVLYFPANCSDGLIFGLNALLR 180
OY 194 TADLQWSSNAOILLDYCSSKGYNISWELGNPNSTFKADIFINGSOGEYIOLHKLL 253
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 181 TADLQWSSNAOILLDYCSSKGYNISWELGNPNSTFKADIFINGSOGEYIOLHKLL 240
OY 254 RKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSVTHHHYLLNGRTATREDFLNP 313
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 241 RKSTFKNAKLYGPDVCGPRKRTAKMLKSFLLKAGGEVIDSVTHHHYLLNGRTATREDFLNP 300
OY 314 DYLDLFISSVQVYFQVVESTPRGKKWMLGETSSAYGCGAPLLSDTFAAGFMWLDKLGISA 373
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 301 DYLDLFISSVQVYFQVVESTPRGKKWMLGETSSAYGCGAPLLSDTFAAGFMWLDKLGISA 360
OY 374 RMGIEVVMKQVYFQVYAGAGNYHLVDENFDPLDPYWLSTLFFKKLVGTRVLMASVOGSKRRKRLV 433
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 361 RMGIEVVMKQVYFQVYAGAGNYHLVDENFDPLDPYWLSTLFFKKLVGTRVLMASVOGSKRRKRLV 420
OY 434 YLHCTNTDNPYKEGDLTLTAIINLHNTKYLRIPYPSNKQVOKYLLRPLGPHGLLSKSV 493
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 421 YLHCTNTDNPYKEGDLTLTAIINLHNTKYLRIPYPSNKQVOKYLLRPLGPHGLLSKSV 480
OY 494 QNLGLTLKMWDDOTLPLPMEKPLRPSSSLGLPAFVSFFVIRNAKVAACI 543
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 481 QNLGLTLKMWDDOTLPLPMEKPLRPSSSLGLPAFVSFFVIRNAKVAACI 530

RESULT 14
AA17083
ID AAY17083 standard; Protein: 532 AA.
XX
AC AAY17083;
XX
DT 21-JUL-1999 (first entry)
DE Seq ID No: 15 of WO9921975.
XX
XX
KW Heparanase; endoglyuronidase; heparan sulfate proteoglycan; enzyme;
KW metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KW atherosclerosis; atherosclerosis; inflammation; tissue development;
KW human; HSPG.
XX
OS Homo sapiens.
XX

```

PH W09921975-A1.
 XX
 PD 06-MAY-1999.
 XX
 PF 28-OCT-1998: 98MO-AU00898.
 XX
 PR 09-DEC-1997: 97AU-0000812.
 PR 28-OCT-1997: 97AU-0000062.
 XX
 PA (AUSU) UNIV AUSTRALIAN NAT.
 XX
 PI Freeman CG, Handorf BJ, Hulett MD, Parish CR;
 XX
 DR WPI: 1999-312956/26.
 DR N-PSDB: AAX37260.
 XX
 PT Polynucleotides encoding mammalian endoglucuronidases, especially
 PT heparanases, useful to promote wound healing
 PS
 PS Claim 6: Page 76-79; 112pp: English.
 CC The invention relates to nucleic acid sequences that encode heparanase
 CC enzymes having endoglucuronidase activity. Recombinant heparanases are
 CC capable of removing the HS side chain from heparan sulfate proteoglycan
 CC (HSPG). Sulfated oligosaccharides, sulphates or HSPG can be used to
 CC inhibit heparanase, this is useful for treatment of a physiological or
 CC medical condition associated with elevated heparanase activity, such as
 CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
 CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
 CC rat heparanases can be used to enhance wound healing, especially
 CC associated with tissue development and repair. The conditions mentioned
 CC above can be diagnosed using specific antibodies, and also using primers
 CC and probes specific for the heparanase polynucleotides. Other uses of the
 CC heparanases include sequencing sulfated molecules such as HSPG.
 XX
 SO Sequence 532 AA:
 Query Match 96.3%; Score 2737; DB 20; Length 532;
 Best Local Similarity 99.8%; Pred. No. 3.6e-263;
 Matches 522; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 1 MLRSKRALPPMLLLGLPGLSPGALPPRAQADVDVDFFTOEPLHLVSPSFLSVT 60
 DB 1 MLRSKRALPPMLLLGLPGLSPGALPPRAQADVDVDFFTOEPLHLVSPSFLSVT 60
 OY 61 IDANLATDPRFLILGSPKRLTARGLSPAYLRFSGTDTDFLPDPKKESTFEESYQWS 120
 DB 61 IDANLATDPRFLILGSPKRLTARGLSPAYLRFSGTDTDFLPDPKKESTFEESYQWS 120
 OY 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFKNSTYSRSSVDVLYTFANCS 180
 DB 121 QVNODICKYGSIPDVEEKLRLMPYOEQLLREHYOKKFKNSTYSRSSVDVLYTFANCS 180
 OY 181 GUDLIFGINALRLTADLQWNSNMAQLLDYCSSKGYNISWELGNNPNSFLKADDFINGS 240
 DB 181 GUDLIFGINALRLTADLQWNSNMAQLLDYCSSKGYNISWELGNNPNSFLKADDFINGS 240
 OY 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNHYL 300
 DB 241 QLGEDYIOLHLKLRKSTFKNAKLYGPDVGOPRRKTAAMKLSFLKAGCEVIDSVTHNHYL 300
 OY 301 NGRTATREDFLNPDLVDFISSVQKVFQVESTPRGKVMWLGETSSAYGGAPLLSDTFA 360
 DB 301 NGRTATREDFLNPDLVDFISSVQKVFQVESTPRGKVMWLGETSSAYGGAPLLSDTFA 360
 OY 361 AGFMHLDLKGLSARMGIEVMQVFFGAGNHLVDENFDPLPDVYLSLLFFKLVYTKYLM 420
 DB 361 AGFMHLDLKGLSARMGIEVMQVFFGAGNHLVDENFDPLPDVYLSLLFFKLVYTKYLM 420
 OY 421 ASVQSSKRRKRLVLYLCTNTDNPARYKEGDLTYALNHNVTYYLRLPPFSNKQYDKYLL 480
 DB 421 ASVQSSKRRKRLVLYLCTNTDNPARYKEGDLTYALNHNVTYYLRLPPFSNKQYDKYLL 480

OY 481 RPLGPHGLSKSVQVNLGTLTKMVDQTLPLPMEXPLRPGSSLG 523
 DB 481 RPLGPHGLSKSVQVNLGTLTKMVDQTLPLPMEXPLRPGSSLG 523
 RESULT 15
 ID ABB07815 standard; protein: 527 AA.
 AC ABB07815;
 DT 03-JUL-2002 (first entry)
 XX
 XX Chicken signal peptide/human heparanase chimeric protein sequence.
 DE
 DE Heparanase; catalytic; cytosolic; antiviral; antibacterial; enzyme;
 KW anti-protozoan; neuroprotective; heparin; chicken; human; chimeric.
 XX
 XX Synthetic.
 OS Gallus gallus.
 OS Homo sapiens.
 FT Key location/Qualifiers
 FT Peptide 1..19
 FT /note= "chicken heparanase signal peptide"
 FT Protein 20..527
 FT /note= "human heparanase mature protein"
 PN US2002034810-A1.
 XX
 XX 21-MAR-2002.
 PD
 PD 16-AUG-2001; 2001US-0930218.
 PF
 PF 20-SEP-2000; 2000US-0666390.
 PR
 PR (INST-) INSIGHT STRATEGY & MARKETING LTD.
 PA Goldsmith O, Pecker I, Vlodavsky I, Michal I, Zcharja E;
 XX WPI: 2002-338926/37.
 DR N-PSDB: ABL40753.
 DR
 DR Nucleic acid encoding avian and reptile heparanase polypeptide is
 PT useful to treat various heparin-related disorders and the signal
 PT peptide is useful in production of membrane-targeted or secreted
 PT recombinant proteins
 PS Disclosure: Page 26-28; 39pp: English.
 XX
 XX The invention relates to an isolated avian and reptile nucleic acid,
 CC encoding a polypeptide with heparanase catalytic activity. The signal
 CC peptide of the nucleic acid can be used to express membrane-associated or
 CC secreted proteins in heterologous expression systems. The encoded
 CC polypeptides can be used to prevent tumor angiogenesis, metastasis and
 CC invasion, and to intervene with pathologies associated with impaired
 CC heparin-binding growth factors, cellular responses to heparin-binding
 CC growth factors and cytokines, cell interaction with plasma lipoproteins,
 CC cellular susceptibility to viral, protozoa and bacterial infections or
 CC disintegration of neurodegenerative plaques. The present sequence
 CC represents a chicken signal peptide/human heparanase chimeric protein
 CC sequence.
 XX
 SO Sequence 527 AA:
 Query Match 94.1%; Score 2673.5; DB 23; Length 527;
 Best Local Similarity 96.8%; Pred. No. 7.6e-257;
 Matches 514; Conservative 4; Mismatches 4; Indels 9; Gaps 1;
 OY 13 LMLLLGLGLSPGALPPRAQADVDVDFFTOEPLHLVSPSFLSVYIDANLATDPRFL 72
 DB 6 LTVLL-----AVPRRTADVDVDFFTOEPLHLVSPSFLSVYIDANLATDPRFL 56

```
OY 73 ILGSPKRLT LARGLSPAYLRFGGTKTDPLIFDKKKESTFEERSYMOOVNODICKYYSI 132
    |||
Db 57 ILGSPKRLT LARGLSPAYLRFGGTKTDPLIFDKKKESTFEERSYMOOVNODICKYYSI 116
    |||
OY 133 PPVVEEKRLLEWPIQEOELLREHYOKKFKNSTSRSSVDVLYTFANCGLDLIFGLNAL 192
    |||
Db 117 PPVVEEKRLLEWPIQEOELLREHYOKKFKNSTSRSSVDVLYTFANCGLDLIFGLNAL 176
    |||
OY 193 RTADLQNNSSNAOLLIDYCSKGYNISMEIGNEPNSFLKKAADIFINGSOIGEDYIOLHKL 252
    |||
Db 177 RTADLQNNSSNAOLLIDYCSKGYNISMEIGNEPNSFLKKAADIFINGSOIGEDYIOLHKL 236
    |||
OY 253 LRKSTFKNAKLYGPDVGOPPRKTAAMLSFLKAGEVIDSVTHHYLLNGRTATREDPLN 312
    |||
Db 237 LRKSTFKNAKLYGPDVGOPPRKTAAMLSFLKAGEVIDSVTHHYLLNGRTATREDPLN 296
    |||
OY 313 PDVLDIFISSVOKFQVESTRPCKKVMIGETSSAYGGAPLLSDTFAAGFMWLDKLGLS 372
    |||
Db 297 PDVLDIFISSVOKFQVESTRPCKKVMIGETSSAYGGAPLLSDTFAAGFMWLDKLGLS 356
    |||
OY 373 ARMGIEVVMROVFFGAGNYHLVDENPDPLPDYMLSLFKKLVGTVKVMASVQSKRRKLR 432
    |||
Db 357 ARMGIEVVMROVFFGAGNYHLVDENPDPLPDYMLSLFKKLVGTVKVMASVQSKRRKLR 416
    |||
OY 433 VYLHCTNTDNPRTKEGDLTYATNLHNVTYLRPLPYPSNKOVDKYLRLPLGPHGLSKS 492
    |||
Db 417 VYLHCTNTDNPRTKEGDLTYATNLHNVTYLRPLPYPSNKOVDKYLRLPLGPHGLSKS 476
    |||
OY 493 VOLNGLTLKKNVDDOTLPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI 543
    |||
Db 477 VOLNGLTLKKNVDDOTLPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI 527
    |||
```

Search completed: November 20, 2002, 11:36:11
Job time : 40 secs

=> dis his

(FILE 'HOME' ENTERED AT 13:53:38 ON 21 NOV 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS' ENTERED AT 13:54:35 ON 21 NOV 2002

L1	406 S PECKER I?/AU OR VLODASKY I?/AU OR FRIEDMAN Y?/AU OR PERETS T?
L2	60 S L1 AND HEPARANASE
L3	12 S L1 AND (HEPARANASE (10N) ANTIBOD?)
L4	9 DUP REM L3 (3 DUPLICATES REMOVED)
L5	79 S (HEPARANASE (10N) ANTIBOD?)
L6	70 S L5 NOT L4
L7	18 S L6 AND PD<19970902
L8	7 DUP REM L7 (11 DUPLICATES REMOVED)

WEST**Create A Case**

Select?	Database	Query	Plural	Op	Thesaurus	Set Name
<input checked="" type="checkbox"/>	USPT	(5968822)[PN]	YES	OR		L1
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	(pecker)[in] or (vlodasky)[in] or (friedman)[in] or (perets)[in]	YES	OR		L2
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	L2 and heparanase	YES	OR		L3
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	antibod\$4and heparanase	YES	OR		L4
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	L4 and @ad<19970902	YES	OR		L5
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	antibod\$4 near heparanase	YES	OR		L6
<input checked="" type="checkbox"/>	USPT,PGPB,JPAB,EPAB,DWPI	L6 and @ad<19970902	YES	OR		L7

Please enter the case name: **Rules for naming Cases**

- Case names can only contain alphanumeric characters including underscore (_).
- Any other special characters or punctuation characters will be automatically removed prior to saving the case.
- All white space characters will be replaced by an underscore.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1644axd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08 "Ask CAS" for self-help around the clock
NEWS	3	Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09 ZDB will be removed from STN
NEWS	5	Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03 New e-mail delivery for search results now available
NEWS	10	Jun 10 MEDLINE Reload
NEWS	11	Jun 10 PCTFULL has been reloaded
NEWS	12	Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29 Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30 NETFIRST to be removed from STN
NEWS	16	Aug 08 CANCERLIT reload
NEWS	17	Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08 NTIS has been reloaded and enhanced
NEWS	19	Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26 Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03 JAPIO has been reloaded and enhanced
NEWS	24	Sep 16 Experimental properties added to the REGISTRY file
NEWS	25	Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS	28	Oct 21 EVENTLINE has been reloaded
NEWS	29	Oct 24 BEILSTEIN adds new search fields
NEWS	30	Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	31	Oct 25 MEDLINE SDI run of October 8, 2002
NEWS	32	Nov 18 DKILIT has been renamed APOLLIT
NEWS EXPRESS		October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:53:38 ON 21 NOV 2002

=> file medline caplus embase biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 13:54:35 ON 21 NOV 2002

FILE 'CAPLUS' ENTERED AT 13:54:35 ON 21 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:54:35 ON 21 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:54:35 ON 21 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s pecker I?/au or vlodasky I?/au or friedman Y?/au or Perets T?/au
L1 406 PECKER I?/AU OR VLODASKY I?/AU OR FRIEDMAN Y?/AU OR PERETS T?/AU

=> s l1 and heparanase
L2 60 L1 AND HEPARANASE

=> s l1 and (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s (heparanase (10N) antibod?)
MISSING OPERATOR 'EPARANASE (10N'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and (heparanase (10N) antibod?)
L3 12 L1 AND (HEPARANASE (10N) ANTIBOD?)

=> dup rem l3

PROCESSING COMPLETED FOR L3
L4 9 DUP REM L3 (3 DUPLICATES REMOVED)

=> dis l4 1-9 ibib abs

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:429402 CAPLUS
DOCUMENT NUMBER: 137:5014
TITLE: Monoclonal anti-**heparanase**
antibodies for treating conditions related to
heparan sulfate proteoglycan-associated growth factor,
chemokine, cytokine or degradative enzyme
INVENTOR(S): Peretz, Tuvia; Miron, Daphna; Shlomi, Yinon;
Pecker, Iris; Ayal-HersHKovitz, Maty;
Vlodavsky, Isreal; Friedmann, Yael
PATENT ASSIGNEE(S): Israel
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S.
Ser. No. 71,618, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002068061	A1	20020606	US 1998-186200	19981104
US 5968822	A	19991019	US 1997-922170	19970902
WO 2000025817	A1	20000511	WO 1999-US25451	19991028
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1126878	A1	20010829	EP 1999-956781	19991028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 751170	B2	20020808	AU 2000-13314	19991028
NO 2001002190	A	20010612	NO 2001-2190	20010503
PRIORITY APPLN. INFO.:			US 1997-922170	A2 19970902
			US 1998-71618	B2 19980501
			US 1998-186200	A 19981104
			WO 1999-US25451	W 19991028
AB Monoclonal antibodies , neutralizing antibodies , humanized antibodies specific to heparanase protein or an immunogenic portion thereof are disclosed. These antibodies are useful for inhibiting heparanase activity and for treating conditions assocd. with altered function of a HSPG-assocd. biol. effector mol., e.g. growth factor, chemokine, cytokine, or degradative enzyme. The condition is angiogenesis, cell proliferation, tumor cell proliferation, invasion of circulating tumor cell, metastasis, inflammatory disorders and autoimmune diseases.				

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:131509 CAPLUS
DOCUMENT NUMBER: 136:195300
TITLE: Genetically modified cells and methods for expressing
recombinant human heparanase and methods of its
purification
INVENTOR(S): Ayal-HersHKovitz, Maty; Moskowitz, Haim; Miron,

Daphna; Gilboa, Ayelet; Mimon, Madelene; Ben-Artzi, Hanna; Yacoby-Zeevi, Oron; **Pecker, Iris**; Peleg, Yoav; Schlomi, Yinon
 PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel
 SOURCE: U.S., 66 pp., Cont.-in-part of U.S. Ser. No. 71,618, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6348344	B1	20020219	US 1999-260038	19990302
US 5968822	A	19991019	US 1997-922170	19970902
US 6177545	B1	20010123	US 1998-71739	19980501
CA 2329142	AA	19991111	CA 1999-2329142	19990429
WO 9957244	A1	19991111	WO 1999-US9256	19990429
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG AU 9937705 A1 19991123 AU 1999-37705 19990429 EP 1076689 A1 20010221 EP 1999-920135 19990429 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI JP 2002513560 T2 20020514 JP 2000-547200 19990429 US 6475763 B1 20021105 US 2000-487716 20000119 US 6426209 B1 20020730 US 2000-635923 20000810 NO 2000005100 A 20001228 NO 2000-5100 20001010				
PRIORITY APPLN. INFO.: US 1997-922170 A2 19970902 US 1998-71618 B2 19980501 US 1998-71739 A2 19980501 US 1999-260038 A 19990302 WO 1999-US9256 W 19990429 US 2000-487716 A1 20000119				
AB Bacterial, yeast, and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis are provided. Thus, cloning of human heparanase cDNA into baculovirus-infected High 5 and Sf21 cells yielded 0.44 and 0.16 mg enzyme/mL, resp. Enzyme purifn. is achieved by cation-exchange chromatog. on Source-S or affinity chromatog. with anti-native heparanase antibodies . Highly active partially proteolytically cleaved forms of heparanase were identified. This led to the construction of recombinant heparanase contg. (1) an enterokinase cleavage site (Ser-Gln-Val-Asn-Gln) leading to cleavage between residues 119 and 120, or (2) a cathepsin L cleavage site leading to cleavage between residues 157 and 158.				
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				
L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:12473 CAPLUS DOCUMENT NUMBER: 134:96257 TITLE: Protein and cDNA sequences of a novel human heparanase gene hnhp1 and its splicing variants				

INVENTOR(S) : **Pecker, Iris**; Michal, Israel; Itzhaki, Hanan
PATENT ASSIGNEE(S) : Insight Strategy & Marketing Ltd., Israel
SOURCE : PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000643	A2	20010104	WO 2000-IL358	20000619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1212341	A1	20020612	EP 2000-937164	20000619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2001005526	A	20011218	NO 2001-5526	20011112
PRIORITY APPLN. INFO.: US 1999-140801P P 19990625				
WO 2000-IL358 W 20000619				

AB The invention provides protein and cDNA sequences of a novel human heparanase gene *hnhp1* and two variants resulted from alternative splicing. The longest clone is 2060 nucleotide long and it contains an open reading frame of 1776 nucleotides, which encodes a polypeptide of 592 amino acids, with a calcd. mol. wt. of 66.5 kDa. The two shorter forms contain an in frame deletion as a result of alternative splicing, one is 162 nucleotides (nt473-634) corresponding to amino acids 150-203, and one is 336 nucleotides (nt473-808) corresponding to amino acids 150-261. The *hnhp1* gene is mapped to chromosome 10, next to the marker SHGC-57721. The tissue distribution of *hnhp1* transcripts is detd. The invention also relates to constructing *hnhp1* gene expression vector to produce recombinant proteins in mammalian cells, which may have **heparanase** or other glycosyl hydrolase activity, its **antibodies**, and antisense oligonucleotide and ribozymes for gene modulation and therapeutic use.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:57239 CAPLUS
DOCUMENT NUMBER: 134:128217
TITLE: Heparanase specific molecular probes and their use in research and medical applications
INVENTOR(S) : **Pecker, Iris**; Vlodavsky, Israel; **Friedman, Yael**; **Perets, Tuvia**
PATENT ASSIGNEE(S) : Insight Strategy & Marketing Ltd., Israel
SOURCE : U.S., 41 pp., Cont.-in-part of U.S. 5,968,822.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6177545	B1	20010123	US 1998-71739	19980501
US 5968822	A	19991019	US 1997-922170	19970902

US 6348344	B1	20020219	US 1999-260038	19990302
WO 9957153	A1	19991111	WO 1999-US9255	19990429

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9938706	A1	19991123	AU 1999-38706	19990429
EP 1073682	A1	20010207	EP 1999-921513	19990429

R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, FI

JP 2002512533	T2	20020423	JP 1999-555528	19990429
US 2002114801	A1	20020822	US 1999-322977	19990601
NO 9906229	A	20000224	NO 1999-6229	19991215
US 6475763	B1	20021105	US 2000-487716	20000119
US 6426209	B1	20020730	US 2000-635923	20000810
US 2002004585	A1	20020110	US 2001-759207	20010116
US 2002102619	A1	20020801	US 2001-944602	20010904

PRIORITY APPLN. INFO.: US 1997-922170 A2 19970902
US 1998-71618 B2 19980501
US 1998-71739 A2 19980501
US 1999-260038 A1 19990302
WO 1999-US9255 W 19990429
US 1999-322977 A1 19990601
US 2000-487716 A1 20000119
US 2001-759207 A1 20010116

AB A variety of heparanase specific mol. probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific mol. probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific mol. probe for therapy of a condition assocd. with expression of heparanase; the use of a heparanase specific mol. probe for quantification of heparanase in a body fluid; the use of a heparanase specific mol. probe for targeted drug delivery; and the use of a heparanase specific mol. probe as a therapeutic agent.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:314574 CAPLUS

DOCUMENT NUMBER: 132:333392

TITLE: **Heparanase activity neutralizing anti-heparanase monoclonal antibody**

INVENTOR(S): Peretz, Tuvia; Miron, Daphna; Shlomi, Yinon; **Pecker, Iris**; Ayal-HersHKovitz, Maty; **Friedman, Yael**; Vlodavsky, Israel

PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Hadasit Medical Research Services & Development Ltd.; Friedman, Mark M.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025817	A1	20000511	WO 1999-US25451	19991028

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2002068061 A1 20020606 US 1998-186200 19981104
 EP 1126878 A1 20010829 EP 1999-956781 19991028
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 AU 751170 B2 20020808 AU 2000-13314 19991028
 NO 2001002190 A 20010612 NO 2001-2190 20010503
 PRIORITY APPLN. INFO.: US 1998-186200 A 19981104
 US 1997-922170 A2 19970902
 US 1998-71618 B2 19980501
 WO 1999-US25451 W 19991028

AB A monoclonal **antibody** elicited by a **heparanase** protein
 or an immunogenic portion thereof, the monoclonal **antibody**
 specifically inhibits **heparanase** activity. The
heparanase-specific monoclonal **antibody** may be human or
 humanized **antibody** and is useful for treating conditions assocd.
 with altered function of a heparan sulfate proteoglycan-assocd. biol.
 effector mol. such as growth factor, chemokine, cytokine and degradative
 enzyme. The condition is selected from the group consisting of
 angiogenesis, cell proliferation, tumor, metastasis, inflammatory
 disorders and autoimmune conditions.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:53938 CAPLUS
 DOCUMENT NUMBER: 132:102821
 TITLE: Method of screening for potential anti-metastatic and
 anti-inflammatory agents using mammalian heparanase as
 a probe
 INVENTOR(S): Ben-Artzi, Hanna; Ayal-HersHKovitz, Maty; Vlodavsky,
 Israel; **Pecker, Iris**; Peleg, Yoav; Miron,
 Daphna
 PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Hadasit
 Medical Research Services & Development Ltd.;
 Friedman, Mark M.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000003036	A1	20000120	WO 1999-US15643	19990712
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6190875	B1	20010220	US 1998-113168	19980710
CA 2335382	AA	20000120	CA 1999-2335382	19990712
AU 9948697	A1	20000201	AU 1999-48697	19990712

EP 1097241 A1 20010509 EP 1999-932382 19990712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002520029 T2 20020709 JP 2000-559256 19990712
NO 2001000136 A 20010309 NO 2001-136 20010109
PRIORITY APPLN. INFO.: US 1998-113168 A 19980710
US 1997-922170 A2 19970902
US 1998-109386 B2 19980702
WO 1999-US15643 W 19990712

AB Qual. and quant. methods are provided for testing an agent for its potential at inhibiting glycosidase catalytic activity, the methods including interacting a glycosidase enzyme with a glycosidase substrate in a presence of the agent and qual. or quant. evaluating an effect of the agent on the catalytic activity of the glycosidase enzyme toward the glycosidase substrate. Preferably the glycosidase enzyme is a heparanase enzyme and the glycosidase substrate is, resp., a heparanase substrate.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2001009022 MEDLINE
DOCUMENT NUMBER: 20476203 PubMed ID: 11021821
TITLE: Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.
AUTHOR: Friedmann Y; Vlodavsky I; Aingorn H; Aviv A; Peretz T; Pecker I; Pappo O
CORPORATE SOURCE: Departments of Oncology and Pathology, Hadassah-Hebrew University Hospital, Jerusalem, and InSight Ltd., Rabin Science Park, Rehovot, Israel.
SOURCE: AMERICAN JOURNAL OF PATHOLOGY, (2000 Oct) 157 (4) 1167-75. Journal code: 0370502. ISSN: 0002-9440.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200010
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001025

AB The human heparanase gene, an endo-beta-glucuronidase that cleaves heparan sulfate at specific intrachain sites, has recently been cloned and shown to function in tumor progression and metastatic spread. Antisense digoxigenin-labeled **heparanase** RNA probe and monoclonal anti-human **heparanase antibodies** were used to examine the expression of the **heparanase** gene and protein in normal, dysplastic, and neoplastic human colonic mucosa. To our knowledge, this is the first systematic study of heparanase expression in human colon cancer. Both the heparanase gene and protein were expressed at early stages of neoplasia, already at the stage of adenoma, but were practically not detected in the adjacent normal-looking colon epithelium. Gradually increasing expression of heparanase was evident as the cells progressed from severe dysplasia through well-differentiated to poorly differentiated colon carcinoma. Deeply invading colon carcinoma cells showed the highest levels of the heparanase mRNA and protein associated with expression of both the gene and enzyme by adjacent desmoplastic stromal fibroblasts. A high expression was also found in colon carcinoma metastases to lung, liver, and lymph nodes, as well as in the accompanying stromal fibroblasts. Moreover, extracts derived from tumor tissue expressed much higher levels of the heparanase protein and activity as compared to the normal colon tissue. In all specimens, the heparanase gene and protein exhibited the same pattern of expression. These results suggest a role of heparanase in colon cancer progression and may have both prognostic and therapeutic applications.

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:723147 CAPLUS

DOCUMENT NUMBER: 131:332967

TITLE: Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same

INVENTOR(S): Ben-Artzi, Hanna; Ayal-HersHKovitz, Maty; Yacoby-Zeevi, Oron; **Pecker, Iris**; Peleg, Yoav; Shlomi, Yinon

PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Friedman, Mark, M.

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957244	A1	19991111	WO 1999-US9256	19990429
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6348344	B1	20020219	US 1999-260038	19990302
CA 2329142	AA	19991111	CA 1999-2329142	19990429
AU 9937705	A1	19991123	AU 1999-37705	19990429
EP 1076689	A1	20010221	EP 1999-920135	19990429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002513560	T2	20020514	JP 2000-547200	19990429
NO 2000005100	A	20001228	NO 2000-5100	20001010

PRIORITY APPLN. INFO.:

US 1998-71618	A	19980501
US 1999-260038	A	19990302
US 1997-922170	A2	19970902
US 1998-71739	A2	19980501
WO 1999-US9256	W	19990429

AB Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis. Heparanase is a glycosylated enzyme involved in catabolism of certain glycosaminoglycans, in tumor cell invasion and metastasis, and possibly in angiogenesis. It has potential therapeutic applications for viral infection, neurodegenerative diseases, restenosis, and atherosclerosis. A signal peptide was incorporated for effective protein secretion in yeast and bacteria and insect and mammalian cells. Protein secretion is achieved by induction by thrombin and calcium ionophores and immune complexes and antigens and mitogens. This work describes prodn. of heparanase on a biotechnol. scale of at least half a liter growth medium by affinity purifn. This large scale propagation of animal cells is described in a Spinner-basket bioreactor. The heparanase enzyme is activated by digestion with a protease such as cathepsin L or trypsin at appropriate pH. A correctly folded catalytically active heparanase is generated.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:723067 CAPLUS

DOCUMENT NUMBER: 131:350261

TITLE: Heparanase specific molecular probes and their use in research and medical applications

INVENTOR(S): Pecker, Iris; Vlodavsky, Israel;

Friedman, Yael; Perets, Tuvia

PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Hadasit

Medical Research Services & Development Ltd.;

Friedman, Mark, M.

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957153	A1	19991111	WO 1999-US9255	19990429
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6177545	B1	20010123	US 1998-71739	19980501
AU 9938706	A1	19991123	AU 1999-38706	19990429
EP 1073682	A1	20010207	EP 1999-921513	19990429
R:	AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, FI			
JP 2002512533	T2	20020423	JP 1999-555528	19990429
NO 9906229	A	20000224	NO 1999-6229	19991215

PRIORITY APPLN. INFO.:

US 1998-71739 A 19980501
US 1997-922170 A2 19970902
WO 1999-US9255 W 19990429

AB A variety of heparanase specific mol. probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific mol. probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific mol. probe for therapy of a condition assocd. with expression of heparanase; the use of a heparanase specific mol. probe for quantification of heparanase in a body fluid; the use of a heparanase specific mol. probe for targeted drug delivery; and the use of a heparanase specific mol. probe as a therapeutic agent.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (heparanase (10N) antibod?)

L5 79 (HEPARANASE (10N) ANTIBOD?)

=> s l5 not l4

L6 70 L5 NOT L4

=> s l6 and PD<19970902

'19970902' NOT A VALID FIELD CODE

3 FILES SEARCHED...

L7 18 L6 AND PD<19970902

=> dup rem l7

PROCESSING COMPLETED FOR L7

=> dis l8 1-7 ibib abs

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
 ACCESSION NUMBER: 1997:763245 CAPLUS
 DOCUMENT NUMBER: 128:47265
 TITLE: Major colocalization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils
 AUTHOR(S): Mollinedo, Faustino; Nakajima, Motowo; Llorens, Ana; Barbosa, Enrique; Callejo, Sagrario; Gajate, Consuelo; Fabra, Angels
 CORPORATE SOURCE: Facultad de Medicina, Laboratory of Signal Transduction and Leucocyte Biology, Instituto de Biologia y Genetica Molecular, Consejo Superior de Investigaciones Cientificas-Universidad de Valladolid, Valladolid, E-47005, Spain
 SOURCE: Biochemical Journal (1997), 327(3), 917-923
 CODEN: BIJOAK; ISSN: 0264-6021
 PUBLISHER: Portland Press Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The expression of cell-surface adhesion proteins and the release of extracellular-matrix degradative enzymes constitute crucial processes for the attachment of neutrophils to the endothelium and for the subsequent extravasation of these cells through the endothelial layer. We have analyzed in resting human neutrophils the subcellular localization of heparanase, a heparan-sulfate-degrading endoglycosidase that can degrade basement-membrane components, thereby facilitating neutrophil passage into the tissue during an inflammatory reaction. By subcellular fractionation of postnuclear supernatants from resting human neutrophils on continuous gradients, we have found that heparanase activity was mainly located in gelatinase-contg. tertiary granules. Using a specific **antibody**, the 96-kDa **heparanase** protein was further located in the gelatinase-rich subcellular fractions. Following immunoblotting and immunopptn. anal. in the distinct subcellular fractions, we also found colocalization of heparanase and Mol (CD11b/CD18), a leukocyte integrin involved in the attachment of neutrophils to the endothelium, in the fractions enriched in gelatinase-contg. tertiary granules. Treatment of human neutrophils with tumor necrosis factor or granulocyte/macrophage colony-stimulating factor induced an increase in the CD11b/CD18 cell-surface expression, as well as the release of both gelatinase (matrix metalloproteinase-9) and heparanase, but not of other granule markers, indicating a major co-localization of gelatinase, heparanase and CD11b/CD18 in the same organelle. Furthermore, confocal laser scanning microscopy using specific **antibodies** against gelatinase and **heparanase** revealed a major co-localization of both enzymes in intracellular cytoplasmic granules. The major localization of heparanase and CD11b/CD18 in the gelatinase-contg. tertiary granule supports the notion that mobilization of this organelle can regulate extravasation on human neutrophils.

L8 ANSWER 2 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V. DUPLICATE 2
 ACCESSION NUMBER: 97266746 EMBASE
 DOCUMENT NUMBER: 1997266746
 TITLE: Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix.
 AUTHOR: Pillarisetti S.; Paka L.; Obunike J.C.; Berglund L.; Goldberg I.J.
 CORPORATE SOURCE: Dr. S. Pillarisetti, Department of Medicine, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, United States.

ps42@columbia.edu
SOURCE: Journal of Clinical Investigation, (1997) 100/4
(867-874).
Refs: 59
ISSN: 0021-9738 CODEN: JCINAO
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Vessel wall subendothelial extracellular matrix, a dense mesh formed of collagens, fibronectin, laminin, and proteoglycans, has important roles in lipid and lipoprotein retention and cell adhesion. In atherosclerosis, vessel wall heparan sulfate proteoglycans (HSPG) are decreased and we therefore tested whether selective loss of HSPG affects lipoprotein retention. A matrix synthesized by aortic endothelial cells and a commercially available matrix (Matrigel; Becton Dickinson Inc., Rutherford, NJ) were used. Treatment of matrix with heparinase/heparitinase (1 U/ml each) increased LDL binding by .apprx. 1.5-fold. Binding of lipoprotein (a) [Lp(a)] to both subendothelial matrix and Matrigel.RTM. increased 2-10-fold when the HSPG were removed by heparinase treatment. Incubation of endothelial cells with oxidized LDL (OxLDL) or lysolecithin resulted in decreased matrix proteoglycans and increased Lp(a) retention by matrix. The effect of OxLDL or lysolecithin on endothelial PG was abolished in the presence of HDL. The decrease in matrix HSPG was associated with production of a heparanase-like activity by OxLDL-stimulated endothelial cells. To test whether removal of HSPG exposes fibronectin, a candidate Lp(a) binding protein in the matrix, antifibronectin antibodies were used. The increased Lp(a) binding after HSPG removal was inhibited 60% by antifibronectin antibodies. Similarly, the increased Lp(a) binding to matrix from OxLDL-treated endothelial cells was inhibited by antifibronectin **antibodies**. We hypothesize that atherogenic lipoproteins stimulate endothelial cell production of **heparanase**. This enzyme reduces HSPG which in turn promotes Lp(a) retention.

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3
ACCESSION NUMBER: 1997:194122 CAPLUS
DOCUMENT NUMBER: 126:262494
TITLE: Human prostate carcinoma cells produce extracellular heparanase
AUTHOR(S): Kosir, Mary Ann; Quinn, Christiane C. V.; Zukowski, Kim L.; Grignon, David J.; Ledbetter, Steven
CORPORATE SOURCE: VA Medical Center, Surgical Service, Detroit, MI, 48201, USA
SOURCE: Journal of Surgical Research (1997), 67(1), 98-105
CODEN: JSGRA2; ISSN: 0022-4804
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The degrdn. of heparan sulfate proteoglycan (HSPG) in basement membranes (BM) has been previously suggested to be accomplished by an endoglycosidase activity called heparanase which has not been isolated outside of platelets. HSPG degrdn. by heparanase has been assocd. with tumor cell invasion, angiogenesis, and growth factor function. In this study, we identify heparanase activity biochem. and immunol. in malignant human prostate carcinoma cells (PC-3M), linking platelet heparanase probes with the tumor heparanase activity obsd. Concd. conditioned medium from PC-3M cells was analyzed by a heparin-Sepharose affinity column. Three peaks eluted with 0.15, 0.35, and 0.5 M NaCl. Each peak was analyzed by incubation with 3H-labeled heparin as well as [3H]HSPG from EHS tumor BM. The 0.5 M peak material degraded [3H]-heparin by 17.2%, with little addnl. degrdn. by the other peaks in comparison to the conditioned medium from

which they were obtained. Likewise, the same amt. of the 0.5 M peak accounted for the majority of degrdn. (30.8%) of 3H-labeled HSPG. Interestingly, for the same amt. of 0.5 M peak material, significantly more HSPG was degraded than heparin under the same conditions. In addn., carrageenan- λ , an inhibitor of glycanase, completely inhibited the degrdn. of heparin and heparan sulfate proteoglycan by the 0.5 M peak. Using **antibody** to the N-terminus domain of platelet **heparanase**, a 60-kDa protein was identified by immunoblot in 0.5 M peak material. Addnl., immunohistochem. staining of human prostate carcinoma specimens showed granular staining at or near the cell membrane and near the luminal surface using **antibody** to the N-terminus and C-terminus domains of platelet **heparanase**. In summary, human prostate carcinoma cells show heparanase activity in conditioned medium that degrades heparin and BM HSPG and is detected by **antibody** to platelet **heparanase**. In addn., the membrane-assocd. staining in tissue sections of prostate cancer strongly correlates with the biochem. and immunol. detection in conditioned medium of human PC-3M cells.

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4
 ACCESSION NUMBER: 1994:627556 CAPLUS
 DOCUMENT NUMBER: 121:227556
 TITLE: immunoselection of GRP94/endoplasmin from a KNRK cell-specific λ .gt11 library using **antibodies** directed against a putative **heparanase** amino-terminal peptide
 AUTHOR(S): De Vouge, Michael W.; Yamazaki, Amy; Bennett, Steffany A.L.; Chen, Jia Hua; Shwed, Philip S.; Couture, Chantal; Birnboim, H. Chaim
 CORPORATE SOURCE: Ottawa Reg. Cancer Cent., Ottawa, ON, K1H 8L6, Can.
 SOURCE: International Journal of Cancer (1994), 56(2), 286-94
 CODEN: IJCNAW; ISSN: 0020-7136
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Induction of an invasive phenotype by metastatic tumor cells results in part from inappropriate expression of extracellular matrix-degrading enzymes normally involved in embryonic morphogenesis, tissue remodelling, angiogenesis and wound healing. Such enzymes include endoglycosidases that degrade heparan sulfate (HS) in endothelial basement membrane, as well as better characterized proteases. Heparanase, an endo- β -D-glucuronidase initially detected in B16 melanoma cells, has been described as a Mr 96,000 glycoprotein with pI of 5.2, and has been immunolocalized to the cell surface and cytoplasm. We have utilized a polyacrylamide-gel-based HS degrdn. assay to demonstrate that KNRK, a rat kidney fibroblast cell line transformed by v-K-ras, exhibits HS-degrading activity similar to that of B16F10 mouse melanoma cells. To immunoselect heparanase-expressing clones from a KNRK-cell-specific λ .gt11 cDNA library, we have also prepd. a rabbit anti-serum directed against a putative amino-terminal peptide of B16F10 cellular heparanase. Lysogens from one clone expressed a β -galactosidase fusion protein whose staining with peptide anti-serum was inhibited by competition with excess peptide. Dideoxy-mediated sequencing of the insert termini of this recombinant revealed that it represents a rat homolog of Mr 94,000 glucose-regulated protein (GRP94/endoplasmin), a mol. chaperone that contains the exact amino-terminal sequence previously attributed to heparanase. Our results call into question the specificity of this peptide sequence, as well as previous immunolocalization studies of heparanase carried out using such anti-sera.

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:190176 CAPLUS
 DOCUMENT NUMBER: 116:190176
 TITLE: **Antibodies**, kits, and methods for

immunochemical localization of **heparanase** in mouse and human melanomas, and characterization of melanoma heparanase

INVENTOR(S): Nicolson, Garth L.; Nakajima, Motowo; Jin, Li
 PATENT ASSIGNEE(S): University of Texas System, USA
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9119197	A1	19911212	WO 1991-US3832	19910530 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9182317	A1	19911231	AU 1991-82317	19910530 <--
AU 641269	B2	19930916		
EP 532695	A1	19930324	EP 1991-913555	19910530 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05509403	T2	19931222	JP 1991-512410	19910530 <--
PRIORITY APPLN. INFO.:			US 1990-530869	19900531
			WO 1991-US3832	19910530

AB **Antibodies** to a glycosaminoglycan endoglycosidase (esp. **heparanase**), as well as kits and methods employing the **antibodies**, are disclosed. **Antibodies** against an N-terminal **heparanase** peptide are produced. These antibodies are used for the detection of heparan sulfate endoglycosidase in human and murine tumors. Purifn. of melanoma heparanase is described. A hemocyanin-coupled **heparanase**-derived peptide was used as an immunogen for **antibody** prodn. Also described is prepn. and reactivity of various substrates (e.g. desulfated or desulfated and acetylated heparan sulfate) with melanoma heparanase. The anti-**heparanase antibodies** of the invention stained metastatic melanoma cells, but did not stain surrounding tissue.

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5

ACCESSION NUMBER: 1990:529983 CAPLUS

DOCUMENT NUMBER: 113:129983

TITLE: Immunochemical localization of heparanase in mouse and human melanomas

AUTHOR(S): Jin, Li; Nakajima, Motowo; Nicolson, Garth L.

CORPORATE SOURCE: M. D. Anderson Cancer Cent., Univ. Texas, Houston, TX, 77030, USA

SOURCE: International Journal of Cancer (1990), 45(6), 1088-95
 CODEN: IJCNAW; ISSN: 0020-7136

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Heparanase, an endo-.beta.-D-glucuronidase, has been assocd. with melanoma metastasis. Polyclonal **antibodies** directed against the murine N-terminal **heparanase** peptide detected a Mr .apprx.97,000 protein on SDS-PAGE of mouse melanoma and human melanoma cell lysates. In an indirect immunocytochem. study, human A375-SM and mouse B16-BL6 melanoma cells were stained with the anti-**heparanase antibodies**. Heparanase antigen was localized in the cytoplasm of permeabilized melanoma cells as well as at the cell surface of unpermeabilized cells. Immunohistochem. staining of frozen sections from syngeneic mouse lungs contg. micrometastases of B16-BL6 melanoma demonstrated heparanase localized in metastatic melanoma cells. Similar studies using frozen sections of malignant melanomas resected from patients indicated that heparanase is localized in invading melanoma cells. These studies suggest that (a) the N-terminus of the heparanase

mol. in mouse and human is antigenically related; (b) heparanase antigens are localized at the cell surface and in the cytoplasm of metastatic human and mouse melanoma cells; and (c) heparanase antigens are enriched in invasive and metastatic murine and human melanomas in vivo.

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 6
ACCESSION NUMBER: 1987:117981 CAPLUS
DOCUMENT NUMBER: 106:117981
TITLE: Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix
AUTHOR(S): Fridman, Rafael; Lider, Ofer; Naparstek, Yaakov; Fuks, Zvi; Vlodavsky, Israel; Cohen, Irun R.
CORPORATE SOURCE: Dep. Radiat., Hadassah Univ. Hosp., Jerusalem, 91120, Israel
SOURCE: Journal of Cellular Physiology (1987), 130(1), 85-92
CODEN: JCELLAX; ISSN: 0021-9541
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antigen-mediated induction of heparanase, an endoglycosidase capable of degrading heparan sulfate from the subendothelial extracellular matrix (ECM), was investigated in a rat T lymphocyte cell line reactive against the basic protein (BP) of myelin. It was found that nonactivated T lymphocytes could be induced to express heparanase activity following exposure to sol. but not to ECM-bound BP. The induction of heparanase was immunolog. specific and independent of the presence of syngeneic or allogeneic antigen-presenting cells (APC). However, anti-IA **antibodies** inhibited **heparanase** expression. Sol. BP induced secretion of heparanase into the culture medium within minutes, despite inhibition of protein synthesis. Cell lysates of T lymphocytes contained heparanase activity. Thus, T lymphocytes secrete a preformed heparanase following exposure to specific antigen.

=> dis his

(FILE 'HOME' ENTERED AT 13:53:38 ON 21 NOV 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS' ENTERED AT 13:54:35 ON 21 NOV 2002

L1 406 S PECKER I?/AU OR VLODASKY I?/AU OR FRIEDMAN Y?/AU OR PERETS T?
L2 60 S L1 AND HEPARANASE
L3 12 S L1 AND (HEPARANASE (10N) ANTIBOD?)
L4 9 DUP REM L3 (3 DUPLICATES REMOVED)
L5 79 S (HEPARANASE (10N) ANTIBOD?)
L6 70 S L5 NOT L4
L7 18 S L6 AND PD<19970902
L8 7 DUP REM L7 (11 DUPLICATES REMOVED)